Version: 2024.01
Loading Scheme...
CPC | COOPERATIVE PATENT CLASSIFICATION | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| C12N | MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q 1/00) [2022-05] NOTES
WARNINGS
|
C12N 1/00 | Microorganisms, e.g. protozoa; Compositions thereof (medicinal preparations containing material from protozoa, bacteria or viruses A61K 35/66, from algae A61K 36/02, from fungi A61K 36/06; preparing medicinal bacterial antigen or antibody compositions, e.g. bacterial vaccines, A61K 39/00); Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor [2021-05] |
C12N 1/005 | . |
C12N 1/02 | . | Separating microorganisms from their culture media [2017-08] |
C12N 1/04 | . |
C12N 1/06 | . | Lysis of microorganisms [2017-08] |
C12N 1/063 | . . | {of yeast} [2013-01] |
C12N 1/066 | . . | {by physical methods} [2013-01] |
C12N 1/08 | . | Reducing the nucleic acid content [2013-01] |
C12N 1/10 | . | Protozoa; Culture media therefor [2013-01] |
C12N 1/105 | . . | {Protozoal isolates} [2021-05] |
C12N 1/12 | . |
C12N 1/125 | . . | {Unicellular algae isolates} [2021-05] |
C12N 1/14 | . |
C12N 1/145 | . . | {Fungal isolates} [2021-05] |
C12N 1/16 | . . | Yeasts; Culture media therefor [2013-01] |
C12N 1/165 | . . . | {Yeast isolates} [2021-05] |
C12N 1/18 | . . . | Baker's yeast; Brewer's yeast [2013-01] |
C12N 1/185 | . . . . | {Saccharomyces isolates} [2021-05] |
C12N 1/20 | . | Bacteria; Culture media therefor [2021-05] |
C12N 1/205 | . . | {Bacterial isolates} [2021-05] |
C12N 1/22 | . | Processes using, or culture media containing, cellulose or hydrolysates thereof [2013-01] |
C12N 1/24 | . | Processes using, or culture media containing, waste sulfite liquor [2013-01] |
C12N 1/26 | . | Processes using, or culture media containing, hydrocarbons (refining of hydrocarbon oils by using microorganisms C10G 32/00) [2017-08] |
C12N 1/28 | . . | aliphatic [2013-01] |
C12N 1/30 | . . . | having five or less carbon atoms [2013-01] |
C12N 1/32 | . | Processes using, or culture media containing, lower alkanols, i.e. C1 to C6 [2013-01] |
C12N 1/34 | . | Processes using foam culture [2013-01] |
C12N 1/36 | . | Adaptation or attenuation of cells [2013-01] |
C12N 1/38 | . | Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound (C12N 1/34 takes precedence) [2013-01] |
C12N 3/00 | Spore forming or isolating processes [2013-01] |
| C12N 5/00 | Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor; (plant reproduction by tissue culture techniques A01H 4/00) [2013-01] NOTE
|
C12N 5/0006 | . | {Modification of the membrane of cells, e.g. cell decoration} [2013-01] |
C12N 5/0012 | . | {Cell encapsulation} [2013-01] |
C12N 5/0018 | . | {Culture media for cell or tissue culture (media for specific animal cell type C12N 5/06)} [2013-01] |
C12N 5/0025 | . . | {Culture media for plant cell or plant tissue culture} [2013-01] |
| C12N 5/0031 | . . | {Serum-free culture media} [2016-05] WARNING
|
C12N 5/0037 | . . | {Serum-free medium, which may still contain naturally-sourced components} [2013-01] |
C12N 5/0043 | . . | {Medium free of human- or animal-derived components} [2013-01] |
C12N 5/005 | . . | {Protein-free medium} [2013-01] |
C12N 5/0056 | . . | {Xeno-free medium} [2013-01] |
C12N 5/0062 | . | {General methods for three-dimensional culture} [2013-01] |
C12N 5/0068 | . | {General culture methods using substrates (for specific animal cell type C12N 5/06)} [2013-01] |
C12N 5/0075 | . . | {using microcarriers} [2013-01] |
C12N 5/0081 | . | {Purging biological preparations of unwanted cells} [2013-01] |
C12N 5/0087 | . . | {Purging against subsets of blood cells, e.g. purging alloreactive T cells} [2013-01] |
C12N 5/0093 | . . | {Purging against cancer cells} [2013-01] |
C12N 5/04 | . |
| C12N 5/06 | . | {Animal cells or tissues; Human cells or tissues (preservation of living cells or tissues A01N 1/02)} [2022-05] NOTE
|
C12N 5/0601 | . . | {Invertebrate cells or tissues, e.g. insect cells; Culture media therefor} [2013-01] |
| C12N 5/0602 | . . | {Vertebrate cells} [2013-01] NOTE
|
C12N 5/0603 | . . . | {Embryonic cells (production of embryos, nuclear transfer A01K 67/027); Embryoid bodies} [2013-01] |
C12N 5/0604 | . . . . | {Whole embryos; Culture medium therefor} [2013-01] |
C12N 5/0605 | . . . . | {Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly} [2013-01] |
C12N 5/0606 | . . . . | {Pluripotent embryonic cells, e.g. embryonic stem cells [ES] (embryonic germ cells C12N 5/0611, induced pluripotent stem cells C12N 5/0696)} [2013-01] |
C12N 5/0607 | . . . | {Non-embryonic pluripotent stem cells, e.g. MASC (induced pluripotent stem cells C12N 5/0696)} [2015-09] |
C12N 5/0608 | . . . | {Germ cells (production of embryos, nuclear transfer A01K 67/027)} [2020-05] |
C12N 5/0609 | . . . . | {Oocytes, oogonia (fertilised oocytes C12N 5/0604)} [2013-01] |
C12N 5/061 | . . . . | {Sperm cells, spermatogonia} [2013-01] |
C12N 5/0611 | . . . . | {Primordial germ cells, e.g. embryonic germ cells [EG]} [2013-01] |
C12N 5/0612 | . . . . | {sorting of gametes, e.g. according to sex or motility} [2013-01] |
C12N 5/0613 | . . . | {Cells from endocrine organs (pancreas C12N 5/0676, gonads C12N 5/0681)} [2013-01] |
C12N 5/0614 | . . . . | {Adrenal gland} [2013-01] |
C12N 5/0615 | . . . . | {Pineal gland} [2013-01] |
C12N 5/0616 | . . . . | {Pituitary gland} [2013-01] |
C12N 5/0617 | . . . . | {Thyroid and parathyroid glands} [2013-01] |
C12N 5/0618 | . . . | {Cells of the nervous system} [2013-01] |
C12N 5/0619 | . . . . | {Neurons} [2013-01] |
C12N 5/062 | . . . . | {Sensory transducers, e.g. photoreceptors; Sensory neurons, e.g. for hearing, taste, smell, pH, touch, temperature, pain} [2013-01] |
C12N 5/0621 | . . . . | {Eye cells, e.g. cornea, iris pigmented cells (photoreceptors C12N 5/062)} [2013-01] |
C12N 5/0622 | . . . . | {Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells} [2013-01] |
C12N 5/0623 | . . . . | {Stem cells} [2013-01] |
C12N 5/0625 | . . . | {Epidermal cells, skin cells; Cells of the oral mucosa} [2013-01] |
C12N 5/0626 | . . . . | {Melanocytes} [2013-01] |
C12N 5/0627 | . . . . | {Hair cells} [2013-01] |
C12N 5/0628 | . . . . . | {Hair stem cells; Hair progenitors (mesenchymal stem cells from hair follicles C12N 5/0666)} [2013-01] |
C12N 5/0629 | . . . . | {Keratinocytes; Whole skin} [2013-01] |
C12N 5/063 | . . . . . | {Kereatinocyte stem cells; Keratinocyte progenitors} [2013-01] |
C12N 5/0631 | . . . . | {Mammary cells} [2013-01] |
C12N 5/0632 | . . . . | {Cells of the oral mucosa} [2013-01] |
C12N 5/0633 | . . . . | {Cells of secretory glands, e.g. parotid gland, salivary glands, sweat glands, lacrymal glands} [2013-01] |
| C12N 5/0634 | . . . | {Cells from the blood or the immune system} [2023-05] NOTE
WARNING
|
| C12N 5/0635 | . . . . | {B lymphocytes} [2023-05] WARNING
|
| C12N 5/0636 | . . . . | {T lymphocytes} [2023-05] WARNING
|
| C12N 5/0637 | . . . . . | {Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg} [2023-05] WARNING
|
| C12N 5/0638 | . . . . . | {Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]} [2023-05] WARNING
|
| C12N 5/0639 | . . . . | {Dendritic cells, e.g. Langherhans cells in the epidermis} [2023-05] WARNING
|
| C12N 5/064 | . . . . . | {Immunosuppressive dendritic cells} [2023-05] WARNING
|
C12N 5/0641 | . . . . | {Erythrocytes} [2013-01] |
C12N 5/0642 | . . . . | {Granulocytes, e.g. basopils, eosinophils, neutrophils, mast cells} [2013-01] |
C12N 5/0643 | . . . . | {Osteoclasts} [2013-01] |
C12N 5/0644 | . . . . | {Platelets; Megakaryocytes} [2013-01] |
| C12N 5/0645 | . . . . | {Macrophages, e.g. Kuepfer cells in the liver; Monocytes} [2023-05] WARNING
|
| C12N 5/0646 | . . . . | {Natural killers cells [NK], NKT cells} [2023-05] WARNING
|
C12N 5/0647 | . . . . | {Haematopoietic stem cells; Uncommitted or multipotent progenitors} [2017-02] |
C12N 5/0648 | . . . . | {Splenocytes} [2013-01] |
C12N 5/065 | . . . . | {Thymocytes} [2013-01] |
C12N 5/0651 | . . . . | {Lymph nodes} [2013-01] |
C12N 5/0652 | . . . | {Cells of skeletal and connective tissues; Mesenchyme} [2013-01] |
C12N 5/0653 | . . . . | {Adipocytes; Adipose tissue} [2013-01] |
C12N 5/0654 | . . . . | {Osteocytes, Osteoblasts, Odontocytes; Bones, Teeth} [2013-01] |
C12N 5/0655 | . . . . | {Chondrocytes; Cartilage} [2013-01] |
C12N 5/0656 | . . . . | {Adult fibroblasts} [2013-01] |
C12N 5/0657 | . . . . | {Cardiomyocytes; Heart cells} [2013-01] |
C12N 5/0658 | . . . . | {Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts} [2013-01] |
C12N 5/0659 | . . . . . | {Satellite cells} [2013-01] |
C12N 5/066 | . . . . | {Tenocytes; Tendons, Ligaments} [2013-01] |
C12N 5/0661 | . . . . | {Smooth muscle cells} [2013-01] |
C12N 5/0662 | . . . . | {Stem cells} [2013-01] |
C12N 5/0663 | . . . . . | {Bone marrow mesenchymal stem cells (BM-MSC)} [2013-01] |
C12N 5/0664 | . . . . . | {Dental pulp stem cells, Dental follicle stem cells} [2013-01] |
C12N 5/0665 | . . . . . | {Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood} [2013-01] |
C12N 5/0666 | . . . . . | {Mesenchymal stem cells from hair follicles} [2013-01] |
C12N 5/0667 | . . . . . | {Adipose-derived stem cells [ADSC]; Adipose stromal stem cells} [2013-01] |
C12N 5/0668 | . . . . . | {Mesenchymal stem cells from other natural sources} [2013-01] |
C12N 5/0669 | . . . . | {Bone marrow stromal cells; Whole bone marrow (isolated stem cells from bone marrow C12N 5/0647, C12N 5/0663)} [2013-01] |
C12N 5/067 | . . . | {Hepatocytes} [2013-01] |
C12N 5/0671 | . . . . | {Three-dimensional culture, tissue culture or organ culture; Encapsulated cells} [2013-01] |
C12N 5/0672 | . . . . | {Stem cells; Progenitor cells; Precursor cells; Oval cells} [2013-01] |
C12N 5/0676 | . . . | {Pancreatic cells} [2013-01] |
C12N 5/0677 | . . . . | {Three-dimensional culture, tissue culture or organ culture; Encapsulated cells} [2013-01] |
C12N 5/0678 | . . . . | {Stem cells; Progenitor cells; Precursor cells} [2013-01] |
C12N 5/0679 | . . . | {Cells of the gastro-intestinal tract} [2013-01] |
C12N 5/068 | . . . . | {Stem cells; Progenitors} [2013-01] |
C12N 5/0681 | . . . | {Cells of the genital tract; Non-germinal cells from gonads} [2020-05] |
C12N 5/0682 | . . . . | {Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells (oocytes C12N 5/0609)} [2013-01] |
C12N 5/0683 | . . . . | {Cells of the male genital tract, e.g. prostate, epididymis; Non-germinal cells from testis, e.g. Leydig cells, Sertoli cells (spermatogonia C12N 5/061)} [2013-01] |
C12N 5/0684 | . . . | {Cells of the urinary tract or kidneys} [2013-01] |
C12N 5/0685 | . . . . | {Bladder epithelial cells} [2013-01] |
C12N 5/0686 | . . . . | {Kidney cells} [2013-01] |
C12N 5/0687 | . . . . | {Renal stem cells; Renal progenitors} [2013-01] |
C12N 5/0688 | . . . | {Cells from the lungs or the respiratory tract} [2013-01] |
C12N 5/0689 | . . . . | {Stem cells; Progenitors} [2013-01] |
C12N 5/069 | . . . | {Vascular Endothelial cells} [2013-01] |
C12N 5/0691 | . . . . | {Vascular smooth muscle cells; 3D culture thereof, e.g. models of blood vessels} [2013-01] |
C12N 5/0692 | . . . . | {Stem cells; Progenitor cells; Precursor cells} [2013-01] |
C12N 5/0693 | . . . | {Tumour cells; Cancer cells} [2013-01] |
C12N 5/0694 | . . . . | {Cells of blood, e.g. leukemia cells, myeloma cells} [2013-01] |
C12N 5/0695 | . . . . | {Stem cells; Progenitor cells; Precursor cells} [2013-01] |
C12N 5/0696 | . . . | {Artificially induced pluripotent stem cells, e.g. iPS} [2013-01] |
C12N 5/0697 | . . | {Artificial constructs associating cells of different lineages, e.g. tissue equivalents (blood vessels C12N 5/0691)} [2013-01] |
C12N 5/0698 | . . . | {Skin equivalents} [2013-01] |
C12N 5/10 | . | Cells modified by introduction of foreign genetic material [2020-05] |
| C12N 7/00 | Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K 39/00) [2017-08] WARNING
|
C12N 7/02 | . | Recovery or purification [2013-01] |
C12N 7/025 | . . | {Packaging cell lines, e.g. transcomplementing cell lines, for production of virus} [2013-01] |
C12N 7/04 | . | Inactivation or attenuation; Producing viral sub-units [2013-01] |
C12N 7/045 | . . | {Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered} [2013-01] |
C12N 7/06 | . . | {Inactivation or attenuation} by chemical treatment [2013-01] |
C12N 7/08 | . . | {Inactivation or attenuation} by serial passage of virus [2013-01] |
| C12N 9/00 | Enzymes; Proenzymes; Compositions thereof (preparations containing enzymes for cleaning teeth A61K 8/66, A61Q 11/00; medicinal preparations containing enzymes or proenzymes A61K 38/43; enzyme containing detergent compositions C11D; {enzymes with nucleic acid structure, e.g. ribozymes, C12N 15/113}); Processes for preparing, activating, inhibiting, separating or purifying enzymes (preparation of malt C12C 1/00) [2017-08] NOTE
|
C12N 9/0002 | . | {Antibodies with enzymatic activity, e.g. abzymes} [2016-08] |
C12N 9/0004 | . | {Oxidoreductases (1.)} [2013-01] |
C12N 9/0006 | . . | {acting on CH-OH groups as donors (1.1)} [2013-01] |
C12N 9/0008 | . . | {acting on the aldehyde or oxo group of donors (1.2)} [2013-01] |
C12N 9/001 | . . | {acting on the CH-CH group of donors (1.3)} [2013-01] |
C12N 9/0012 | . . | {acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)} [2013-01] |
C12N 9/0014 | . . . | {acting on the CH-NH2 group of donors (1.4)} [2013-01] |
C12N 9/0016 | . . . . | {with NAD or NADP as acceptor (1.4.1)} [2013-01] |
C12N 9/0018 | . . . . . | {Phenylalanine dehydrogenase (1.4.1.20)} [2013-01] |
C12N 9/002 | . . . . | {with a cytochrome as acceptor (1.4.2)} [2013-01] |
C12N 9/0022 | . . . . | {with oxygen as acceptor (1.4.3)} [2013-01] |
C12N 9/0024 | . . . . . | {D-Amino acid oxidase (1.4.3.3)} [2013-01] |
C12N 9/0026 | . . . | {acting on CH-NH groups of donors (1.5)} [2013-01] |
C12N 9/0028 | . . . . | {with NAD or NADP as acceptor (1.5.1)} [2013-01] |
C12N 9/003 | . . . . . | {Dihydrofolate reductase [DHFR] (1.5.1.3)} [2013-01] |
C12N 9/0032 | . . . . | {with oxygen as acceptor (1.5.3)} [2013-01] |
C12N 9/0034 | . . . . . | {Sarcosine oxidase (1.5.3.1)} [2013-01] |
C12N 9/0036 | . . . | {acting on NADH or NADPH (1.6)} [2013-01] |
C12N 9/0038 | . . . . | {with a heme protein as acceptor (1.6.2)} [2013-01] |
C12N 9/004 | . . . . . | {Cytochrome-b5 reductase (1.6.2.2)} [2013-01] |
C12N 9/0042 | . . . . . | {NADPH-cytochrome P450 reductase (1.6.2.4)} [2013-01] |
C12N 9/0044 | . . . | {acting on other nitrogen compounds as donors (1.7)} [2013-01] |
C12N 9/0046 | . . . . | {with oxygen as acceptor (1.7.3)} [2013-01] |
C12N 9/0048 | . . . . . | {Uricase (1.7.3.3)} [2013-01] |
C12N 9/0051 | . . | {acting on a sulfur group of donors (1.8)} [2013-01] |
C12N 9/0053 | . . | {acting on a heme group of donors (1.9)} [2013-01] |
C12N 9/0055 | . . | {acting on diphenols and related substances as donors (1.10)} [2013-01] |
C12N 9/0057 | . . . | {with oxygen as acceptor (1.10.3)} [2013-01] |
C12N 9/0059 | . . . . | {Catechol oxidase (1.10.3.1), i.e. tyrosinase} [2013-01] |
C12N 9/0061 | . . . . | {Laccase (1.10.3.2)} [2013-01] |
C12N 9/0063 | . . . . | {Ascorbate oxidase (1.10.3.3)} [2013-01] |
C12N 9/0065 | . . | {acting on hydrogen peroxide as acceptor (1.11)} [2013-01] |
C12N 9/0067 | . . | {acting on hydrogen as donor (1.12)} [2013-01] |
C12N 9/0069 | . . | {acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)} [2013-01] |
C12N 9/0071 | . . | {acting on paired donors with incorporation of molecular oxygen (1.14)} [2013-01] |
C12N 9/0073 | . . . | {with NADH or NADPH as one donor, and incorporation of one atom of oxygen 1.14.13} [2013-01] |
C12N 9/0075 | . . . . | {Nitric-oxide synthase (1.14.13.39)} [2013-01] |
C12N 9/0077 | . . . | {with a reduced iron-sulfur protein as one donor (1.14.15)} [2013-01] |
C12N 9/0079 | . . . . | {Steroid 11 beta monooxygenase (P-450 protein)(1.14.15.4)} [2013-01] |
C12N 9/0081 | . . . . | {Cholesterol monooxygenase (cytochrome P 450scc)(1.14.15.6)} [2013-01] |
C12N 9/0083 | . . . | {Miscellaneous (1.14.99)} [2013-01] |
C12N 9/0085 | . . . . | {Steroid 17 alpha-monooxygenase (1.14.99.9)} [2013-01] |
C12N 9/0087 | . . . . | {Steroid 21-monooxygenase (1.14.99.10)} [2013-01] |
C12N 9/0089 | . . | {acting on superoxide as acceptor (1.15)} [2013-01] |
C12N 9/0091 | . . | {oxidizing metal ions (1.16)} [2013-01] |
C12N 9/0093 | . . | {acting on CH or CH2 groups (1.17)} [2013-01] |
C12N 9/0095 | . . | {acting on iron-sulfur proteins as donor (1.18)} [2013-01] |
C12N 9/0097 | . . | {acting on reduced flavodoxin as donor (1.19)} [2013-01] |
C12N 9/10 | . |
C12N 9/1003 | . . | {transferring one-carbon groups (2.1)} [2013-01] |
C12N 9/1007 | . . . | {Methyltransferases (general) (2.1.1.)} [2013-01] |
C12N 9/1011 | . . . . | {Catechol O-methyltransferase (2.1.1.6)} [2013-01] |
C12N 9/1014 | . . . | {Hydroxymethyl-, formyl-transferases (2.1.2)} [2013-01] |
C12N 9/1018 | . . . | {Carboxy- and carbamoyl transferases (2.1.3)} [2013-01] |
C12N 9/1022 | . . | {transferring aldehyde or ketonic groups (2.2)} [2013-01] |
C12N 9/1025 | . . | {Acyltransferases (2.3)} [2013-01] |
C12N 9/1029 | . . . | {transferring groups other than amino-acyl groups (2.3.1)} [2013-01] |
C12N 9/1033 | . . . . | {Chloramphenicol O-acetyltransferase (2.3.1.28)} [2013-01] |
C12N 9/1037 | . . . . | {Naringenin-chalcone synthase (2.3.1.74), i.e. chalcone synthase} [2013-01] |
C12N 9/104 | . . . | {Aminoacyltransferases (2.3.2)} [2013-01] |
C12N 9/1044 | . . . . | {Protein-glutamine gamma-glutamyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII} [2013-01] |
C12N 9/1048 | . . | {Glycosyltransferases (2.4)} [2013-01] |
C12N 9/1051 | . . . | {Hexosyltransferases (2.4.1)} [2013-01] |
C12N 9/1055 | . . . . | {Levansucrase (2.4.1.10)} [2013-01] |
C12N 9/1059 | . . . . | {Cellulose synthases (2.4.1.12; 2.4.1.29)} [2013-01] |
C12N 9/1062 | . . . . | {Sucrose synthase (2.4.1.13)} [2013-01] |
C12N 9/1066 | . . . . | {Sucrose phosphate synthase (2.4.1.14)} [2013-01] |
C12N 9/107 | . . . . | {1,4-Alpha-glucan branching enzyme (2.4.1.18)} [2013-01] |
C12N 9/1074 | . . . . | {Cyclomaltodextrin glucanotransferase (2.4.1.19)} [2013-01] |
C12N 9/1077 | . . . | {Pentosyltransferases (2.4.2)} [2013-01] |
C12N 9/1081 | . . . | {transferring other glycosyl groups (2.4.99)} [2013-01] |
C12N 9/1085 | . . | {transferring alkyl or aryl groups other than methyl groups (2.5)} [2013-01] |
C12N 9/1088 | . . . | {Glutathione transferase (2.5.1.18)} [2013-01] |
C12N 9/1092 | . . . | {3-Phosphoshikimate 1-carboxyvinyltransferase (2.5.1.19), i.e. 5-enolpyruvylshikimate-3-phosphate synthase} [2013-01] |
C12N 9/1096 | . . | {transferring nitrogenous groups (2.6)} [2013-01] |
C12N 9/12 | . . | transferring phosphorus containing groups, e.g. kinases (2.7) [2013-01] |
C12N 9/1205 | . . . | {Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases} [2013-01] |
C12N 9/1211 | . . . . | {Thymidine kinase (2.7.1.21)} [2013-01] |
C12N 9/1217 | . . . | {Phosphotransferases with a carboxyl group as acceptor (2.7.2)} [2013-01] |
C12N 9/1223 | . . . | {Phosphotransferases with a nitrogenous group as acceptor (2.7.3)} [2013-01] |
C12N 9/1229 | . . . | {Phosphotransferases with a phosphate group as acceptor (2.7.4)} [2013-01] |
C12N 9/1235 | . . . | {Diphosphotransferases (2.7.6)} [2013-01] |
C12N 9/1241 | . . . | {Nucleotidyltransferases (2.7.7)} [2013-01] |
C12N 9/1247 | . . . . | {DNA-directed RNA polymerase (2.7.7.6)} [2013-01] |
C12N 9/1252 | . . . . | {DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase} [2013-01] |
C12N 9/1258 | . . . . | {Polyribonucleotide nucleotidyltransferase (2.7.7.8), i.e. polynucleotide phosphorylase} [2013-01] |
C12N 9/1264 | . . . . | {DNA nucleotidylexotransferase (2.7.7.31), i.e. terminal nucleotidyl transferase} [2013-01] |
C12N 9/127 | . . . . | {RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase} [2017-01] |
C12N 9/1276 | . . . . | {RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase} [2013-01] |
C12N 9/1282 | . . . . | {RNA uridylyltransferase (2.7.7.52)} [2013-01] |
C12N 9/1288 | . . . | {Transferases for other substituted phosphate groups (2.7.8)} [2013-01] |
C12N 9/1294 | . . . | {Phosphotransferases with paired acceptors (2.7.9)} [2013-01] |
C12N 9/13 | . . | {transferring sulfur containing groups (2.8)} [2013-01] |
C12N 9/14 | . | Hydrolases (3) [2013-01] |
C12N 9/16 | . . | acting on ester bonds (3.1) [2013-01] |
C12N 9/18 | . . . | Carboxylic ester hydrolases {(3.1.1)} [2013-01] |
C12N 9/20 | . . . . | Triglyceride splitting, e.g. by means of lipase [2013-01] |
C12N 9/22 | . . . |
C12N 9/24 | . . | acting on glycosyl compounds (3.2) [2013-01] |
C12N 9/2402 | . . . | {hydrolysing O- and S- glycosyl compounds (3.2.1)} [2013-01] |
C12N 9/2405 | . . . . | {Glucanases} [2013-01] |
C12N 9/2408 | . . . . . | {acting on alpha -1,4-glucosidic bonds} [2013-01] |
C12N 9/2411 | . . . . . . | {Amylases} [2013-01] |
C12N 9/2414 | . . . . . . . | {Alpha-amylase (3.2.1.1.)} [2013-01] |
C12N 9/2417 | . . . . . . . . | {from microbiological source} [2013-01] |
C12N 9/242 | . . . . . . . . . | {Fungal source} [2013-01] |
C12N 9/2422 | . . . . . . . . | {from plant source} [2013-01] |
C12N 9/2425 | . . . . . . . | {Beta-amylase (3.2.1.2)} [2013-01] |
C12N 9/2428 | . . . . . . . | {Glucan 1,4-alpha-glucosidase (3.2.1.3), i.e. glucoamylase} [2013-01] |
C12N 9/2431 | . . . . . . | {Beta-fructofuranosidase (3.2.1.26), i.e. invertase} [2013-01] |
C12N 9/2434 | . . . . . | {acting on beta-1,4-glucosidic bonds} [2013-01] |
C12N 9/2437 | . . . . . . | {Cellulases (3.2.1.4; 3.2.1.74; 3.2.1.91; 3.2.1.150)} [2013-01] |
C12N 9/244 | . . . . . . | {Endo-1,3(4)-beta-glucanase (3.2.1.6)} [2013-01] |
C12N 9/2442 | . . . . . . | {Chitinase (3.2.1.14)} [2013-01] |
C12N 9/2445 | . . . . . . | {Beta-glucosidase (3.2.1.21)} [2013-01] |
C12N 9/2448 | . . . . . . | {Licheninase (3.2.1.73)} [2013-01] |
C12N 9/2451 | . . . . . | {acting on alpha-1,6-glucosidic bonds} [2013-01] |
C12N 9/2454 | . . . . . . | {Dextranase (3.2.1.11)} [2013-01] |
C12N 9/2457 | . . . . . . | {Pullulanase (3.2.1.41)} [2013-01] |
C12N 9/246 | . . . . . . | {Isoamylase (3.2.1.68)} [2013-01] |
C12N 9/2462 | . . . . | {Lysozyme (3.2.1.17)} [2013-01] |
C12N 9/2465 | . . . . | {acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)} [2013-01] |
C12N 9/2468 | . . . . | {acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)} [2013-01] |
C12N 9/2471 | . . . . . | {Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase} [2013-01] |
C12N 9/2474 | . . . . | {Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase} [2017-01] |
C12N 9/2477 | . . . . | {Hemicellulases not provided in a preceding group} [2013-01] |
C12N 9/248 | . . . . . | {Xylanases} [2013-01] |
C12N 9/2482 | . . . . . . | {Endo-1,4-beta-xylanase (3.2.1.8)} [2013-01] |
C12N 9/2485 | . . . . . . | {Xylan endo-1,3-beta-xylosidase (3.2.1.32), i.e. endo-1,3-beta-xylanase} [2013-01] |
C12N 9/2488 | . . . . . | {Mannanases} [2013-01] |
C12N 9/2491 | . . . . . . | {Beta-mannosidase (3.2.1.25), i.e. mannanase} [2013-01] |
C12N 9/2494 | . . . . . . | {Mannan endo-1,4-beta-mannosidase (3.2.1.78), i.e. endo-beta-mannanase} [2013-01] |
C12N 9/2497 | . . . | {hydrolysing N- glycosyl compounds (3.2.2)} [2013-01] |
C12N 9/48 | . . | acting on peptide bonds (3.4) [2013-01] |
C12N 9/485 | . . . | {Exopeptidases (3.4.11-3.4.19)} [2013-01] |
C12N 9/50 | . . . | Proteinases {, e.g. Endopeptidases (3.4.21-3.4.25)} [2021-08] |
C12N 9/503 | . . . . | {derived from viruses} [2013-01] |
C12N 9/506 | . . . . . | {derived from RNA viruses} [2013-01] |
| C12N 9/52 | . . . . | derived from bacteria {or Archaea} [2021-08] NOTE
|
C12N 9/54 | . . . . . | bacteria being Bacillus [2013-01] |
C12N 9/58 | . . . . | derived from fungi [2013-01] |
C12N 9/60 | . . . . . | from yeast [2013-01] |
C12N 9/62 | . . . . . | from Aspergillus [2013-01] |
C12N 9/63 | . . . . | {derived from plants} [2013-01] |
C12N 9/64 | . . . . | derived from animal tissue [2013-01] |
C12N 9/6402 | . . . . . | {from non-mammals} [2013-01] |
C12N 9/6405 | . . . . . . | {not being snakes} [2013-01] |
C12N 9/6408 | . . . . . . . | {Serine endopeptidases (3.4.21)} [2013-01] |
C12N 9/641 | . . . . . . . | {Cysteine endopeptidases (3.4.22)} [2013-01] |
C12N 9/6413 | . . . . . . . | {Aspartic endopeptidases (3.4.23)} [2013-01] |
C12N 9/6416 | . . . . . . . | {Metalloendopeptidases (3.4.24)} [2013-01] |
C12N 9/6418 | . . . . . . | {from snakes} [2013-01] |
C12N 9/6421 | . . . . . | {from mammals} [2013-01] |
C12N 9/6424 | . . . . . . | {Serine endopeptidases (3.4.21)} [2013-01] |
C12N 9/6427 | . . . . . . . | {Chymotrypsins (3.4.21.1; 3.4.21.2); Trypsin (3.4.21.4)} [2013-01] |
C12N 9/6429 | . . . . . . . | {Thrombin (3.4.21.5)} [2013-01] |
C12N 9/6432 | . . . . . . . | {Coagulation factor Xa (3.4.21.6)} [2013-01] |
C12N 9/6435 | . . . . . . . | {Plasmin (3.4.21.7), i.e. fibrinolysin} [2013-01] |
C12N 9/6437 | . . . . . . . | {Coagulation factor VIIa (3.4.21.21)} [2013-01] |
C12N 9/644 | . . . . . . . | {Coagulation factor IXa (3.4.21.22)} [2013-01] |
C12N 9/6443 | . . . . . . . | {Coagulation factor XIa (3.4.21.27)} [2013-01] |
C12N 9/6445 | . . . . . . . | {Kallikreins (3.4.21.34; 3.4.21.35)} [2013-01] |
C12N 9/6448 | . . . . . . . | {Elastases, e.g. pancreatic elastase (3.4.21.36); leukocyte elastase (3.4.31.37)} [2013-01] |
C12N 9/6451 | . . . . . . . | {Coagulation factor XIIa (3.4.21.38)} [2013-01] |
C12N 9/6454 | . . . . . . . | {Dibasic site splicing serine proteases, e.g. kexin (3.4.21.61); furin (3.4.21.75) and other proprotein convertases} [2013-01] |
C12N 9/6456 | . . . . . . . | {Plasminogen activators} [2013-01] |
C12N 9/6459 | . . . . . . . . | {t-plasminogen activator (3.4.21.68), i.e. tPA} [2013-01] |
C12N 9/6462 | . . . . . . . . | {u-Plasminogen activator (3.4.21.73), i.e. urokinase} [2013-01] |
C12N 9/6464 | . . . . . . . | {Protein C (3.4.21.69)} [2013-01] |
C12N 9/6467 | . . . . . . . | {Granzymes, e.g. granzyme A (3.4.21.78); granzyme B (3.4.21.79)} [2017-01] |
C12N 9/647 | . . . . . . . | {Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups} [2013-01] |
C12N 9/6472 | . . . . . . | {Cysteine endopeptidases (3.4.22)} [2013-01] |
C12N 9/6475 | . . . . . . . | {Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63)} [2013-01] |
C12N 9/6478 | . . . . . . | {Aspartic endopeptidases (3.4.23)} [2013-01] |
C12N 9/6481 | . . . . . . . | {Pepsins (3.4.23.1; 3.4.23.2; 3.4.23.3)} [2013-01] |
C12N 9/6483 | . . . . . . . | {Chymosin (3.4.23.4), i.e. rennin} [2013-01] |
C12N 9/6486 | . . . . . . . | {Renin (3.4.23.15)} [2013-01] |
C12N 9/6489 | . . . . . . | {Metalloendopeptidases (3.4.24)} [2013-01] |
C12N 9/6491 | . . . . . . . | {Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)} [2017-08] |
C12N 9/6494 | . . . . . . . | {Neprilysin (3.4.24.11), i.e. enkephalinase or neutral-endopeptidase 24.11} [2013-01] |
C12N 9/6497 | . . . . . . . | {Endothelin-converting enzyme (3.4.24.71)} [2013-01] |
C12N 9/78 | . . | acting on carbon to nitrogen bonds other than peptide bonds (3.5) [2013-01] |
C12N 9/80 | . . . | acting on amide bonds in linear amides {(3.5.1)} [2013-01] |
C12N 9/82 | . . . . | Asparaginase {(3.5.1.1)} [2013-01] |
C12N 9/84 | . . . . | Penicillin amidase {(3.5.1.11)} [2013-01] |
C12N 9/86 | . . . | acting on amide bonds in cyclic amides, e.g. penicillinase {(3.5.2)} [2013-01] |
C12N 9/88 | . | Lyases (4.) [2013-01] |
C12N 9/90 | . | Isomerases (5.) [2013-01] |
C12N 9/92 | . . | Glucose isomerase {(5.3.1.5; 5.3.1.9; 5.3.1.18)} [2013-01] |
C12N 9/93 | . | {Ligases (6)} [2013-01] |
C12N 9/94 | . | Pancreatin [2013-01] |
C12N 9/96 | . | Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates [2013-01] |
C12N 9/98 | . |
C12N 9/99 | . | Enzyme inactivation by chemical treatment [2013-01] |
C12N 11/00 | Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof [2013-01] |
C12N 11/02 | . | Enzymes or microbial cells immobilised on or in an organic carrier [2020-01] |
C12N 11/04 | . . | entrapped within the carrier, e.g. gel or hollow fibres [2020-01] |
C12N 11/06 | . . | attached to the carrier via a bridging agent [2013-01] |
C12N 11/08 | . . | the carrier being a synthetic polymer [2022-05] |
C12N 11/082 | . . . | obtained by reactions only involving carbon-to-carbon unsaturated bonds [2022-05] |
C12N 11/084 | . . . . | Polymers containing vinyl alcohol units [2020-01] |
C12N 11/087 | . . . . | Acrylic polymers [2020-01] |
C12N 11/089 | . . . | obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds [2022-05] |
C12N 11/091 | . . . . | Phenol resins; Amino resins [2020-01] |
C12N 11/093 | . . . . | Polyurethanes [2020-01] |
C12N 11/096 | . . . . | Polyesters; Polyamides [2020-01] |
C12N 11/098 | . . . | formed in the presence of the enzymes or microbial cells [2022-05] |
C12N 11/10 | . . | the carrier being a carbohydrate [2020-01] |
C12N 11/12 | . . . | Cellulose or derivatives thereof [2017-08] |
C12N 11/14 | . | Enzymes or microbial cells immobilised on or in an inorganic carrier [2020-01] |
C12N 11/16 | . | Enzymes or microbial cells immobilised on or in a biological cell [2020-01] |
C12N 11/18 | . | Multi-enzyme systems [2013-01] |
C12N 13/00 | Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves [2017-08] |
C12N 15/00 | Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (mutants or genetically engineered microorganisms, per se C12N 1/00, C12N 5/00, C12N 7/00; new plants per se A01H; plant reproduction by tissue culture techniques A01H 4/00; new animals per se A01K 67/00; use of medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases, gene therapy A61K 48/00) [2017-08] |
C12N 15/01 | . | Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor [2013-01] |
C12N 15/02 | . | Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion {(monoclonal antibodies C07K 16/00; apparatus for cell fusion C12M)} [2013-01] |
C12N 15/03 | . . | Bacteria [2013-01] |
C12N 15/04 | . . | Fungi [2013-01] |
C12N 15/09 | . | Recombinant DNA-technology [2013-01] |
| C12N 15/10 | . . | Processes for the isolation, preparation or purification of DNA or RNA (chemical preparation of DNA or RNA C07H 21/00; preparation of non-structural polynucleotides from microorganisms or with enzymes C12P 19/34) [2022-05] NOTE
|
C12N 15/1003 | . . . | {Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor} [2013-01] |
C12N 15/1006 | . . . . | {by means of a solid support carrier, e.g. particles, polymers} [2013-01] |
C12N 15/101 | . . . . . | {by chromatography, e.g. electrophoresis, ion-exchange, reverse phase} [2013-01] |
C12N 15/1013 | . . . . . | {by using magnetic beads} [2013-01] |
C12N 15/1017 | . . . . | {by filtration, e.g. using filters, frits, membranes} [2013-01] |
C12N 15/102 | . . . | {Mutagenizing nucleic acids} [2013-01] |
C12N 15/1027 | . . . . | {by DNA shuffling, e.g. RSR, STEP, RPR} [2013-01] |
C12N 15/1031 | . . . . | {mutagenesis by gene assembly, e.g. assembly by oligonucleotide extension PCR} [2013-01] |
C12N 15/1034 | . . . | {Isolating an individual clone by screening libraries} [2013-01] |
C12N 15/1037 | . . . . | {Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display} [2013-01] |
C12N 15/1041 | . . . . | {Ribosome/Polysome display, e.g. SPERT, ARM} [2013-01] |
C12N 15/1044 | . . . . | {Preparation or screening of libraries displayed on scaffold proteins} [2016-11] |
C12N 15/1048 | . . . . | {SELEX} [2013-01] |
C12N 15/1051 | . . . . | {Gene trapping, e.g. exon-, intron-, IRES-, signal sequence-trap cloning, trap vectors} [2013-01] |
C12N 15/1055 | . . . . | {Protein x Protein interaction, e.g. two hybrid selection} [2013-01] |
C12N 15/1058 | . . . . | {Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms} [2013-01] |
C12N 15/1062 | . . . . | {mRNA-Display, e.g. polypeptide and encoding template are connected covalently} [2013-01] |
C12N 15/1065 | . . . . | {Preparation or screening of tagged libraries, e.g. tagged microorganisms by STM-mutagenesis, tagged polynucleotides, gene tags} [2013-01] |
C12N 15/1072 | . . . . | {Differential gene expression library synthesis, e.g. subtracted libraries, differential screening} [2013-01] |
C12N 15/1075 | . . . . | {by coupling phenotype to genotype, not provided for in other groups of this subclass} [2013-01] |
C12N 15/1079 | . . . . | {Screening libraries by altering the phenotype or phenotypic trait of the host (reporter assays C12N 15/1086)} [2013-01] |
C12N 15/1082 | . . . . | {Preparation or screening gene libraries by chromosomal integration of polynucleotide sequences, HR-, site-specific-recombination, transposons, viral vectors} [2013-01] |
C12N 15/1086 | . . . . | {Preparation or screening of expression libraries, e.g. reporter assays} [2013-01] |
C12N 15/1089 | . . . . | {Design, preparation, screening or analysis of libraries using computer algorithms} [2013-01] |
C12N 15/1093 | . . . . | {General methods of preparing gene libraries, not provided for in other subgroups} [2013-01] |
C12N 15/1096 | . . . | {cDNA Synthesis; Subtracted cDNA library construction, e.g. RT, RT-PCR} [2013-01] |
| C12N 15/11 | . . | DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H 21/00); {Non-coding nucleic acids having a biological activity} [2016-05] NOTE
|
C12N 15/111 | . . . | {General methods applicable to biologically active non-coding nucleic acids} [2013-01] |
C12N 15/113 | . . . | Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N 15/8218)} [2017-01] |
C12N 15/1131 | . . . . | {against viruses} [2013-01] |
C12N 15/1132 | . . . . . | {against retroviridae, e.g. HIV} [2013-01] |
C12N 15/1133 | . . . . . | {against herpetoviridae, e.g. HSV} [2013-01] |
C12N 15/1135 | . . . . | {against oncogenes or tumor suppressor genes} [2013-01] |
C12N 15/1136 | . . . . | {against growth factors, growth regulators, cytokines, lymphokines or hormones} [2013-01] |
C12N 15/1137 | . . . . | {against enzymes (viral enzymes C12N 15/1131; receptors C12N 15/1138)} [2013-01] |
C12N 15/1138 | . . . . | {against receptors or cell surface proteins} [2013-01] |
| C12N 15/115 | . . . | Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith {; Nucleic acids binding to non-nucleic acids, e.g. aptamers} [2017-08] NOTE
|
C12N 15/117 | . . . | Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs [2013-01] |
| C12N 15/52 | . . . | Genes encoding for enzymes or proenzymes [2013-01] NOTE
|
| C12N 15/62 | . . . | DNA sequences coding for fusion proteins [2013-01] NOTE
|
C12N 15/63 | . . | Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression [2013-01] |
C12N 15/635 | . . . | {Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline} [2013-01] |
| C12N 15/64 | . . . | General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host [2022-05] NOTE
|
| C12N 15/65 | . . . | NOTE
|
| C12N 15/66 | . . . | General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease [2022-05] NOTES
|
C12N 15/67 | . . . | General methods for enhancing the expression [2013-01] |
C12N 15/68 | . . . . | Stabilisation of the vector [2013-01] |
C12N 15/69 | . . . . | Increasing the copy number of the vector [2013-01] |
C12N 15/71 | . . . . | Expression systems using regulatory sequences derived from the trp-operon [2013-01] |
C12N 15/72 | . . . . | Expression systems using regulatory sequences derived from the lac-operon [2013-01] |
C12N 15/73 | . . . . | Expression systems using phage (lambda) regulatory sequences [2013-01] |
C12N 15/743 | . . . . | {for Agrobacterium; Rhizobium; Bradyrhizobium} [2013-01] |
C12N 15/746 | . . . . | {for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)} [2013-01] |
C12N 15/75 | . . . . | for Bacillus [2013-01] |
C12N 15/76 | . . . . | for Actinomyces; for Streptomyces [2013-01] |
C12N 15/77 | . . . . | for Corynebacterium; for Brevibacterium [2013-01] |
C12N 15/78 | . . . . | for Pseudomonas [2013-01] |
| C12N 15/79 | . . . | Vectors or expression systems specially adapted for eukaryotic hosts [2013-01] NOTE
|
C12N 15/80 | . . . . | for fungi [2013-01] |
C12N 15/8201 | . . . . . | {Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation} [2013-01] |
C12N 15/8202 | . . . . . . | {by biological means, e.g. cell mediated or natural vector} [2013-01] |
C12N 15/8203 | . . . . . . . | {Virus mediated transformation} [2013-01] |
C12N 15/8205 | . . . . . . . | {Agrobacterium mediated transformation} [2013-01] |
C12N 15/8206 | . . . . . . | {by physical or chemical, i.e. non-biological, means, e.g. electroporation, PEG mediated} [2013-01] |
C12N 15/8207 | . . . . . . . | {by mechanical means, e.g. microinjection, particle bombardment, silicon whiskers} [2013-01] |
| C12N 15/8209 | . . . . . . | {Selection, visualisation of transformants, reporter constructs, e.g. antibiotic resistance markers} [2013-01] NOTE
|
C12N 15/821 | . . . . . . . | {Non-antibiotic resistance markers, e.g. morphogenetic, metabolic markers} [2015-07] |
C12N 15/8212 | . . . . . . . . | {Colour markers, e.g. beta-glucoronidase [GUS], green fluorescent protein [GFP], carotenoid} [2015-07] |
C12N 15/8213 | . . . . . . | {Targeted insertion of genes into the plant genome by homologous recombination} [2013-01] |
C12N 15/8214 | . . . . . . | {Plastid transformation} [2013-01] |
C12N 15/8216 | . . . . . | {Methods for controlling, regulating or enhancing expression of transgenes in plant cells} [2013-01] |
C12N 15/8217 | . . . . . . | {Gene switch} [2015-07] |
C12N 15/8218 | . . . . . . | {Antisense, co-suppression, viral induced gene silencing [VIGS], post-transcriptional induced gene silencing [PTGS]} [2015-07] |
C12N 15/822 | . . . . . . | {Reducing position variability, e.g. by the use of scaffold attachment region/matrix attachment region (SAR/MAR); Use of SAR/MAR to regulate gene expression} [2015-07] |
C12N 15/8221 | . . . . . . | {Transit peptides} [2015-07] |
C12N 15/8222 | . . . . . . | {Developmentally regulated expression systems, tissue, organ specific, temporal or spatial regulation} [2013-01] |
C12N 15/8223 | . . . . . . . | {Vegetative tissue-specific promoters} [2015-07] |
C12N 15/8225 | . . . . . . . . | {Leaf-specific, e.g. including petioles, stomata} [2015-07] |
C12N 15/8226 | . . . . . . . . | {Stem-specific, e.g. including tubers, beets} [2015-07] |
C12N 15/8227 | . . . . . . . . | {Root-specific} [2015-07] |
C12N 15/8229 | . . . . . . . . | {Meristem-specific, e.g. nodal, apical} [2015-07] |
C12N 15/823 | . . . . . . . | {Reproductive tissue-specific promoters} [2015-07] |
C12N 15/8231 | . . . . . . . . | {Male-specific, e.g. anther, tapetum, pollen} [2015-07] |
C12N 15/8233 | . . . . . . . . | {Female-specific, e.g. pistil, ovule} [2015-07] |
C12N 15/8234 | . . . . . . . . | {Seed-specific, e.g. embryo, endosperm} [2015-07] |
C12N 15/8235 | . . . . . . . . | {Fruit-specific} [2015-07] |
C12N 15/8237 | . . . . . . | {Externally regulated expression systems} [2013-01] |
C12N 15/8238 | . . . . . . . | {chemically inducible, e.g. tetracycline} [2015-07] |
C12N 15/8239 | . . . . . . . | {pathogen inducible} [2015-07] |
C12N 15/8241 | . . . . . | {Phenotypically and genetically modified plants via recombinant DNA technology} [2013-01] |
C12N 15/8242 | . . . . . . | {with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits} [2013-01] |
C12N 15/8243 | . . . . . . . | {involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine} [2013-01] |
C12N 15/8245 | . . . . . . . . | {involving modified carbohydrate or sugar alcohol metabolism, e.g. starch biosynthesis} [2013-01] |
C12N 15/8246 | . . . . . . . . . | {Non-starch polysaccharides, e.g. cellulose, fructans, levans} [2015-07] |
C12N 15/8247 | . . . . . . . . | {involving modified lipid metabolism, e.g. seed oil composition} [2013-01] |
C12N 15/8249 | . . . . . . . . | {involving ethylene biosynthesis, senescence or fruit development, e.g. modified tomato ripening, cut flower shelf-life} [2013-01] |
| C12N 15/825 | . . . . . . . . | {involving pigment biosynthesis} [2013-01] NOTE
|
C12N 15/8251 | . . . . . . . . | {Amino acid content, e.g. synthetic storage proteins, altering amino acid biosynthesis} [2013-01] |
C12N 15/8253 | . . . . . . . . . | {Methionine or cysteine} [2015-07] |
C12N 15/8254 | . . . . . . . . . | {Tryptophan or lysine} [2015-07] |
C12N 15/8255 | . . . . . . . . | {involving lignin biosynthesis} [2015-07] |
C12N 15/8257 | . . . . . . . | {for the production of primary gene products, e.g. pharmaceutical products, interferon} [2013-01] |
C12N 15/8258 | . . . . . . . . | {for the production of oral vaccines (antigens) or immunoglobulins} [2013-01] |
C12N 15/8259 | . . . . . . . | {Phytoremediation} [2015-07] |
C12N 15/8261 | . . . . . . | {with agronomic (input) traits, e.g. crop yield} [2013-01] |
C12N 15/8262 | . . . . . . . | {involving plant development} [2020-05] |
C12N 15/8263 | . . . . . . . . | {Ablation; Apoptosis} [2015-07] |
C12N 15/8265 | . . . . . . . . | {Transgene containment, e.g. gene dispersal} [2015-07] |
C12N 15/8266 | . . . . . . . . | {Abscission; Dehiscence; Senescence} [2015-07] |
C12N 15/8267 | . . . . . . . . | {Seed dormancy, germination or sprouting} [2015-07] |
C12N 15/8269 | . . . . . . . . | {Photosynthesis} [2015-07] |
C12N 15/827 | . . . . . . . . | {Flower development or morphology, e.g. flowering promoting factor [FPF]} [2015-07] |
C12N 15/8271 | . . . . . . . | {for stress resistance, e.g. heavy metal resistance} [2013-01] |
C12N 15/8273 | . . . . . . . . | {for drought, cold, salt resistance} [2015-07] |
C12N 15/8274 | . . . . . . . . | {for herbicide resistance} [2013-01] |
C12N 15/8275 | . . . . . . . . . | {Glyphosate} [2015-07] |
C12N 15/8277 | . . . . . . . . . | {Phosphinotricin} [2015-07] |
C12N 15/8278 | . . . . . . . . . | {Sulfonylurea} [2015-07] |
C12N 15/8279 | . . . . . . . . | {for biotic stress resistance, pathogen resistance, disease resistance} [2013-01] |
C12N 15/8281 | . . . . . . . . . | {for bacterial resistance} [2015-07] |
C12N 15/8282 | . . . . . . . . . | {for fungal resistance} [2015-07] |
C12N 15/8283 | . . . . . . . . . | {for virus resistance} [2013-01] |
C12N 15/8285 | . . . . . . . . . | {for nematode resistance} [2013-01] |
C12N 15/8286 | . . . . . . . . . | {for insect resistance} [2013-01] |
C12N 15/8287 | . . . . . . . | {for fertility modification, e.g. apomixis} [2013-01] |
C12N 15/8289 | . . . . . . . . | {Male sterility} [2015-07] |
C12N 15/829 | . . . . . . . . | {Female sterility} [2015-07] |
C12N 15/8291 | . . . . . . . | {Hormone-influenced development} [2015-07] |
C12N 15/8293 | . . . . . . . . | {Abscisic acid [ABA]} [2015-07] |
C12N 15/8294 | . . . . . . . . | {Auxins} [2015-07] |
C12N 15/8295 | . . . . . . . . | {Cytokinins} [2015-07] |
C12N 15/8297 | . . . . . . . . | {Gibberellins; GA3} [2015-07] |
C12N 15/8298 | . . . . . . . . | {Brassinosteroids} [2015-07] |
C12N 15/85 | . . . . | for animal cells [2013-01] |
| C12N 15/8509 | . . . . . | {for producing genetically modified animals, e.g. transgenic} [2018-01] NOTE
|
C12N 2015/8518 | . . . . . . | {expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles} [2013-01] |
C12N 2015/8527 | . . . . . . | {for producing animal models, e.g. for tests or diseases} [2013-01] |
C12N 2015/8536 | . . . . . . . | {Animal models for genetic diseases} [2013-01] |
C12N 2015/8545 | . . . . . . . . | {for Alzheimer''s disease} [2013-01] |
C12N 2015/8554 | . . . . . . . . . | {Invertebrates models for Alzheimer''s disease} [2013-01] |
C12N 2015/8563 | . . . . . . . . | {for autoimmune diseases, e.g. Insulin-dependent diabetes mellitus} [2013-01] |
C12N 2015/8572 | . . . . . . . | {Animal models for proliferative diseases, e.g. comprising an oncogene} [2013-01] |
C12N 2015/8581 | . . . . . . . | {Animal models for infectious diseases, e.g. AIDS} [2013-01] |
C12N 2015/859 | . . . . . . . | {Animal models comprising reporter system for screening tests} [2013-01] |
| C12N 15/86 | . . . . . | Viral vectors [2013-01] WARNING
|
C12N 15/861 | . . . . . . | Adenoviral vectors [2013-01] |
C12N 15/8613 | . . . . . . . | {Chimaeric vector systems comprising heterologous sequences for production of another viral vector} [2013-01] |
C12N 15/8616 | . . . . . . . | {Special methods for targeting systems} [2013-01] |
C12N 15/863 | . . . . . . | Poxviral vectors, {e.g. entomopoxvirus} [2013-01] |
C12N 15/8633 | . . . . . . . | {Avian poxviral vectors} [2013-01] |
C12N 15/8636 | . . . . . . . | {Vaccina virus vectors} [2013-01] |
C12N 15/864 | . . . . . . | Parvoviral vectors {, e.g. parvovirus, densovirus} [2017-08] |
C12N 15/8645 | . . . . . . . | {Adeno-associated virus} [2013-01] |
C12N 15/866 | . . . . . . | Baculoviral vectors [2013-01] |
C12N 15/867 | . . . . . . | Retroviral vectors [2013-01] |
C12N 15/8673 | . . . . . . . | {Special methods for packaging systems} [2013-01] |
C12N 15/8676 | . . . . . . . | {Special methods for targeting systems} [2013-01] |
C12N 15/869 | . . . . . . | Herpesviral vectors [2013-01] |
C12N 15/8695 | . . . . . . . | {Herpes simplex virus-based vectors} [2013-01] |
C12N 15/87 | . . | Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation [2013-01] |
C12N 15/873 | . . . | Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos [2013-01] |
C12N 15/877 | . . . . | Techniques for producing new mammalian cloned embryos [2017-02] |
C12N 15/8771 | . . . . . | {Bovine embryos} [2013-01] |
C12N 15/8772 | . . . . . | {Caprine embryos} [2013-01] |
C12N 15/8773 | . . . . . | {Ovine embryos} [2013-01] |
C12N 15/8775 | . . . . . | {Murine embryos} [2013-01] |
C12N 15/8776 | . . . . . | {Primate embryos} [2013-01] |
C12N 15/8777 | . . . . . | {Rabbit embryos} [2013-01] |
C12N 15/8778 | . . . . . | {Swine embryos} [2013-01] |
C12N 15/88 | . . . | using microencapsulation, e.g. using {amphiphile} liposome vesicle [2017-08] |
C12N 15/89 | . . . | using microinjection [2017-08] |
C12N 15/895 | . . . . | {using biolistic methods} [2013-01] |
C12N 15/90 | . . . | Stable introduction of foreign DNA into chromosome [2013-01] |
C12N 15/902 | . . . . | {using homologous recombination} [2013-01] |
C12N 15/905 | . . . . . | {in yeast} [2018-01] |
C12N 15/907 | . . . . . | {in mammalian cells} [2013-01] |
| C12N 2303/00 | Indexing codes associated with general methodologies in the field of biologically active non-coding nucleic acids [2013-01] NOTE
|
| C12N 2310/00 | Structure or type of the nucleic acid [2022-05] NOTE
|
C12N 2310/10 | . | Type of nucleic acid [2013-01] |
C12N 2310/11 | . . | Antisense [2013-01] |
C12N 2310/111 | . . . | spanning the whole gene, or a large part of it [2013-01] |
C12N 2310/113 | . . . | targeting other non-coding nucleic acids, e.g. antagomirs [2013-01] |
C12N 2310/12 | . . | catalytic nucleic acids, e.g. ribozymes [2013-01] |
C12N 2310/121 | . . . | Hammerhead [2013-01] |
C12N 2310/122 | . . . | Hairpin [2013-01] |
C12N 2310/123 | . . . | Hepatitis delta [2013-01] |
C12N 2310/124 | . . . | based on group I or II introns [2013-01] |
C12N 2310/1241 | . . . . | Tetrahymena [2013-01] |
C12N 2310/126 | . . . | involving RNAse P [2013-01] |
C12N 2310/127 | . . . | DNAzymes [2013-01] |
C12N 2310/128 | . . . | processing or releasing ribozyme [2013-01] |
C12N 2310/13 | . . | Decoys [2013-01] |
C12N 2310/14 | . . | interfering N.A. [2013-01] |
C12N 2310/141 | . . . | MicroRNAs, miRNAs [2013-01] |
C12N 2310/15 | . . | Nucleic acids forming more than 2 strands, e.g. TFOs [2013-01] |
C12N 2310/151 | . . . | more than 3 strands, e.g. tetrads, H-DNA [2013-01] |
C12N 2310/152 | . . . | on a single-stranded target, e.g. fold-back TFOs [2013-01] |
C12N 2310/153 | . . . | with the aid of a protein, e.g. recombinase [2013-01] |
C12N 2310/16 | . . | Aptamers [2013-01] |
C12N 2310/17 | . . | Immunomodulatory nucleic acids [2013-01] |
C12N 2310/18 | . . |
C12N 2310/20 | . . | involving clustered regularly interspaced short palindromic repeats [CRISPRs] [2017-05] |
C12N 2310/30 | . | Chemical structure [2013-01] |
C12N 2310/31 | . . | of the backbone [2013-01] |
C12N 2310/311 | . . . | Phosphotriesters [2013-01] |
C12N 2310/312 | . . . | Phosphonates [2013-01] |
C12N 2310/3125 | . . . . | Methylphosphonates [2013-01] |
C12N 2310/313 | . . . | Phosphorodithioates [2013-01] |
C12N 2310/314 | . . . | Phosphoramidates [2013-01] |
C12N 2310/3145 | . . . . | with the nitrogen in 3' or 5'-position [2013-01] |
C12N 2310/315 | . . . | Phosphorothioates [2013-01] |
C12N 2310/316 | . . . | Phosphonothioates [2013-01] |
C12N 2310/317 | . . . | with an inverted bond, e.g. a cap structure [2013-01] |
C12N 2310/318 | . . . | where the PO2 is completely replaced, e.g. MMI or formacetal [2013-01] |
C12N 2310/3181 | . . . . | Peptide nucleic acid, PNA [2013-01] |
C12N 2310/3183 | . . . . | Diol linkers, e.g. glycols or propanediols [2013-01] |
C12N 2310/319 | . . . | linked by 2'-5' linkages, i.e. having a free 3'-position [2013-01] |
C12N 2310/32 | . . | of the sugar [2013-01] |
C12N 2310/321 | . . . | 2'-O-R Modification [2013-01] |
C12N 2310/322 | . . . | 2'-R Modification [2013-01] |
C12N 2310/323 | . . . | modified ring structure [2013-01] |
C12N 2310/3231 | . . . . | having an additional ring, e.g. LNA, ENA [2013-01] |
C12N 2310/3233 | . . . . | Morpholino-type ring [2013-01] |
C12N 2310/3235 | . . . . | having the O of the ribose replaced by another atom [2013-01] |
C12N 2310/33 | . . | of the base [2013-01] |
C12N 2310/331 | . . . | Universal or degenerate base [2013-01] |
C12N 2310/332 | . . . | Abasic residue [2013-01] |
C12N 2310/333 | . . . | Modified A [2013-01] |
C12N 2310/334 | . . . | Modified C [2013-01] |
C12N 2310/3341 | . . . . | 5-Methylcytosine [2013-01] |
C12N 2310/335 | . . . | Modified T or U [2013-01] |
C12N 2310/336 | . . . | Modified G [2013-01] |
C12N 2310/337 | . . . | in alpha-anomeric form [2013-01] |
C12N 2310/34 | . . | Spatial arrangement of the modifications [2013-01] |
C12N 2310/341 | . . . | Gapmers, i.e. of the type ===---=== [2013-01] |
C12N 2310/342 | . . . | Hemimers, i.e. of the type ====---- [2013-01] |
C12N 2310/343 | . . . | having patterns, e.g. ==--==--==-- [2013-01] |
C12N 2310/344 | . . . | Position-specific modifications, e.g. on every purine, at the 3'-end [2013-01] |
C12N 2310/345 | . . . | having at least two different backbone modifications [2013-01] |
C12N 2310/346 | . . . | having a combination of backbone and sugar modifications [2013-01] |
C12N 2310/35 | . . | Nature of the modification [2013-01] |
C12N 2310/351 | . . . | Conjugate [2013-01] |
C12N 2310/3511 | . . . . | intercalating or cleaving agent [2013-01] |
C12N 2310/3513 | . . . . | Protein; Peptide [2013-01] |
C12N 2310/3515 | . . . . | Lipophilic moiety, e.g. cholesterol [2013-01] |
C12N 2310/3517 | . . . . | Marker; Tag [2013-01] |
C12N 2310/3519 | . . . . | Fusion with another nucleic acid [2013-01] |
C12N 2310/352 | . . . | linked to the nucleic acid via a carbon atom [2013-01] |
C12N 2310/3521 | . . . . | Methyl [2013-01] |
C12N 2310/3523 | . . . . | Allyl [2013-01] |
C12N 2310/3525 | . . . . | MOE, methoxyethoxy [2013-01] |
C12N 2310/3527 | . . . . | Other alkyl chain [2013-01] |
C12N 2310/3529 | . . . . | Aromatic substituent [2013-01] |
C12N 2310/353 | . . . | linked to the nucleic acid via an atom other than carbon [2013-01] |
C12N 2310/3531 | . . . . | Hydrogen [2016-11] |
C12N 2310/3533 | . . . . | Halogen [2016-11] |
C12N 2310/3535 | . . . . | Nitrogen [2016-11] |
C12N 2310/50 | . | Physical structure [2013-01] |
C12N 2310/51 | . . | in polymeric form, e.g. multimers, concatemers [2013-01] |
C12N 2310/52 | . . | branched [2013-01] |
C12N 2310/53 | . . | partially self-complementary or closed [2013-01] |
C12N 2310/531 | . . . | Stem-loop; Hairpin [2013-01] |
C12N 2310/532 | . . . | Closed or circular [2013-01] |
C12N 2310/533 | . . . | having a mismatch or nick in at least one of the strands [2013-01] |
C12N 2320/00 | Applications; Uses [2013-01] |
C12N 2320/10 | . | in screening processes [2013-01] |
C12N 2320/11 | . . | for the determination of target sites, i.e. of active nucleic acids [2013-01] |
C12N 2320/12 | . . | in functional genomics, i.e. for the determination of gene function [2013-01] |
C12N 2320/13 | . . | in a process of directed evolution, e.g. SELEX, acquiring a new function [2013-01] |
C12N 2320/30 | . | Special therapeutic applications [2013-01] |
C12N 2320/31 | . . | Combination therapy [2013-01] |
C12N 2320/32 | . . | Special delivery means, e.g. tissue-specific [2013-01] |
C12N 2320/33 | . . | Alteration of splicing [2013-01] |
C12N 2320/34 | . . | Allele or polymorphism specific uses [2013-01] |
C12N 2320/35 | . . | based on a specific dosage / administration regimen [2013-01] |
C12N 2320/50 | . | Methods for regulating/modulating their activity [2013-01] |
C12N 2320/51 | . . | modulating the chemical stability, e.g. nuclease-resistance [2013-01] |
C12N 2320/52 | . . | modulating the physical stability, e.g. GC-content [2013-01] |
C12N 2320/53 | . . | reducing unwanted side-effects [2013-01] |
C12N 2330/00 | Production [2013-01] |
C12N 2330/10 | . | naturally occurring [2013-01] |
C12N 2330/30 | . | chemically synthesised [2013-01] |
C12N 2330/31 | . . | Libraries, arrays [2013-01] |
C12N 2330/50 | . | Biochemical production, i.e. in a transformed host cell [2013-01] |
C12N 2330/51 | . . | Specially adapted vectors [2013-01] |
C12N 2500/00 | Specific components of cell culture medium [2013-01] |
C12N 2500/02 | . | Atmosphere, e.g. low oxygen conditions [2013-01] |
C12N 2500/05 | . | Inorganic components [2013-01] |
C12N 2500/10 | . . |
C12N 2500/12 | . . . | Light metals, i.e. alkali, alkaline earth, Be, Al, Mg [2013-01] |
C12N 2500/14 | . . . . | Calcium; Ca chelators; Calcitonin [2013-01] |
C12N 2500/16 | . . . . | Magnesium; Mg chelators [2013-01] |
C12N 2500/20 | . . . | Transition metals [2013-01] |
C12N 2500/22 | . . . . |
C12N 2500/24 | . . . . | Iron; Fe chelators; Transferrin [2013-01] |
C12N 2500/25 | . . . . . | Insulin-transferrin; Insulin-transferrin-selenium [2013-01] |
C12N 2500/30 | . | Organic components (metal chelators C12N 2500/10; calcitonin C12N 2500/14; transferrin C12N 2500/24) [2013-01] |
C12N 2500/32 | . . | Amino acids [2013-01] |
C12N 2500/33 | . . . | other than alpha-amino carboxylic acids, e.g. beta-amino acids, taurine [2013-01] |
C12N 2500/34 | . . | Sugars [2013-01] |
C12N 2500/35 | . . | Polyols, e.g. glycerin, inositol [2013-01] |
C12N 2500/36 | . . | Lipids [2013-01] |
C12N 2500/38 | . . | Vitamins [2013-01] |
C12N 2500/40 | . . | Nucleotides, nucleosides, bases (cyclic nucleotides C12N 2501/01, anti-neoplasic drugs C12N 2501/06) [2013-01] |
C12N 2500/42 | . . | Organic phosphate, e.g. beta glycerophosphate [2013-01] |
C12N 2500/44 | . . | Thiols, e.g. mercaptoethanol [2013-01] |
C12N 2500/46 | . . | Amines, e.g. putrescine [2013-01] |
C12N 2500/50 | . | Soluble polymers, e.g. polyethyleneglycol [PEG] [2013-01] |
C12N 2500/60 | . | Buffer, e.g. pH regulation, osmotic pressure [2013-01] |
C12N 2500/62 | . . | DMSO [2013-01] |
C12N 2500/70 | . |
C12N 2500/72 | . . | from bacteria [2013-01] |
C12N 2500/74 | . . | from fungi, e.g. yeasts [2013-01] |
C12N 2500/76 | . . | from plants [2013-01] |
C12N 2500/78 | . . | from protozoa [2013-01] |
C12N 2500/80 | . . | from animals [2013-01] |
C12N 2500/82 | . . . | from invertebrates [2013-01] |
C12N 2500/84 | . . . | from mammals [2013-01] |
C12N 2500/90 | . | Serum-free medium, which may still contain naturally-sourced components [2013-01] |
C12N 2500/92 | . . | Medium free of human- or animal-derived components [2013-01] |
C12N 2500/95 | . . | Protein-free medium and culture conditions [2013-01] |
C12N 2500/98 | . | Xeno-free medium and culture conditions [2013-01] |
| C12N 2500/99 | . | Serum-free medium [2016-05] WARNING
|
| C12N 2501/00 | Active agents used in cell culture processes, e.g. differentation [2013-01] NOTE
|
C12N 2501/01 | . | Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin [2013-01] |
C12N 2501/02 | . | Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes [2013-01] |
C12N 2501/03 | . | Compounds acting on the NO pathway, e.g. nitrososarginine [2013-01] |
C12N 2501/04 | . | Immunosuppressors, e.g. cyclosporin, tacrolimus [2013-01] |
C12N 2501/05 | . | Adjuvants [2013-01] |
C12N 2501/051 | . . | Lipid A (MPA, MPL) [2013-01] |
C12N 2501/052 | . . | Lipopolysaccharides [LPS] [2013-01] |
C12N 2501/054 | . . | Muramyle peptides [2013-01] |
C12N 2501/056 | . . | Immunostimulating oligonucleotides, e.g. CpG [2013-01] |
C12N 2501/06 | . | Anti-neoplasic drugs, anti-retroviral drugs, e.g. azacytidine, cyclophosphamide [2013-01] |
C12N 2501/065 | . | Modulators of histone acetylation [2013-01] |
C12N 2501/07 | . | Heat shock proteins [2013-01] |
C12N 2501/10 | . | Growth factors [2013-01] |
C12N 2501/105 | . . | Insulin-like growth factors [IGF] [2013-01] |
C12N 2501/11 | . . | Epidermal growth factor [EGF] [2013-01] |
C12N 2501/113 | . . | Acidic fibroblast growth factor (aFGF, FGF-1) [2013-01] |
C12N 2501/115 | . . | Basic fibroblast growth factor (bFGF, FGF-2) [2013-01] |
C12N 2501/117 | . . | Keratinocyte growth factors (KGF-1, i.e. FGF-7; KGF-2, i.e. FGF-12) [2013-01] |
C12N 2501/119 | . . | Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10 [2013-01] |
C12N 2501/12 | . . | Hepatocyte growth factor [HGF] [2013-01] |
C12N 2501/125 | . . | Stem cell factor [SCF], c-kit ligand [KL] [2013-01] |
C12N 2501/13 | . . | Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins [2013-01] |
C12N 2501/135 | . . | Platelet-derived growth factor [PDGF] [2013-01] |
C12N 2501/14 | . . | Erythropoietin [EPO] [2013-01] |
C12N 2501/145 | . . | Thrombopoietin [TPO] [2013-01] |
C12N 2501/148 | . . | Transforming growth factor alpha [TGF-a] [2013-01] |
C12N 2501/15 | . . | Transforming growth factor beta (TGF-β) [2017-08] |
C12N 2501/155 | . . | Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor [2013-01] |
C12N 2501/16 | . . | Activin; Inhibin; Mullerian inhibiting substance [2013-01] |
C12N 2501/165 | . . | Vascular endothelial growth factor [VEGF] [2013-01] |
C12N 2501/17 | . . | Angiopoietin [2013-01] |
C12N 2501/175 | . . | Cardiotrophin [2013-01] |
C12N 2501/18 | . . | Liver cell growth factor (LCGF, Gly-His-Lys) [2013-01] |
C12N 2501/185 | . . | Osteoprotegerin; Osteoclast differentiation factor (ODF, RANKL) [2013-01] |
C12N 2501/19 | . . | Growth and differentiation factors [GDF] [2013-01] |
C12N 2501/195 | . . | Heregulin, neu differentiation factor [2013-01] |
C12N 2501/20 | . | Cytokines; Chemokines [2013-01] |
C12N 2501/21 | . . | Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4 [2013-01] |
C12N 2501/22 | . . | Colony stimulating factors (G-CSF, GM-CSF) [2013-01] |
C12N 2501/23 | . . | Interleukins [IL] [2013-01] |
C12N 2501/2301 | . . . | Interleukin-1 (IL-1) [2013-01] |
C12N 2501/2302 | . . . | Interleukin-2 (IL-2) [2013-01] |
C12N 2501/2303 | . . . | Interleukin-3 (IL-3) [2013-01] |
C12N 2501/2304 | . . . | Interleukin-4 (IL-4) [2013-01] |
C12N 2501/2305 | . . . | Interleukin-5 (IL-5) [2013-01] |
C12N 2501/2306 | . . . | Interleukin-6 (IL-6) [2013-01] |
C12N 2501/2307 | . . . | Interleukin-7 (IL-7) [2013-01] |
C12N 2501/2308 | . . . | Interleukin-8 (IL-8) [2013-01] |
C12N 2501/2309 | . . . | Interleukin-9 (IL-9) [2013-01] |
C12N 2501/231 | . . . | Interleukin-10 (IL-10) [2013-01] |
C12N 2501/2311 | . . . | Interleukin-11 (IL-11) [2013-01] |
C12N 2501/2312 | . . . | Interleukin-12 (IL-12) [2013-01] |
C12N 2501/2313 | . . . | Interleukin-13 (IL-13) [2013-01] |
C12N 2501/2314 | . . . | Interleukin-14 (IL-14) [2013-01] |
C12N 2501/2315 | . . . | Interleukin-15 (IL-15) [2013-01] |
C12N 2501/2316 | . . . | Interleukin-16 (IL-16) [2013-01] |
C12N 2501/2317 | . . . | Interleukin-17 (IL-17) [2013-01] |
C12N 2501/2318 | . . . | Interleukin-18 (IL-18) [2013-01] |
C12N 2501/2319 | . . . | Interleukin-19 (IL-19) [2013-01] |
C12N 2501/232 | . . . | Interleukin-20 (IL-20) [2013-01] |
C12N 2501/2321 | . . . | Interleukin-21 (IL-21) [2013-01] |
C12N 2501/2322 | . . . | Interleukin-22 (IL-22) [2013-01] |
C12N 2501/2323 | . . . | Interleukin-23 (IL-23) [2013-01] |
C12N 2501/2324 | . . . | Interleukin-24 (IL-24) [2013-01] |
C12N 2501/2325 | . . . | Interleukin-25 (IL-25) [2013-01] |
C12N 2501/2326 | . . . | Interleukin-26 (IL-26) [2013-01] |
C12N 2501/2327 | . . . | Interleukin-27 (IL-27) [2013-01] |
C12N 2501/2328 | . . . | Interleukin-28 (IL-28) [2013-01] |
C12N 2501/2329 | . . . | Interleukin-29 (IL-29) [2013-01] |
C12N 2501/233 | . . . | Interleukin-30 (IL-30) [2013-01] |
C12N 2501/2331 | . . . | Interleukin-31 (IL-31) [2013-01] |
C12N 2501/2332 | . . . | Interleukin-32 (IL-32) [2013-01] |
C12N 2501/2333 | . . . | Interleukin-33 (IL-33) [2013-01] |
C12N 2501/2334 | . . . | Interleukin-34 (IL-34) [2013-01] |
C12N 2501/2335 | . . . | Interleukin-35 (IL-35) [2013-01] |
C12N 2501/235 | . . . | Leukemia inhibitory factor [LIF] [2013-01] |
C12N 2501/237 | . . | Oncostatin M [OSM] [2013-01] |
C12N 2501/24 | . . | Interferons [IFN] [2013-01] |
C12N 2501/25 | . . | Tumour necrosing factors [TNF] [2013-01] |
C12N 2501/26 | . . | Flt-3 ligand (CD135L, flk-2 ligand) [2013-01] |
C12N 2501/30 | . | Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin C12N 2501/85) [2013-01] |
C12N 2501/305 | . . | Growth hormone [GH], aka. somatotropin [2013-01] |
C12N 2501/31 | . . | Pituitary sex hormones, e.g. follicle-stimulating hormone [FSH], luteinising hormone [LH]; Chorionic gonadotropins [2013-01] |
C12N 2501/315 | . . | Prolactin [2013-01] |
C12N 2501/32 | . . | Angiotensins [AT], angiotensinogen [2013-01] |
C12N 2501/33 | . . | Insulin (together with transferrin C12N 2500/25; Insulin-like growth factors C12N 2501/105) [2013-01] |
C12N 2501/335 | . . | Glucagon; Glucagon-like peptide [GLP]; Exendin [2013-01] |
C12N 2501/34 | . . | Calcitonin; Calcitonin-gene related peptide [CGRO]; Amylin [2013-01] |
C12N 2501/345 | . . | Gastrin; Cholecystokinins [CCK] [2013-01] |
C12N 2501/35 | . . | Vasoactive intestinal peptide [VIP]; Pituitary adenylate cyclase activating polypeptide [PACAP] [2013-01] |
C12N 2501/355 | . . | Leptin [2013-01] |
C12N 2501/36 | . . | Somatostatin [2013-01] |
C12N 2501/365 | . . | Endothelin [2013-01] |
C12N 2501/37 | . . | Parathyroid hormone [PTH] [2013-01] |
C12N 2501/375 | . . | Thyroid stimulating hormone [TSH] [2013-01] |
C12N 2501/38 | . . | with nuclear receptors [2013-01] |
C12N 2501/385 | . . . | of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR] [2013-01] |
C12N 2501/39 | . . . | Steroid hormones [2013-01] |
C12N 2501/392 | . . . . | Sexual steroids [2013-01] |
C12N 2501/395 | . . . | Thyroid hormones [2013-01] |
C12N 2501/40 | . | Regulators of development [2013-01] |
C12N 2501/405 | . . | Cell cycle regulated proteins, e.g. cyclins, cyclin-dependant kinases [2013-01] |
C12N 2501/41 | . . | Hedgehog proteins; Cyclopamine (inhibitor) [2013-01] |
C12N 2501/415 | . . | Wnt; Frizzeled [2013-01] |
C12N 2501/42 | . . | Notch; Delta; Jagged; Serrate [2013-01] |
C12N 2501/48 | . . | Regulators of apoptosis [2013-01] |
C12N 2501/50 | . | Cell markers; Cell surface determinants [2013-01] |
C12N 2501/505 | . . | CD4; CD8 [2013-01] |
C12N 2501/51 | . . | B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand) [2013-01] |
C12N 2501/515 | . . | CD3, T-cell receptor complex [2013-01] |
C12N 2501/52 | . . | CD40, CD40-ligand (CD154) [2013-01] |
C12N 2501/53 | . . | CD2 [2013-01] |
C12N 2501/58 | . . | Adhesion molecules, e.g. ICAM, VCAM, CD18 (ligand), CD11 (ligand), CD49 (ligand) [2013-01] |
C12N 2501/585 | . . | Integrins [2013-01] |
C12N 2501/59 | . . | Lectins [2013-01] |
C12N 2501/599 | . . | with CD designations not provided for elsewhere [2013-01] |
C12N 2501/60 | . | Transcription factors [2013-01] |
C12N 2501/602 | . . | Sox-2 [2013-01] |
C12N 2501/603 | . . | Oct-3/4 [2013-01] |
C12N 2501/604 | . . | Klf-4 [2013-01] |
C12N 2501/605 | . . | Nanog [2013-01] |
C12N 2501/606 | . . | c-Myc [2013-01] |
C12N 2501/608 | . . | Lin28 [2013-01] |
C12N 2501/65 | . | MicroRNA [2017-08] |
C12N 2501/70 | . | Enzymes [2013-01] |
C12N 2501/71 | . . | Oxidoreductases (EC 1.) [2013-01] |
C12N 2501/72 | . . |
C12N 2501/724 | . . . | Glycosyltransferases (EC 2.4.) [2013-01] |
C12N 2501/727 | . . . | Kinases (EC 2.7.) [2013-01] |
C12N 2501/73 | . . | Hydrolases (EC 3.) [2013-01] |
C12N 2501/734 | . . . | Proteases (EC 3.4.) [2013-01] |
C12N 2501/80 | . | Neurotransmitters; Neurohormones [2013-01] |
C12N 2501/805 | . . | Acetylcholine [2013-01] |
C12N 2501/81 | . . | Adrenaline [2013-01] |
C12N 2501/815 | . . | Dopamine [2013-01] |
C12N 2501/82 | . . | Histamine [2013-01] |
C12N 2501/825 | . . | Serotonine (5-HT); Melatonine [2013-01] |
C12N 2501/83 | . . | Tachykinins, e.g. substance P [2013-01] |
C12N 2501/835 | . . | Neuropeptide Y [NPY]; Peptide YY [PYY] [2013-01] |
C12N 2501/84 | . . | Excitatory amino acids [2013-01] |
C12N 2501/845 | . . | Gamma amino butyric acid [GABA] [2013-01] |
C12N 2501/85 | . | Hormones derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin [2013-01] |
C12N 2501/855 | . . | Corticotropin [ACTH] [2013-01] |
C12N 2501/86 | . . | Melanocyte-stimulating hormone [MSH] [2013-01] |
C12N 2501/90 | . | Polysaccharides [2013-01] |
C12N 2501/905 | . . | Hyaluronic acid [2013-01] |
C12N 2501/91 | . . | Heparin [2013-01] |
| C12N 2501/998 | . | Proteins not provided for elsewhere [2013-01] NOTE
|
| C12N 2501/999 | . | Small molecules not provided for elsewhere [2013-01] NOTE
|
C12N 2502/00 | Coculture with; Conditioned medium produced by [2013-01] |
C12N 2502/02 | . | embryonic cells [2013-01] |
C12N 2502/025 | . . | extra-embryonic cells, e.g. amniotic epithelium, placental cells, Wharton's jelly [2013-01] |
C12N 2502/03 | . | non-embryonic pluripotent stem cells [2013-01] |
C12N 2502/04 | . | germ cells [2013-01] |
C12N 2502/07 | . | endocrine cells [2013-01] |
C12N 2502/072 | . . | adrenal cells [2013-01] |
C12N 2502/074 | . . | pinealocytes [2013-01] |
C12N 2502/076 | . . | pituitary cells [2013-01] |
C12N 2502/078 | . . | thyroid, parathyroid cells [2013-01] |
C12N 2502/08 | . | cells of the nervous system [2013-01] |
C12N 2502/081 | . . | neurons [2013-01] |
C12N 2502/083 | . . | sensory transducers [2013-01] |
C12N 2502/085 | . . | eye cells [2013-01] |
C12N 2502/086 | . . | glial cells [2013-01] |
C12N 2502/088 | . . | neural stem cells [2013-01] |
C12N 2502/09 | . | epidermal cells, skin cells, oral mucosa cells [2013-01] |
C12N 2502/091 | . . | melanocytes [2013-01] |
C12N 2502/092 | . . | hair cells [2013-01] |
C12N 2502/094 | . . | keratinocytes [2013-01] |
C12N 2502/095 | . . | mammary cells [2013-01] |
C12N 2502/097 | . . | oral mucosa cells [2013-01] |
C12N 2502/098 | . . | cells of secretory glands, e.g. parotid gland, salivary glands, sweat glands, lacrymal glands [2013-01] |
C12N 2502/11 | . | blood or immune system cells [2013-01] |
C12N 2502/1107 | . . | B cells [2013-01] |
C12N 2502/1114 | . . | T cells [2013-01] |
C12N 2502/1121 | . . | Dendritic cells [2013-01] |
C12N 2502/1128 | . . | Erythrocytes [2013-01] |
C12N 2502/1135 | . . | Granulocytes [2013-01] |
C12N 2502/1142 | . . | Osteoclasts [2013-01] |
C12N 2502/115 | . . | Platelets, megakaryocytes [2013-01] |
C12N 2502/1157 | . . | Monocytes, macrophages [2013-01] |
C12N 2502/1164 | . . | NK cells [2013-01] |
C12N 2502/1171 | . . | Haematopoietic stem cells [2013-01] |
C12N 2502/1178 | . . | Spleen cells [2013-01] |
C12N 2502/1185 | . . | Thymus cells [2013-01] |
C12N 2502/1192 | . . | Lymphatic cells [2013-01] |
C12N 2502/13 | . | connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts" [2013-01] |
C12N 2502/1305 | . . | Adipocytes [2013-01] |
C12N 2502/1311 | . . | Osteocytes, osteoblasts, odontoblasts [2013-01] |
C12N 2502/1317 | . . | Chondrocytes [2013-01] |
C12N 2502/1323 | . . | Adult fibroblasts [2013-01] |
C12N 2502/1329 | . . | Cardiomyocytes [2013-01] |
C12N 2502/1335 | . . | Skeletal muscle cells, myocytes, myoblasts, myotubes [2013-01] |
C12N 2502/1341 | . . | Tenocytes, cells from tendons and ligaments [2013-01] |
C12N 2502/1347 | . . | Smooth muscle cells [2013-01] |
C12N 2502/1352 | . . | Mesenchymal stem cells [2013-01] |
C12N 2502/1358 | . . . | Bone marrow mesenchymal stem cells (BM-MSC) [2013-01] |
C12N 2502/1364 | . . . | Dental pulp stem cells, dental follicle stem cells [2013-01] |
C12N 2502/137 | . . . | Blood-borne mesenchymal stem cells, e.g. Msc from umbilical cord blood [2013-01] |
C12N 2502/1376 | . . . | Mesenchymal stem cells from hair follicles [2013-01] |
C12N 2502/1382 | . . . | Adipose-derived stem cells [ADSC], adipose stromal stem cells [2013-01] |
C12N 2502/1388 | . . . | Mesenchymal stem cells from other natural sources [2013-01] |
C12N 2502/1394 | . . | Bone marrow stromal cells; whole marrow [2013-01] |
C12N 2502/14 | . | hepatocytes [2013-01] |
C12N 2502/22 | . | pancreatic cells [2013-01] |
C12N 2502/23 | . | Gastro-intestinal tract cells [2013-01] |
C12N 2502/24 | . | Genital tract cells, non-germinal cells from gonads [2013-01] |
C12N 2502/243 | . . | Cells of the female genital tract, non-germinal ovarian cells [2013-01] |
C12N 2502/246 | . . | Cells of the male genital tract, non-germinal testis cells [2013-01] |
C12N 2502/25 | . | Urinary tract cells, renal cells [2013-01] |
C12N 2502/253 | . . | Bladder cells [2013-01] |
C12N 2502/256 | . . | Renal cells [2013-01] |
C12N 2502/27 | . | Lung cells, respiratory tract cells [2013-01] |
C12N 2502/28 | . | Vascular endothelial cells [2013-01] |
C12N 2502/30 | . | tumour cells [2013-01] |
C12N 2502/45 | . | Artificially induced pluripotent stem cells [2013-01] |
C12N 2502/50 | . | invertebrate cells [2013-01] |
C12N 2502/70 | . | Non-animal cells [2013-01] |
| C12N 2502/99 | . | genetically modified cells [2013-01] NOTE
|
C12N 2503/00 | Use of cells in diagnostics [2013-01] |
C12N 2503/02 | . | Drug screening [2013-01] |
C12N 2503/04 | . | Screening or testing on artificial tissues [2013-01] |
C12N 2503/06 | . . | Screening or testing on artificial skin [2013-01] |
| C12N 2506/00 | Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells [2013-01] NOTE
|
C12N 2506/02 | . | from embryonic cells [2013-01] |
C12N 2506/025 | . . | from extra-embryonic cells, e.g. trophoblast, placenta [2013-01] |
C12N 2506/03 | . | from non-embryonic pluripotent stem cells [2013-01] |
C12N 2506/04 | . | from germ cells [2013-01] |
C12N 2506/07 | . | from endocrine cells [2013-01] |
C12N 2506/072 | . . | from adrenal cells [2013-01] |
C12N 2506/074 | . . | from pinealocytes [2013-01] |
C12N 2506/076 | . . | from pituitary cells [2013-01] |
C12N 2506/078 | . . | from thyroid, parathyroid cells [2013-01] |
C12N 2506/08 | . | from cells of the nervous system [2013-01] |
C12N 2506/09 | . | from epidermal cells, from skin cells, from oral mucosa cells [2013-01] |
C12N 2506/091 | . . | from melanocytes [2013-01] |
C12N 2506/092 | . . | from hair cells [2013-01] |
C12N 2506/094 | . . | from keratinocytes [2013-01] |
C12N 2506/095 | . . | from mammary cells [2013-01] |
C12N 2506/097 | . . | from oral mucosa cells [2013-01] |
C12N 2506/098 | . . | from cells of secretory glands, e.g. parotid gland, salivary glands, sweat glands, lacrymal glands [2013-01] |
C12N 2506/11 | . | from blood or immune system cells [2013-01] |
C12N 2506/115 | . . | from monocytes, from macrophages [2013-01] |
C12N 2506/13 | . | from connective tissue cells, from mesenchymal cells [2013-01] |
C12N 2506/1307 | . . | from adult fibroblasts [2013-01] |
C12N 2506/1315 | . . | from cardiomyocytes [2013-01] |
C12N 2506/1323 | . . | from skeletal muscle cells [2013-01] |
C12N 2506/133 | . . | from tenocytes [2013-01] |
C12N 2506/1338 | . . | from smooth muscle cells [2013-01] |
C12N 2506/1346 | . . | from mesenchymal stem cells [2013-01] |
C12N 2506/1353 | . . . | from bone marrow mesenchymal stem cells (BM-MSC) [2013-01] |
C12N 2506/1361 | . . . | from dental pulp or dental follicle stem cells [2013-01] |
C12N 2506/1369 | . . . | from blood-borne mesenchymal stem cells, e.g. MSC from umbilical blood [2013-01] |
C12N 2506/1376 | . . . | from mesenchymal stem cells derived from hair follicles [2013-01] |
C12N 2506/1384 | . . . | from adipose-derived stem cells [ADSC], from adipose stromal stem cells [2013-01] |
C12N 2506/1392 | . . . | from mesenchymal stem cells from other natural sources [2013-01] |
C12N 2506/14 | . | from hepatocytes [2013-01] |
C12N 2506/22 | . | from pancreatic cells [2013-01] |
C12N 2506/23 | . | from cells of the gastro-intestinal tract [2013-01] |
C12N 2506/24 | . | from cells of the genital tract, from non-germinal gonad cells [2013-01] |
C12N 2506/243 | . . | from cells of the female genital tract cells, from non-germinal ovarian cells [2013-01] |
C12N 2506/246 | . . | from cells of the male genital tract cells, from non-germinal testis cells [2013-01] |
C12N 2506/25 | . | from renal cells, from cells of the urinary tract [2013-01] |
C12N 2506/27 | . | from lung cells, from cells of the respiratory tract [2013-01] |
C12N 2506/28 | . | from vascular endothelial cells [2013-01] |
| C12N 2506/30 | . | from cancer cells, e.g. reversion of tumour cells [2013-01] NOTE
|
C12N 2506/45 | . | from artificially induced pluripotent stem cells [2013-01] |
C12N 2509/00 | Methods for the dissociation of cells, e.g. specific use of enzymes [2013-01] |
C12N 2509/10 | . | Mechanical dissociation [2013-01] |
C12N 2510/00 | Genetically modified cells [2013-01] |
C12N 2510/02 | . | Cells for production [2013-01] |
C12N 2510/04 | . | Immortalised cells [2013-01] |
C12N 2511/00 | Cells for large scale production [2013-01] |
C12N 2513/00 | 3D culture [2013-01] |
C12N 2517/00 | Cells related to new breeds of animals [2013-01] |
C12N 2517/02 | . | Cells from transgenic animals [2013-01] |
C12N 2517/04 | . | Cells produced using nuclear transfer [2013-01] |
C12N 2517/10 | . | Conditioning of cells for in vitro fecondation or nuclear transfer [2013-01] |
C12N 2521/00 | Culture process characterised by the use of hydrostatic pressure, flow or shear forces [2013-01] |
C12N 2521/10 | . | Sound, e.g. ultrasounds [2013-01] |
C12N 2523/00 | Culture process characterised by temperature [2013-01] |
C12N 2525/00 | Culture process characterised by gravity, e.g. microgravity [2013-01] |
C12N 2527/00 | Culture process characterised by the use of mechanical forces, e.g. strain, vibration [2013-01] |
C12N 2529/00 | Culture process characterised by the use of electromagnetic stimulation [2013-01] |
C12N 2529/10 | . | Stimulation by light [2013-01] |
C12N 2531/00 | Microcarriers [2013-01] |
C12N 2533/00 | Supports or coatings for cell culture, characterised by material [2013-01] |
C12N 2533/10 | . | Mineral substrates [2013-01] |
C12N 2533/12 | . . | Glass [2013-01] |
C12N 2533/14 | . . | Ceramic [2013-01] |
C12N 2533/18 | . . | Calcium salts, e.g. apatite, Mineral components from bones, teeth, shells [2013-01] |
C12N 2533/20 | . | Small organic molecules [2013-01] |
C12N 2533/30 | . |
C12N 2533/32 | . . | Polylysine, polyornithine [2013-01] |
C12N 2533/40 | . . | Polyhydroxyacids, e.g. polymers of glycolic or lactic acid (PGA, PLA, PLGA); Bioresorbable polymers [2013-01] |
C12N 2533/50 | . | Proteins [2013-01] |
C12N 2533/52 | . . | Fibronectin; Laminin [2013-01] |
C12N 2533/54 | . . | Collagen; Gelatin [2013-01] |
C12N 2533/56 | . . | Fibrin; Thrombin [2013-01] |
C12N 2533/70 | . | Polysaccharides [2013-01] |
C12N 2533/72 | . . | Chitin, chitosan [2013-01] |
C12N 2533/74 | . . | Alginate [2013-01] |
C12N 2533/76 | . . | Agarose, agar-agar [2013-01] |
C12N 2533/78 | . . | Cellulose [2013-01] |
C12N 2533/80 | . . | Hyaluronan [2013-01] |
C12N 2533/90 | . | Substrates of biological origin, e.g. extracellular matrix, decellularised tissue [2013-01] |
C12N 2533/92 | . . | Amnion; Decellularised dermis or mucosa [2013-01] |
C12N 2535/00 | Supports or coatings for cell culture characterised by topography [2013-01] |
C12N 2535/10 | . | Patterned coating [2013-01] |
C12N 2537/00 | Supports and/or coatings for cell culture characterised by physical or chemical treatment [2013-01] |
C12N 2537/10 | . | Cross-linking [2013-01] |
C12N 2539/00 | Supports and/or coatings for cell culture characterised by properties [2013-01] |
C12N 2539/10 | . | Coating allowing for selective detachment of cells, e.g. thermoreactive coating [2013-01] |
Viruses [2022-02] |
C12N 2710/00 | dsDNA viruses [2022-02] |
C12N 2710/00011 | . | Details [2022-02] |
C12N 2710/00021 | . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2710/00022 | . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2710/00023 | . . | Virus like particles [VLP] [2013-01] |
C12N 2710/00031 | . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2710/00032 | . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2710/00033 | . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2710/00034 | . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2710/00041 | . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2710/00042 | . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2710/00043 | . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2710/00044 | . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2710/00045 | . . . | Special targeting system for viral vectors [2013-01] |
C12N 2710/00051 | . . | Methods of production or purification of viral material [2013-01] |
C12N 2710/00052 | . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2710/00061 | . . | Methods of inactivation or attenuation [2013-01] |
C12N 2710/00062 | . . . | by genetic engineering [2013-01] |
C12N 2710/00063 | . . . | by chemical treatment [2013-01] |
C12N 2710/00064 | . . . | by serial passage [2013-01] |
C12N 2710/00071 | . . | Demonstrated in vivo effect [2013-01] |
C12N 2710/00088 | . . | for redistribution [2022-02] |
C12N 2710/10011 | . . | Adenoviridae [2013-01] |
C12N 2710/10021 | . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2710/10022 | . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2710/10023 | . . . | Virus like particles [VLP] [2013-01] |
C12N 2710/10031 | . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2710/10032 | . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2710/10033 | . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2710/10034 | . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2710/10041 | . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2710/10042 | . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2710/10043 | . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2710/10044 | . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2710/10045 | . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2710/10051 | . . . | Methods of production or purification of viral material [2013-01] |
C12N 2710/10052 | . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2710/10061 | . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2710/10062 | . . . . | by genetic engineering [2013-01] |
C12N 2710/10063 | . . . . | by chemical treatment [2013-01] |
C12N 2710/10064 | . . . . | by serial passage [2013-01] |
C12N 2710/10071 | . . . | Demonstrated in vivo effect [2013-01] |
C12N 2710/10088 | . . . | for redistribution [2022-02] |
C12N 2710/10111 | . . . | Atadenovirus, e.g. ovine adenovirus D [2013-01] |
C12N 2710/10121 | . . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2710/10122 | . . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2710/10123 | . . . . | Virus like particles [VLP] [2013-01] |
C12N 2710/10131 | . . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2710/10132 | . . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2710/10133 | . . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2710/10134 | . . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2710/10141 | . . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2710/10142 | . . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2710/10143 | . . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2710/10144 | . . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2710/10145 | . . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2710/10151 | . . . . | Methods of production or purification of viral material [2013-01] |
C12N 2710/10152 | . . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2710/10161 | . . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2710/10162 | . . . . . | by genetic engineering [2013-01] |
C12N 2710/10163 | . . . . . | by chemical treatment [2013-01] |
C12N 2710/10164 | . . . . . | by serial passage [2013-01] |
C12N 2710/10171 | . . . . | Demonstrated in vivo effect [2013-01] |
C12N 2710/10188 | . . . . | for redistribution [2022-02] |
C12N 2710/10211 | . . . | Aviadenovirus, e.g. fowl adenovirus A [2013-01] |
C12N 2710/10221 | . . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2710/10222 | . . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2710/10223 | . . . . | Virus like particles [VLP] [2013-01] |
C12N 2710/10231 | . . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2710/10232 | . . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2710/10233 | . . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2710/10234 | . . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2710/10241 | . . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2710/10242 | . . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2710/10243 | . . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2710/10244 | . . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2710/10245 | . . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2710/10251 | . . . . | Methods of production or purification of viral material [2013-01] |
C12N 2710/10252 | . . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2710/10261 | . . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2710/10262 | . . . . . | by genetic engineering [2013-01] |
C12N 2710/10263 | . . . . . | by chemical treatment [2013-01] |
C12N 2710/10264 | . . . . . | by serial passage [2013-01] |
C12N 2710/10271 | . . . . | Demonstrated in vivo effect [2013-01] |
C12N 2710/10288 | . . . . | for redistribution [2022-02] |
C12N 2710/10311 | . . . | Mastadenovirus, e.g. human or simian adenoviruses [2013-01] |
C12N 2710/10321 | . . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2710/10322 | . . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2710/10323 | . . . . | Virus like particles [VLP] [2013-01] |
C12N 2710/10331 | . . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2710/10332 | . . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2710/10333 | . . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2710/10334 | . . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2710/10341 | . . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2710/10342 | . . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2710/10343 | . . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2710/10344 | . . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2710/10345 | . . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2710/10351 | . . . . | Methods of production or purification of viral material [2013-01] |
C12N 2710/10352 | . . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2710/10361 | . . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2710/10362 | . . . . . | by genetic engineering [2013-01] |
C12N 2710/10363 | . . . . . | by chemical treatment [2013-01] |
C12N 2710/10364 | . . . . . | by serial passage [2013-01] |
C12N 2710/10371 | . . . . | Demonstrated in vivo effect [2013-01] |
C12N 2710/10388 | . . . . | for redistribution [2022-02] |
C12N 2710/12011 | . . | Asfarviridae [2013-01] |
C12N 2710/12021 | . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2710/12022 | . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2710/12023 | . . . | Virus like particles [VLP] [2013-01] |
C12N 2710/12031 | . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2710/12032 | . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2710/12033 | . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2710/12034 | . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2710/12041 | . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2710/12042 | . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2710/12043 | . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2710/12044 | . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2710/12045 | . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2710/12051 | . . . | Methods of production or purification of viral material [2013-01] |
C12N 2710/12052 | . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2710/12061 | . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2710/12062 | . . . . | by genetic engineering [2013-01] |
C12N 2710/12063 | . . . . | by chemical treatment [2013-01] |
C12N 2710/12064 | . . . . | by serial passage [2013-01] |
C12N 2710/12071 | . . . | Demonstrated in vivo effect [2013-01] |
C12N 2710/12088 | . . . | for redistribution [2022-02] |
C12N 2710/14011 | . . | Baculoviridae [2013-01] |
C12N 2710/14021 | . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2710/14022 | . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2710/14023 | . . . | Virus like particles [VLP] [2013-01] |
C12N 2710/14031 | . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2710/14032 | . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2710/14033 | . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2710/14034 | . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2710/14041 | . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2710/14042 | . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2710/14043 | . . . . | viral genome or elements thereof as genetic vectore [2013-01] |
C12N 2710/14044 | . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2710/14045 | . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2710/14051 | . . . | Methods of production or purification of viral material [2013-01] |
C12N 2710/14052 | . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2710/14061 | . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2710/14062 | . . . . | by genetic engineering [2013-01] |
C12N 2710/14063 | . . . . | by chemical treatment [2013-01] |
C12N 2710/14064 | . . . . | by serial passage [2013-01] |
C12N 2710/14071 | . . . | Demonstrated in vivo effect [2013-01] |
C12N 2710/14088 | . . . | for redistribution [2022-02] |
C12N 2710/14111 | . . . | Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus [2013-01] |
C12N 2710/14121 | . . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2710/14122 | . . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2710/14123 | . . . . | Virus like particles [VLP] [2013-01] |
C12N 2710/14131 | . . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2710/14132 | . . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2710/14133 | . . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2710/14134 | . . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2710/14141 | . . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2710/14142 | . . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2710/14143 | . . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2710/14144 | . . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2710/14145 | . . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2710/14151 | . . . . | Methods of production or purification of viral material [2013-01] |
C12N 2710/14152 | . . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2710/14161 | . . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2710/14162 | . . . . . | by genetic engineering [2013-01] |
C12N 2710/14163 | . . . . . | by chemical treatment [2013-01] |
C12N 2710/14164 | . . . . . | by serial passage [2013-01] |
C12N 2710/14171 | . . . . | Demonstrated in vivo effect [2013-01] |
C12N 2710/14188 | . . . . | For redistribution [2013-01] |
C12N 2710/16011 | . . | Herpesviridae [2013-01] |
C12N 2710/16021 | . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2710/16022 | . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2710/16023 | . . . | Virus like particles [VLP] [2013-01] |
C12N 2710/16031 | . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2710/16032 | . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2710/16033 | . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2710/16034 | . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2710/16041 | . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2710/16042 | . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2710/16043 | . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2710/16044 | . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2710/16045 | . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2710/16051 | . . . | Methods of production or purification of viral material [2013-01] |
C12N 2710/16052 | . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2710/16061 | . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2710/16062 | . . . . | by genetic engineering [2013-01] |
C12N 2710/16063 | . . . . | by chemical treatment [2013-01] |
C12N 2710/16064 | . . . . | by serial passage [2013-01] |
C12N 2710/16071 | . . . | Demonstrated in vivo effect [2013-01] |
C12N 2710/16088 | . . . | for redistribution [2022-02] |
C12N 2710/16111 | . . . | Cytomegalovirus, e.g. human herpesvirus 5 [2013-01] |
C12N 2710/16121 | . . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2710/16122 | . . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2710/16123 | . . . . | Virus like particles [VLP] [2013-01] |
C12N 2710/16131 | . . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2710/16132 | . . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2710/16133 | . . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2710/16134 | . . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2710/16141 | . . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2710/16142 | . . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2710/16143 | . . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2710/16144 | . . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2710/16145 | . . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2710/16151 | . . . . | Methods of production or purification of viral material [2013-01] |
C12N 2710/16152 | . . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2710/16161 | . . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2710/16162 | . . . . . | by genetic engineering [2013-01] |
C12N 2710/16163 | . . . . . | by chemical treatment [2013-01] |
C12N 2710/16164 | . . . . . | by serial passage [2013-01] |
C12N 2710/16171 | . . . . | Demonstrated in vivo effect [2013-01] |
C12N 2710/16188 | . . . . | for redistribution [2022-02] |
C12N 2710/16211 | . . . | Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus [2013-01] |
C12N 2710/16221 | . . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2017-02] |
C12N 2710/16222 | . . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2710/16223 | . . . . | Virus like particles [VLP] [2013-01] |
C12N 2710/16231 | . . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2710/16232 | . . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2710/16233 | . . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2710/16234 | . . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2710/16241 | . . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2710/16242 | . . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2710/16243 | . . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2710/16244 | . . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2710/16245 | . . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2710/16251 | . . . . | Methods of production or purification of viral material [2013-01] |
C12N 2710/16252 | . . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2710/16261 | . . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2710/16262 | . . . . . | by genetic engineering [2013-01] |
C12N 2710/16263 | . . . . . | by chemical treatment [2013-01] |
C12N 2710/16264 | . . . . . | by serial passage [2013-01] |
C12N 2710/16271 | . . . . | Demonstrated in vivo effect [2013-01] |
C12N 2710/16288 | . . . . | for redistribution [2022-02] |
C12N 2710/16311 | . . . | Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV [2013-01] |
C12N 2710/16321 | . . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2710/16322 | . . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2710/16323 | . . . . | Virus like particles [VLP] [2013-01] |
C12N 2710/16331 | . . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2710/16332 | . . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2710/16333 | . . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2710/16334 | . . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2710/16341 | . . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2710/16342 | . . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2710/16343 | . . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2710/16344 | . . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2710/16345 | . . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2710/16351 | . . . . | Methods of production or purification of viral material [2013-01] |
C12N 2710/16352 | . . . . . | relating to complementin g cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2710/16361 | . . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2710/16362 | . . . . . | by genetic engineering [2013-01] |
C12N 2710/16363 | . . . . . | by chemical treatment [2013-01] |
C12N 2710/16364 | . . . . . | by serial passage [2013-01] |
C12N 2710/16371 | . . . . | Demonstrated in vivo effect [2013-01] |
C12N 2710/16388 | . . . . | for redistribution [2022-02] |
C12N 2710/16411 | . . . | Rhadinovirus, e.g. human herpesvirus 8 [2013-01] |
C12N 2710/16421 | . . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2710/16422 | . . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2710/16423 | . . . . | Virus like particles [VLP] [2013-01] |
C12N 2710/16431 | . . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2710/16432 | . . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2710/16433 | . . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2710/16434 | . . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2710/16441 | . . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2710/16442 | . . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2710/16443 | . . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2710/16444 | . . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2710/16445 | . . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2710/16451 | . . . . | Methods of production or purification of viral material [2013-01] |
C12N 2710/16452 | . . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2710/16461 | . . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2710/16462 | . . . . . | by genetic engineering [2013-01] |
C12N 2710/16463 | . . . . . | by chemical treatment [2013-01] |
C12N 2710/16464 | . . . . . | by serial passage [2013-01] |
C12N 2710/16471 | . . . . | Demonstrated in vivo effect [2013-01] |
C12N 2710/16488 | . . . . | for redistribution [2022-02] |
C12N 2710/16511 | . . . | Roseolovirus, e.g. human herpesvirus 6, 7 [2013-01] |
C12N 2710/16521 | . . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2710/16522 | . . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2710/16523 | . . . . | Virus like particles [VLP] [2013-01] |
C12N 2710/16531 | . . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2710/16532 | . . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2710/16533 | . . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2710/16534 | . . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral [2013-01] |
C12N 2710/16541 | . . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2710/16542 | . . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2710/16543 | . . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2710/16544 | . . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2710/16545 | . . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2710/16551 | . . . . | Methods of production or purification of viral material [2013-01] |
C12N 2710/16552 | . . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2710/16561 | . . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2710/16562 | . . . . . | by genetic engineering [2013-01] |
C12N 2710/16563 | . . . . . | by chemical treatment [2013-01] |
C12N 2710/16564 | . . . . . | by serial passage [2013-01] |
C12N 2710/16571 | . . . . | Demonstrated in vivo effect [2013-01] |
C12N 2710/16588 | . . . . | for redistribution [2022-02] |
C12N 2710/16611 | . . . | Simplexvirus, e.g. human herpesvirus 1, 2 [2013-01] |
C12N 2710/16621 | . . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2710/16622 | . . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2710/16623 | . . . . | Virus like particles [VLP] [2013-01] |
C12N 2710/16631 | . . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2710/16632 | . . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2710/16633 | . . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2710/16634 | . . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2710/16641 | . . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2710/16642 | . . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2710/16643 | . . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2710/16644 | . . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2710/16645 | . . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2710/16651 | . . . . | Methods of production or purification of viral material [2013-01] |
C12N 2710/16652 | . . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2710/16661 | . . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2710/16662 | . . . . . | by genetic engineering [2013-01] |
C12N 2710/16663 | . . . . . | by chemical treatment [2013-01] |
C12N 2710/16664 | . . . . . | by serial passage [2013-01] |
C12N 2710/16671 | . . . . | Demonstrated in vivo effect [2013-01] |
C12N 2710/16688 | . . . . | for redistribution [2022-02] |
C12N 2710/16711 | . . . | Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies [2013-01] |
C12N 2710/16721 | . . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2710/16722 | . . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2710/16723 | . . . . | Virus like particles [VLP] [2013-01] |
C12N 2710/16731 | . . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2710/16732 | . . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2710/16733 | . . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2710/16734 | . . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2710/16741 | . . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2710/16742 | . . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2710/16743 | . . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2710/16744 | . . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2710/16745 | . . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2710/16751 | . . . . | Methods of production or purification of viral material [2013-01] |
C12N 2710/16752 | . . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2710/16761 | . . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2710/16762 | . . . . . | by genetic engineering [2013-01] |
C12N 2710/16763 | . . . . . | by chemical treatment [2013-01] |
C12N 2710/16764 | . . . . . | by serial passage [2013-01] |
C12N 2710/16771 | . . . . | Demonstrated in vivo effect [2013-01] |
C12N 2710/16788 | . . . . | for redistribution [2022-02] |
C12N 2710/18011 | . . | Nimaviridae [2013-01] |
C12N 2710/18021 | . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2710/18022 | . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2710/18023 | . . . | Virus like particles [VLP] [2013-01] |
C12N 2710/18031 | . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2710/18032 | . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2710/18033 | . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2710/18034 | . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2710/18041 | . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2710/18042 | . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2710/18043 | . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2710/18044 | . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2710/18045 | . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2710/18051 | . . . | Methods of production or purification of viral material [2013-01] |
C12N 2710/18052 | . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2710/18061 | . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2710/18062 | . . . . | by genetic engineering [2013-01] |
C12N 2710/18063 | . . . . | by chemical treatment [2013-01] |
C12N 2710/18064 | . . . . | by serial passage [2013-01] |
C12N 2710/18071 | . . . | Demonstrated in vivo effect [2013-01] |
C12N 2710/18088 | . . . | for redistribution [2022-02] |
C12N 2710/20011 | . . | Papillomaviridae [2013-01] |
C12N 2710/20021 | . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2710/20022 | . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2710/20023 | . . . | Virus like particles [VLP] [2013-01] |
C12N 2710/20031 | . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2710/20032 | . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2710/20033 | . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2710/20034 | . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2710/20041 | . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2710/20042 | . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2710/20043 | . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2710/20044 | . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2710/20045 | . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2710/20051 | . . . | Methods of production or purification of viral material [2013-01] |
C12N 2710/20052 | . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2710/20061 | . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2710/20062 | . . . . | by genetic engineering [2013-01] |
C12N 2710/20063 | . . . . | by chemical treatment [2013-01] |
C12N 2710/20064 | . . . . | by serial passage [2013-01] |
C12N 2710/20071 | . . . | Demonstrated in vivo effect [2013-01] |
C12N 2710/20088 | . . . | for redistribution [2022-02] |
C12N 2710/22011 | . . | Polyomaviridae, e.g. polyoma, SV40, JC [2013-01] |
C12N 2710/22021 | . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2710/22022 | . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2710/22023 | . . . | Virus like particles [VLP] [2013-01] |
C12N 2710/22031 | . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2710/22032 | . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2710/22033 | . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2710/22034 | . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2710/22041 | . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2710/22042 | . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2710/22043 | . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2710/22044 | . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2710/22045 | . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2710/22051 | . . . | Methods of production or purification of viral material [2013-01] |
C12N 2710/22052 | . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2710/22061 | . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2710/22062 | . . . . | by genetic engineering [2013-01] |
C12N 2710/22063 | . . . . | by chemical treatment [2013-01] |
C12N 2710/22064 | . . . . | by serial passage [2013-01] |
C12N 2710/22071 | . . . | Demonstrated in vivo effect [2013-01] |
C12N 2710/22088 | . . . | for redistribution [2022-02] |
C12N 2710/24011 | . . | Poxviridae [2013-01] |
C12N 2710/24021 | . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2710/24022 | . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2710/24023 | . . . | Virus like particles [VLP] [2013-01] |
C12N 2710/24031 | . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2710/24032 | . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2710/24033 | . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2710/24034 | . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2710/24041 | . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2710/24042 | . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2710/24043 | . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2710/24044 | . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2710/24045 | . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2710/24051 | . . . | Methods of production or purification of viral material [2013-01] |
C12N 2710/24052 | . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2710/24061 | . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2710/24062 | . . . . | by genetic engineering [2013-01] |
C12N 2710/24063 | . . . . | by chemical treatment [2013-01] |
C12N 2710/24064 | . . . . | by serial passage [2013-01] |
C12N 2710/24071 | . . . | Demonstrated in vivo effect [2013-01] |
C12N 2710/24088 | . . . | for redistribution [2022-02] |
C12N 2710/24111 | . . . | Orthopoxvirus, e.g. vaccinia virus, variola [2013-01] |
C12N 2710/24121 | . . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2710/24122 | . . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2710/24123 | . . . . | Virus like particles [VLP] [2013-01] |
C12N 2710/24131 | . . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2710/24132 | . . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2710/24133 | . . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2710/24134 | . . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2710/24141 | . . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2710/24142 | . . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2710/24143 | . . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2710/24144 | . . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2710/24145 | . . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2710/24151 | . . . . | Methods of production or purification of viral material [2013-01] |
C12N 2710/24152 | . . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2710/24161 | . . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2710/24162 | . . . . . | by genetic engineering [2013-01] |
C12N 2710/24163 | . . . . . | by chemical treatment [2013-01] |
C12N 2710/24164 | . . . . . | by serial passage [2013-01] |
C12N 2710/24171 | . . . . | Demonstrated in vivo effect [2013-01] |
C12N 2710/24188 | . . . . | for redistribution [2022-02] |
C12N 2710/24211 | . . . | Parapoxvirus, e.g. Orf virus [2013-01] |
C12N 2710/24221 | . . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2710/24222 | . . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2710/24223 | . . . . | Virus like particles [VLP] [2013-01] |
C12N 2710/24231 | . . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2710/24232 | . . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2710/24233 | . . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2710/24234 | . . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2710/24241 | . . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2710/24242 | . . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2710/24243 | . . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2710/24244 | . . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2710/24245 | . . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2710/24251 | . . . . | Methods of production or purification of viral material [2013-01] |
C12N 2710/24252 | . . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2710/24261 | . . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2710/24262 | . . . . . | by genetic engineering [2013-01] |
C12N 2710/24263 | . . . . . | by chemical treatment [2013-01] |
C12N 2710/24264 | . . . . . | by serial passage [2013-01] |
C12N 2710/24271 | . . . . | Demonstrated in vivo effect [2013-01] |
C12N 2710/24288 | . . . . | for redistribution [2022-02] |
C12N 2720/00 | dsRNA viruses [2022-02] |
C12N 2720/00011 | . | Details [2022-02] |
C12N 2720/00021 | . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2720/00022 | . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2720/00023 | . . | Virus like particles [VLP] [2013-01] |
C12N 2720/00031 | . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2720/00032 | . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2720/00033 | . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2720/00034 | . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2720/00041 | . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2720/00042 | . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2720/00043 | . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2720/00044 | . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2720/00045 | . . . | Special targeting system for viral vectors [2013-01] |
C12N 2720/00051 | . . | Methods of production or purification of viral material [2013-01] |
C12N 2720/00052 | . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2720/00061 | . . | Methods of inactivation or attenuation [2013-01] |
C12N 2720/00062 | . . . | by genetic engineering [2013-01] |
C12N 2720/00063 | . . . | by chemical treatment [2013-01] |
C12N 2720/00064 | . . . | by serial passage [2013-01] |
C12N 2720/00071 | . . | Demonstrated in vivo effect [2013-01] |
C12N 2720/00088 | . . | for redistribution [2022-02] |
C12N 2720/10011 | . . | Birnaviridae [2013-01] |
C12N 2720/10021 | . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2720/10022 | . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2720/10023 | . . . | Virus like particles [VLP] [2013-01] |
C12N 2720/10031 | . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2720/10032 | . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2720/10033 | . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2720/10034 | . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2720/10041 | . . . | Use of virus, viral particle or viral elements as a vector [2020-01] |
C12N 2720/10042 | . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2720/10043 | . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2720/10044 | . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2720/10045 | . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2720/10051 | . . . | Methods of production or purification of viral material [2013-01] |
C12N 2720/10052 | . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2720/10061 | . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2720/10062 | . . . . | by genetic engineering [2013-01] |
C12N 2720/10063 | . . . . | by chemical treatment [2013-01] |
C12N 2720/10064 | . . . . | by serial passage [2013-01] |
C12N 2720/10071 | . . . | Demonstrated in vivo effect [2013-01] |
C12N 2720/10088 | . . . | for redistribution [2022-02] |
C12N 2720/12011 | . . | Reoviridae [2013-01] |
C12N 2720/12021 | . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2720/12022 | . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2720/12023 | . . . | Virus like particles [VLP] [2013-01] |
C12N 2720/12031 | . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2720/12032 | . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2720/12033 | . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2720/12034 | . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2720/12041 | . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2720/12042 | . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2720/12043 | . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2720/12044 | . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2720/12045 | . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2720/12051 | . . . | Methods of production or purification of viral material [2013-01] |
C12N 2720/12052 | . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2720/12061 | . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2720/12062 | . . . . | by genetic engineering [2013-01] |
C12N 2720/12063 | . . . . | by chemical treatment [2013-01] |
C12N 2720/12064 | . . . . | by serial passage [2013-01] |
C12N 2720/12071 | . . . | Demonstrated in vivo effect [2013-01] |
C12N 2720/12088 | . . . | for redistribution [2022-02] |
C12N 2720/12111 | . . . | Orbivirus, e.g. bluetongue virus [2013-01] |
C12N 2720/12121 | . . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2720/12122 | . . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2720/12123 | . . . . | Virus like particles [VLP] [2013-01] |
C12N 2720/12131 | . . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2720/12132 | . . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2720/12133 | . . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2720/12134 | . . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2720/12141 | . . . . | Use of virus, viral particle or viral elements as a vector [2020-01] |
C12N 2720/12142 | . . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2720/12143 | . . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2720/12144 | . . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2720/12145 | . . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2720/12151 | . . . . | Methods of production or purification of viral material [2013-01] |
C12N 2720/12152 | . . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2720/12161 | . . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2720/12162 | . . . . . | by genetic engineering [2013-01] |
C12N 2720/12163 | . . . . . | by chemical treatment [2013-01] |
C12N 2720/12164 | . . . . . | by serial passage [2013-01] |
C12N 2720/12171 | . . . . | Demonstrated in vivo effect [2013-01] |
C12N 2720/12188 | . . . . | for redistribution [2022-02] |
C12N 2720/12211 | . . . | Orthoreovirus, e.g. mammalian orthoreovirus [2013-01] |
C12N 2720/12221 | . . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2720/12222 | . . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2720/12223 | . . . . | Virus like particles [VLP] [2013-01] |
C12N 2720/12231 | . . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2720/12232 | . . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2720/12233 | . . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2720/12234 | . . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2720/12241 | . . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2720/12242 | . . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2720/12243 | . . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2720/12244 | . . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2720/12245 | . . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2720/12251 | . . . . | Methods of production or purification of viral material [2013-01] |
C12N 2720/12252 | . . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2720/12261 | . . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2720/12262 | . . . . . | by genetic engineering [2013-01] |
C12N 2720/12263 | . . . . . | by chemical treatment [2013-01] |
C12N 2720/12264 | . . . . . | by serial passage [2013-01] |
C12N 2720/12271 | . . . . | Demonstrated in vivo effect [2013-01] |
C12N 2720/12288 | . . . . | for redistribution [2022-02] |
C12N 2720/12311 | . . . | Rotavirus, e.g. rotavirus A [2013-01] |
C12N 2720/12321 | . . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2720/12322 | . . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2720/12323 | . . . . | Virus like particles [VLP] [2013-01] |
C12N 2720/12331 | . . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2720/12332 | . . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2720/12333 | . . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2720/12334 | . . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2720/12341 | . . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2720/12342 | . . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2720/12343 | . . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2720/12344 | . . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2720/12345 | . . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2720/12351 | . . . . | Methods of production or purification of viral material [2013-01] |
C12N 2720/12352 | . . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2720/12361 | . . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2720/12362 | . . . . . | by genetic engineering [2013-01] |
C12N 2720/12363 | . . . . . | by chemical treatment [2013-01] |
C12N 2720/12364 | . . . . . | by serial passage [2013-01] |
C12N 2720/12371 | . . . . | Demonstrated in vivo effect [2013-01] |
C12N 2720/12388 | . . . . | for redistribution [2022-02] |
C12N 2730/00 | Reverse transcribing DNA viruses [2022-02] |
C12N 2730/00011 | . | Details [2022-02] |
C12N 2730/00021 | . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2730/00022 | . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2730/00023 | . . | Virus like particles [VLP] [2013-01] |
C12N 2730/00031 | . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2730/00032 | . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2730/00033 | . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2730/00034 | . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2730/00041 | . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2730/00042 | . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2730/00043 | . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2730/00044 | . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2730/00045 | . . . | Special targeting system for viral vectors [2013-01] |
C12N 2730/00051 | . . | Methods of production or purification of viral material [2013-01] |
C12N 2730/00052 | . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2730/00061 | . . | Methods of inactivation or attenuation [2013-01] |
C12N 2730/00062 | . . . | by genetic engineering [2013-01] |
C12N 2730/00063 | . . . | by chemical treatment [2013-01] |
C12N 2730/00064 | . . . | by serial passage [2013-01] |
C12N 2730/00071 | . . | Demonstrated in vivo effect [2013-01] |
C12N 2730/00088 | . . | for redistribution [2022-02] |
C12N 2730/10011 | . . | Hepadnaviridae [2013-01] |
C12N 2730/10021 | . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2730/10022 | . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2730/10023 | . . . | Virus like particles [VLP] [2013-01] |
C12N 2730/10031 | . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2730/10032 | . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2730/10033 | . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2730/10034 | . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2730/10041 | . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2730/10042 | . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2730/10043 | . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2730/10044 | . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2730/10045 | . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2730/10051 | . . . | Methods of production or purification of viral material [2013-01] |
C12N 2730/10052 | . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2730/10061 | . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2730/10062 | . . . . | by genetic engineering [2013-01] |
C12N 2730/10063 | . . . . | by chemical treatment [2013-01] |
C12N 2730/10064 | . . . . | by serial passage [2013-01] |
C12N 2730/10071 | . . . | Demonstrated in vivo effect [2013-01] |
C12N 2730/10088 | . . . | for redistribution [2022-02] |
C12N 2730/10111 | . . . | Orthohepadnavirus, e.g. hepatitis B virus [2013-01] |
C12N 2730/10121 | . . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2730/10122 | . . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2730/10123 | . . . . | Virus like particles [VLP] [2013-01] |
C12N 2730/10131 | . . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2730/10132 | . . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2730/10133 | . . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2730/10134 | . . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2730/10141 | . . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2730/10142 | . . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2730/10143 | . . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2730/10144 | . . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2730/10145 | . . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2730/10151 | . . . . | Methods of production or purification of viral material [2013-01] |
C12N 2730/10152 | . . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2730/10161 | . . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2730/10162 | . . . . . | by genetic engineering [2013-01] |
C12N 2730/10163 | . . . . . | by chemical treatment [2013-01] |
C12N 2730/10164 | . . . . . | by serial passage [2013-01] |
C12N 2730/10171 | . . . . | Demonstrated in vivo effect [2013-01] |
C12N 2730/10188 | . . . . | for redistribution [2022-02] |
C12N 2740/00 | Reverse transcribing RNA viruses [2022-02] |
C12N 2740/00011 | . | Details [2022-02] |
C12N 2740/00021 | . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2740/00022 | . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2740/00023 | . . | Virus like particles [VLP] [2013-01] |
C12N 2740/00031 | . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2740/00032 | . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2740/00033 | . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2740/00034 | . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2740/00041 | . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2740/00042 | . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2740/00043 | . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2740/00044 | . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2740/00045 | . . . | Special targeting system for viral vectors [2013-01] |
C12N 2740/00051 | . . | Methods of production or purification of viral material [2013-01] |
C12N 2740/00052 | . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2740/00061 | . . | Methods of inactivation or attenuation [2013-01] |
C12N 2740/00062 | . . . | by genetic engineering [2013-01] |
C12N 2740/00063 | . . . | by chemical treatment [2013-01] |
C12N 2740/00064 | . . . | by serial passage [2013-01] |
C12N 2740/00071 | . . | Demonstrated in vivo effect [2013-01] |
C12N 2740/00088 | . . | for redistribution [2022-02] |
C12N 2740/10011 | . . | Retroviridae [2013-01] |
C12N 2740/10021 | . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2740/10022 | . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2740/10023 | . . . | Virus like particles [VLP] [2013-01] |
C12N 2740/10031 | . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2740/10032 | . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2740/10033 | . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2740/10034 | . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2740/10041 | . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2740/10042 | . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2740/10043 | . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2740/10044 | . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2740/10045 | . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2740/10051 | . . . | Methods of production or purification of viral material [2013-01] |
C12N 2740/10052 | . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2740/10061 | . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2740/10062 | . . . . | by genetic engineering [2013-01] |
C12N 2740/10063 | . . . . | by chemical treatment [2013-01] |
C12N 2740/10064 | . . . . | by serial passage [2013-01] |
C12N 2740/10071 | . . . | Demonstrated in vivo effect [2013-01] |
C12N 2740/10088 | . . . | for redistribution [2022-02] |
C12N 2740/11011 | . . . | Alpharetrovirus, e.g. avian leucosis virus [2013-01] |
C12N 2740/11021 | . . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2740/11022 | . . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2740/11023 | . . . . | Virus like particles [VLP] [2013-01] |
C12N 2740/11031 | . . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2740/11032 | . . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2740/11033 | . . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2740/11034 | . . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2740/11041 | . . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2740/11042 | . . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2740/11043 | . . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2740/11044 | . . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2740/11045 | . . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2740/11051 | . . . . | Methods of production or purification of viral material [2013-01] |
C12N 2740/11052 | . . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2740/11061 | . . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2740/11062 | . . . . . | by genetic engineering [2013-01] |
C12N 2740/11063 | . . . . . | by chemical treatment [2013-01] |
C12N 2740/11064 | . . . . . | by serial passage [2013-01] |
C12N 2740/11071 | . . . . | Demonstrated in vivo effect [2013-01] |
C12N 2740/11088 | . . . . | for redistribution [2022-02] |
C12N 2740/12011 | . . . | Betaretrovirus, e.g. mouse mammary tumour virus [2013-01] |
C12N 2740/12021 | . . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2740/12022 | . . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2740/12023 | . . . . | Virus like particles [VLP] [2013-01] |
C12N 2740/12031 | . . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2740/12032 | . . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2740/12033 | . . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2740/12034 | . . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2740/12041 | . . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2740/12042 | . . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2740/12043 | . . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2740/12044 | . . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2740/12045 | . . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2740/12051 | . . . . | Methods of production or purification of viral material [2013-01] |
C12N 2740/12052 | . . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2740/12061 | . . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2740/12062 | . . . . . | by genetic engineering [2013-01] |
C12N 2740/12063 | . . . . . | by chemical treatment [2013-01] |
C12N 2740/12064 | . . . . . | by serial passage [2013-01] |
C12N 2740/12071 | . . . . | Demonstrated in vivo effect [2013-01] |
C12N 2740/12088 | . . . . | for redistribution [2022-02] |
C12N 2740/13011 | . . . | Gammaretrovirus, e.g. murine leukeamia virus [2013-01] |
C12N 2740/13021 | . . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2740/13022 | . . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2740/13023 | . . . . | Virus like particles [VLP] [2013-01] |
C12N 2740/13031 | . . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2740/13032 | . . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2740/13033 | . . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2740/13034 | . . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2740/13041 | . . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2740/13042 | . . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2740/13043 | . . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2740/13044 | . . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2740/13045 | . . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2740/13051 | . . . . | Methods of production or purification of viral material [2013-01] |
C12N 2740/13052 | . . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2740/13061 | . . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2740/13062 | . . . . . | by genetic engineering [2013-01] |
C12N 2740/13063 | . . . . . | by chemical treatment [2013-01] |
C12N 2740/13064 | . . . . . | by serial passage [2013-01] |
C12N 2740/13071 | . . . . | Demonstrated in vivo effect [2013-01] |
C12N 2740/13088 | . . . . | for redistribution [2022-02] |
C12N 2740/14011 | . . . | Deltaretrovirus, e.g. bovine leukeamia virus [2013-01] |
C12N 2740/14021 | . . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2740/14022 | . . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2740/14023 | . . . . | Virus like particles [VLP] [2013-01] |
C12N 2740/14031 | . . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2740/14032 | . . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2740/14033 | . . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2740/14034 | . . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2740/14041 | . . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2740/14042 | . . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2740/14043 | . . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2740/14044 | . . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2740/14045 | . . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2740/14051 | . . . . | Methods of production or purification of viral material [2013-01] |
C12N 2740/14052 | . . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2740/14061 | . . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2740/14062 | . . . . . | by genetic engineering [2013-01] |
C12N 2740/14063 | . . . . . | by chemical treatment [2013-01] |
C12N 2740/14064 | . . . . . | by serial passage [2013-01] |
C12N 2740/14071 | . . . . | Demonstrated in vivo effect [2013-01] |
C12N 2740/14088 | . . . . | for redistribution [2022-02] |
C12N 2740/15011 | . . . | Lentivirus, not HIV, e.g. FIV, SIV [2013-01] |
C12N 2740/15021 | . . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2740/15022 | . . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2740/15023 | . . . . | Virus like particles [VLP] [2013-01] |
C12N 2740/15031 | . . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2740/15032 | . . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2740/15033 | . . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2740/15034 | . . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2740/15041 | . . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2740/15042 | . . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2740/15043 | . . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2740/15044 | . . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2740/15045 | . . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2740/15051 | . . . . | Methods of production or purification of viral material [2013-01] |
C12N 2740/15052 | . . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2740/15061 | . . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2740/15062 | . . . . . | by genetic engineering [2013-01] |
C12N 2740/15063 | . . . . . | by chemical treatment [2013-01] |
C12N 2740/15064 | . . . . . | by serial passage [2013-01] |
C12N 2740/15071 | . . . . | Demonstrated in vivo effect [2013-01] |
C12N 2740/15088 | . . . . | for redistribution [2022-02] |
C12N 2740/16011 | . . . | Human Immunodeficiency Virus, HIV [2013-01] |
C12N 2740/16021 | . . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2740/16022 | . . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2740/16023 | . . . . | Virus like particles [VLP] [2013-01] |
C12N 2740/16031 | . . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2740/16032 | . . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2740/16033 | . . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2740/16034 | . . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2740/16041 | . . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2740/16042 | . . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2740/16043 | . . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2740/16044 | . . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2740/16045 | . . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2740/16051 | . . . . | Methods of production or purification of viral material [2013-01] |
C12N 2740/16052 | . . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2740/16061 | . . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2740/16062 | . . . . . | by genetic engineering [2013-01] |
C12N 2740/16063 | . . . . . | by chemical treatment [2013-01] |
C12N 2740/16064 | . . . . . | by serial passage [2013-01] |
C12N 2740/16071 | . . . . | Demonstrated in vivo effect [2013-01] |
C12N 2740/16088 | . . . . | for redistribution [2022-02] |
C12N 2740/16111 | . . . . | concerning HIV env [2013-01] |
C12N 2740/16122 | . . . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2740/16134 | . . . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2740/16171 | . . . . . | Demonstrated in vivo effect [2013-01] |
C12N 2740/16188 | . . . . . | for redistribution [2022-02] |
C12N 2740/16211 | . . . . | concerning HIV gagpol [2013-01] |
C12N 2740/16222 | . . . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2740/16234 | . . . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2740/16271 | . . . . . | Demonstrated in vivo effect [2013-01] |
C12N 2740/16288 | . . . . . | for redistribution [2022-02] |
C12N 2740/16311 | . . . . | concerning HIV regulatory proteins [2013-01] |
C12N 2740/16322 | . . . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2740/16334 | . . . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2740/16371 | . . . . . | Demonstrated in vivo effect [2013-01] |
C12N 2740/16388 | . . . . . | for redistribution [2022-02] |
C12N 2740/17011 | . . . | Spumavirus, e.g. chimpanzee foamy virus [2013-01] |
C12N 2740/17021 | . . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2740/17022 | . . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2740/17023 | . . . . | Virus like particles [VLP] [2013-01] |
C12N 2740/17031 | . . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2740/17032 | . . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2740/17033 | . . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2740/17034 | . . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2740/17041 | . . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2740/17042 | . . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2740/17043 | . . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2740/17044 | . . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2740/17045 | . . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2740/17051 | . . . . | Methods of production or purification of viral material [2013-01] |
C12N 2740/17052 | . . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2740/17061 | . . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2740/17062 | . . . . . | by genetic engineering [2013-01] |
C12N 2740/17063 | . . . . . | by chemical treatment [2013-01] |
C12N 2740/17064 | . . . . . | by serial passage [2013-01] |
C12N 2740/17071 | . . . . | Demonstrated in vivo effect [2013-01] |
C12N 2740/17088 | . . . . | for redistribution [2022-02] |
C12N 2750/00 | ssDNA viruses [2022-02] |
C12N 2750/00011 | . | Details [2022-02] |
C12N 2750/00021 | . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2750/00022 | . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2750/00023 | . . | Virus like particles [VLP] [2013-01] |
C12N 2750/00031 | . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2750/00032 | . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2750/00033 | . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2750/00034 | . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2750/00041 | . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2750/00042 | . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2750/00043 | . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2750/00044 | . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2750/00045 | . . . | Special targeting system for viral vectors [2013-01] |
C12N 2750/00051 | . . | Methods of production or purification of viral material [2013-01] |
C12N 2750/00052 | . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2750/00061 | . . | Methods of inactivation or attenuation [2013-01] |
C12N 2750/00062 | . . . | by genetic engineering [2013-01] |
C12N 2750/00063 | . . . | by chemical treatment [2013-01] |
C12N 2750/00064 | . . . | by serial passage [2013-01] |
C12N 2750/00071 | . . | Demonstrated in vivo effect [2013-01] |
C12N 2750/00088 | . . | for redistribution [2022-02] |
C12N 2750/10011 | . . | Circoviridae [2013-01] |
C12N 2750/10021 | . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2750/10022 | . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2750/10023 | . . . | Virus like particles [VLP] [2013-01] |
C12N 2750/10031 | . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2750/10032 | . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2750/10033 | . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2750/10034 | . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2750/10041 | . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2750/10042 | . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2750/10043 | . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2750/10044 | . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2750/10045 | . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2750/10051 | . . . | Methods of production or purification of viral material [2013-01] |
C12N 2750/10052 | . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2750/10061 | . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2750/10062 | . . . . | by genetic engineering [2013-01] |
C12N 2750/10063 | . . . . | by chemical treatment [2013-01] |
C12N 2750/10064 | . . . . | by serial passage [2013-01] |
C12N 2750/10071 | . . . | Demonstrated in vivo effect [2013-01] |
C12N 2750/10088 | . . . | for redistribution [2022-02] |
C12N 2750/12011 | . . | Geminiviridae [2013-01] |
C12N 2750/12021 | . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2750/12022 | . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2750/12023 | . . . | Virus like particles [VLP] [2013-01] |
C12N 2750/12031 | . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2750/12032 | . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2750/12033 | . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2750/12034 | . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2750/12041 | . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2750/12042 | . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2750/12043 | . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2750/12044 | . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2750/12045 | . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2750/12051 | . . . | Methods of production or purification of viral material [2013-01] |
C12N 2750/12052 | . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2750/12061 | . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2750/12062 | . . . . | by genetic engineering [2013-01] |
C12N 2750/12063 | . . . . | by chemical treatment [2013-01] |
C12N 2750/12064 | . . . . | by serial passage [2013-01] |
C12N 2750/12071 | . . . | Demonstrated in vivo effect [2013-01] |
C12N 2750/12088 | . . . | for redistribution [2022-02] |
C12N 2750/14011 | . . | Parvoviridae [2013-01] |
C12N 2750/14021 | . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2750/14022 | . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2750/14023 | . . . | Virus like particles [VLP] [2013-01] |
C12N 2750/14031 | . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2750/14032 | . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2750/14033 | . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2750/14034 | . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2750/14041 | . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2750/14042 | . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2750/14043 | . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2750/14044 | . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2750/14045 | . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2750/14051 | . . . | Methods of production or purification of viral material [2013-01] |
C12N 2750/14052 | . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2750/14061 | . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2750/14062 | . . . . | by genetic engineering [2013-01] |
C12N 2750/14063 | . . . . | by chemical treatment [2013-01] |
C12N 2750/14064 | . . . . | by serial passage [2013-01] |
C12N 2750/14071 | . . . | Demonstrated in vivo effect [2013-01] |
C12N 2750/14088 | . . . | for redistribution [2022-02] |
C12N 2750/14111 | . . . | Dependovirus, e.g. adenoassociated viruses [2013-01] |
C12N 2750/14121 | . . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2750/14122 | . . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2750/14123 | . . . . | Virus like particles [VLP] [2013-01] |
C12N 2750/14131 | . . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2750/14132 | . . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2750/14133 | . . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2750/14134 | . . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2750/14141 | . . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2750/14142 | . . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2750/14143 | . . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2750/14144 | . . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2750/14145 | . . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2750/14151 | . . . . | Methods of production or purification of viral material [2013-01] |
C12N 2750/14152 | . . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2750/14161 | . . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2750/14162 | . . . . . | by genetic engineering [2013-01] |
C12N 2750/14163 | . . . . . | by chemical treatment [2013-01] |
C12N 2750/14164 | . . . . . | by serial passage [2013-01] |
C12N 2750/14171 | . . . . | Demonstrated in vivo effect [2013-01] |
C12N 2750/14188 | . . . . | for redistribution [2022-02] |
C12N 2750/14211 | . . . | Erythrovirus, e.g. B19 virus [2013-01] |
C12N 2750/14221 | . . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2750/14222 | . . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2750/14223 | . . . . | Virus like particles [VLP] [2013-01] |
C12N 2750/14231 | . . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2750/14232 | . . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2750/14233 | . . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2750/14234 | . . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2750/14241 | . . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2750/14242 | . . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2750/14243 | . . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2750/14244 | . . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2750/14245 | . . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2750/14251 | . . . . | Methods of production or purification of viral material [2013-01] |
C12N 2750/14252 | . . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2750/14261 | . . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2750/14262 | . . . . . | by genetic engineering [2013-01] |
C12N 2750/14263 | . . . . . | by chemical treatment [2013-01] |
C12N 2750/14264 | . . . . . | by serial passage [2013-01] |
C12N 2750/14271 | . . . . | Demonstrated in vivo effect [2013-01] |
C12N 2750/14288 | . . . . | for redistribution [2022-02] |
C12N 2750/14311 | . . . | Parvovirus, e.g. minute virus of mice [2013-01] |
C12N 2750/14321 | . . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2750/14322 | . . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2750/14323 | . . . . | Virus like particles [VLP] [2013-01] |
C12N 2750/14331 | . . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2750/14332 | . . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2750/14333 | . . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2750/14334 | . . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2750/14341 | . . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2750/14342 | . . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2750/14343 | . . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2750/14344 | . . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2750/14345 | . . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2750/14351 | . . . . | Methods of production or purification of viral material [2013-01] |
C12N 2750/14352 | . . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2750/14361 | . . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2750/14362 | . . . . . | by genetic engineering [2013-01] |
C12N 2750/14363 | . . . . . | by chemical treatment [2013-01] |
C12N 2750/14364 | . . . . . | by serial passage [2013-01] |
C12N 2750/14371 | . . . . | Demonstrated in vivo effect [2013-01] |
C12N 2750/14388 | . . . . | for redistribution [2022-02] |
C12N 2760/00 | ssRNA viruses negative-sense [2022-02] |
C12N 2760/00011 | . | Details [2022-02] |
C12N 2760/00021 | . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2760/00022 | . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2760/00023 | . . | Virus like particles [VLP] [2013-01] |
C12N 2760/00031 | . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2760/00032 | . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2760/00033 | . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2760/00034 | . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2760/00041 | . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2760/00042 | . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2760/00043 | . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2760/00044 | . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2760/00045 | . . . | Special targeting system for viral vectors [2013-01] |
C12N 2760/00051 | . . | Methods of production or purification of viral material [2013-01] |
C12N 2760/00052 | . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2760/00061 | . . | Methods of inactivation or attenuation [2013-01] |
C12N 2760/00062 | . . . | by genetic engineering [2013-01] |
C12N 2760/00063 | . . . | by chemical treatment [2013-01] |
C12N 2760/00064 | . . . | by serial passage [2013-01] |
C12N 2760/00071 | . . | Demonstrated in vivo effect [2013-01] |
C12N 2760/00088 | . . | for redistribution [2022-02] |
C12N 2760/10011 | . . | Arenaviridae [2013-01] |
C12N 2760/10021 | . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2760/10022 | . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2760/10023 | . . . | Virus like particles [VLP] [2013-01] |
C12N 2760/10031 | . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2760/10032 | . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2760/10033 | . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2760/10034 | . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2760/10041 | . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2760/10042 | . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2760/10043 | . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2760/10044 | . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2760/10045 | . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2760/10051 | . . . | Methods of production or purification of viral material [2013-01] |
C12N 2760/10052 | . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2760/10061 | . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2760/10062 | . . . . | by genetic engineering [2013-01] |
C12N 2760/10063 | . . . . | by chemical treatment [2013-01] |
C12N 2760/10064 | . . . . | by serial passage [2013-01] |
C12N 2760/10071 | . . . | Demonstrated in vivo effect [2013-01] |
C12N 2760/10088 | . . . | for redistribution [2022-02] |
C12N 2760/10111 | . . . | Deltavirus, e.g. hepatitis delta virus [2013-01] |
C12N 2760/10121 | . . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2760/10122 | . . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2760/10123 | . . . . | Virus like particles [VLP] [2013-01] |
C12N 2760/10131 | . . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2760/10132 | . . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2760/10133 | . . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2760/10134 | . . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2760/10141 | . . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2760/10142 | . . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2760/10143 | . . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2760/10144 | . . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2760/10145 | . . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2760/10151 | . . . . | Methods of production or purification of viral material [2013-01] |
C12N 2760/10152 | . . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2760/10161 | . . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2760/10162 | . . . . . | by genetic engineering [2013-01] |
C12N 2760/10163 | . . . . . | by chemical treatment [2013-01] |
C12N 2760/10164 | . . . . . | by serial passage [2013-01] |
C12N 2760/10171 | . . . . | Demonstrated in vivo effect [2013-01] |
C12N 2760/10188 | . . . . | for redistribution [2022-02] |
C12N 2760/12011 | . . | Bunyaviridae [2013-01] |
C12N 2760/12021 | . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2760/12022 | . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2760/12023 | . . . | Virus like particles [VLP] [2013-01] |
C12N 2760/12031 | . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2760/12032 | . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2760/12033 | . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2760/12034 | . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2760/12041 | . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2760/12042 | . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2760/12043 | . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2760/12044 | . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2760/12045 | . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2760/12051 | . . . | Methods of production or purification of viral material [2013-01] |
C12N 2760/12052 | . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2760/12061 | . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2760/12062 | . . . . | by genetic engineering [2013-01] |
C12N 2760/12063 | . . . . | by chemical treatment [2013-01] |
C12N 2760/12064 | . . . . | by serial passage [2013-01] |
C12N 2760/12071 | . . . | Demonstrated in vivo effect [2013-01] |
C12N 2760/12088 | . . . | for redistribution [2022-02] |
C12N 2760/12111 | . . . | Hantavirus, e.g. Hantaan virus [2013-01] |
C12N 2760/12121 | . . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2760/12122 | . . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2760/12123 | . . . . | Virus like particles [VLP] [2013-01] |
C12N 2760/12131 | . . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2760/12132 | . . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2760/12133 | . . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2760/12134 | . . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2760/12141 | . . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2760/12142 | . . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2760/12143 | . . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2760/12144 | . . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2760/12145 | . . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2760/12151 | . . . . | Methods of production or purification of viral material [2013-01] |
C12N 2760/12152 | . . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2760/12161 | . . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2760/12162 | . . . . . | by genetic engineering [2013-01] |
C12N 2760/12163 | . . . . . | by chemical treatment [2013-01] |
C12N 2760/12164 | . . . . . | by serial passage [2013-01] |
C12N 2760/12171 | . . . . | Demonstrated in vivo effect [2013-01] |
C12N 2760/12188 | . . . . | for redistribution [2022-02] |
C12N 2760/12211 | . . . | Phlebovirus, e.g. Rift Valley fever virus [2013-01] |
C12N 2760/12221 | . . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2760/12222 | . . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2760/12223 | . . . . | Virus like particles [VLP] [2013-01] |
C12N 2760/12231 | . . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2760/12232 | . . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2760/12233 | . . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2760/12234 | . . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2760/12241 | . . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2760/12242 | . . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2760/12243 | . . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2760/12244 | . . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2760/12245 | . . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2760/12251 | . . . . | Methods of production or purification of viral material [2013-01] |
C12N 2760/12252 | . . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2760/12261 | . . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2760/12262 | . . . . . | by genetic engineering [2013-01] |
C12N 2760/12263 | . . . . . | by chemical treatment [2013-01] |
C12N 2760/12264 | . . . . . | by serial passage [2013-01] |
C12N 2760/12271 | . . . . | Demonstrated in vivo effect [2013-01] |
C12N 2760/12288 | . . . . | for redistribution [2022-02] |
C12N 2760/14011 | . . | Filoviridae [2013-01] |
C12N 2760/14021 | . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2760/14022 | . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2760/14023 | . . . | Virus like particles [VLP] [2013-01] |
C12N 2760/14031 | . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2760/14032 | . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2760/14033 | . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2760/14034 | . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2760/14041 | . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2760/14042 | . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2760/14043 | . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2760/14044 | . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2760/14045 | . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2760/14051 | . . . | Methods of production or purification of viral material [2013-01] |
C12N 2760/14052 | . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2760/14061 | . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2760/14062 | . . . . | by genetic engineering [2013-01] |
C12N 2760/14063 | . . . . | by chemical treatment [2013-01] |
C12N 2760/14064 | . . . . | by serial passage [2013-01] |
C12N 2760/14071 | . . . | Demonstrated in vivo effect [2013-01] |
C12N 2760/14088 | . . . | for redistribution [2022-02] |
C12N 2760/14111 | . . . | Ebolavirus, e.g. Zaire ebolavirus [2013-01] |
C12N 2760/14121 | . . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2760/14122 | . . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2760/14123 | . . . . | Virus like particles [VLP] [2013-01] |
C12N 2760/14131 | . . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2760/14132 | . . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2760/14133 | . . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2760/14134 | . . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2760/14141 | . . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2760/14142 | . . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2760/14143 | . . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2760/14144 | . . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2760/14145 | . . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2760/14151 | . . . . | Methods of production or purification of viral material [2013-01] |
C12N 2760/14152 | . . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2760/14161 | . . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2760/14162 | . . . . . | by genetic engineering [2013-01] |
C12N 2760/14163 | . . . . . | by chemical treatment [2013-01] |
C12N 2760/14164 | . . . . . | by serial passage [2013-01] |
C12N 2760/14171 | . . . . | Demonstrated in vivo effect [2013-01] |
C12N 2760/14188 | . . . . | for redistribution [2022-02] |
C12N 2760/14211 | . . . | Marburgvirus, e.g. lake Victoria marburgvirus [2013-01] |
C12N 2760/14221 | . . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2760/14222 | . . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2760/14223 | . . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2760/14231 | . . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2760/14232 | . . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2760/14233 | . . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2760/14234 | . . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2760/14241 | . . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2760/14242 | . . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2760/14243 | . . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2760/14244 | . . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2760/14245 | . . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2760/14251 | . . . . | Methods of production or purification of viral material [2013-01] |
C12N 2760/14252 | . . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2760/14261 | . . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2760/14262 | . . . . . | by genetic engineering [2013-01] |
C12N 2760/14263 | . . . . . | by chemical treatment [2013-01] |
C12N 2760/14264 | . . . . . | by serial passage [2013-01] |
C12N 2760/14271 | . . . . | Demonstrated in vivo effect [2013-01] |
C12N 2760/14288 | . . . . | for redistribution [2022-02] |
C12N 2760/16011 | . . | Orthomyxoviridae [2013-01] |
C12N 2760/16021 | . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2760/16022 | . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2760/16023 | . . . | Virus like particles [VLP] [2013-01] |
C12N 2760/16031 | . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2760/16032 | . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2760/16033 | . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2760/16034 | . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2760/16041 | . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2760/16042 | . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2760/16043 | . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2760/16044 | . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2760/16045 | . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2760/16051 | . . . | Methods of production or purification of viral material [2013-01] |
C12N 2760/16052 | . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2760/16061 | . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2760/16062 | . . . . | by genetic engineering [2013-01] |
C12N 2760/16063 | . . . . | by chemical treatment [2013-01] |
C12N 2760/16064 | . . . . | by serial passage [2013-01] |
C12N 2760/16071 | . . . | Demonstrated in vivo effect [2013-01] |
C12N 2760/16088 | . . . | for redistribution [2022-02] |
C12N 2760/16111 | . . . | Influenzavirus A, i.e. influenza A virus [2013-01] |
C12N 2760/16121 | . . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2760/16122 | . . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2760/16123 | . . . . | Virus like particles [VLP] [2013-01] |
C12N 2760/16131 | . . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2760/16132 | . . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2760/16133 | . . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2760/16134 | . . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2760/16141 | . . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2760/16142 | . . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2760/16143 | . . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2760/16144 | . . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2760/16145 | . . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2760/16151 | . . . . | Methods of production or purification of viral material [2013-01] |
C12N 2760/16152 | . . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2760/16161 | . . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2760/16162 | . . . . . | by genetic engineering [2013-01] |
C12N 2760/16163 | . . . . . | by chemical treatment [2013-01] |
C12N 2760/16164 | . . . . . | by serial passage [2013-01] |
C12N 2760/16171 | . . . . | Demonstrated in vivo effect [2013-01] |
C12N 2760/16188 | . . . . | for redistribution [2022-02] |
C12N 2760/16211 | . . . | Influenzavirus B, i.e. influenza B virus [2013-01] |
C12N 2760/16221 | . . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2760/16222 | . . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2760/16223 | . . . . | Virus like particles [VLP] [2013-01] |
C12N 2760/16231 | . . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2760/16232 | . . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2760/16233 | . . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2760/16234 | . . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2760/16241 | . . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2760/16242 | . . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2760/16243 | . . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2760/16244 | . . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2760/16245 | . . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2760/16251 | . . . . | Methods of production or purification of viral material [2013-01] |
C12N 2760/16252 | . . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2760/16261 | . . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2760/16262 | . . . . . | by genetic engineering [2013-01] |
C12N 2760/16263 | . . . . . | by chemical treatment [2013-01] |
C12N 2760/16264 | . . . . . | by serial passage [2013-01] |
C12N 2760/16271 | . . . . | Demonstrated in vivo effect [2013-01] |
C12N 2760/16288 | . . . . | for redistribution [2022-02] |
C12N 2760/16311 | . . . | Influenzavirus C, i.e. influenza C virus [2013-01] |
C12N 2760/16321 | . . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2760/16322 | . . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2760/16323 | . . . . | Virus like particles [VLP] [2013-01] |
C12N 2760/16331 | . . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2760/16332 | . . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2760/16333 | . . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2760/16334 | . . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2760/16341 | . . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2760/16342 | . . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2760/16343 | . . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2760/16344 | . . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2760/16345 | . . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2760/16351 | . . . . | Methods of production or purification of viral material [2013-01] |
C12N 2760/16352 | . . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2760/16361 | . . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2760/16362 | . . . . . | by genetic engineering [2013-01] |
C12N 2760/16363 | . . . . . | by chemical treatment [2013-01] |
C12N 2760/16364 | . . . . . | by serial passage [2013-01] |
C12N 2760/16371 | . . . . | Demonstrated in vivo effect [2013-01] |
C12N 2760/16388 | . . . . | for redistribution [2022-02] |
C12N 2760/18011 | . . | Paramyxoviridae [2013-01] |
C12N 2760/18021 | . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2760/18022 | . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2760/18023 | . . . | Virus like particles [VLP] [2013-01] |
C12N 2760/18031 | . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2760/18032 | . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2760/18033 | . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2760/18034 | . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2760/18041 | . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2760/18042 | . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2760/18043 | . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2760/18044 | . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2760/18045 | . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2760/18051 | . . . | Methods of production or purification of viral material [2013-01] |
C12N 2760/18052 | . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2760/18061 | . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2760/18062 | . . . . | by genetic engineering [2013-01] |
C12N 2760/18063 | . . . . | by chemical treatment [2013-01] |
C12N 2760/18064 | . . . . | by serial passage [2013-01] |
C12N 2760/18071 | . . . | Demonstrated in vivo effect [2013-01] |
C12N 2760/18088 | . . . | for redistribution [2022-02] |
C12N 2760/18111 | . . . | Avulavirus, e.g. Newcastle disease virus [2013-01] |
C12N 2760/18121 | . . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2760/18122 | . . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2760/18123 | . . . . | Virus like particles [VLP] [2013-01] |
C12N 2760/18131 | . . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2760/18132 | . . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2760/18133 | . . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2760/18134 | . . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2760/18141 | . . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2760/18142 | . . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2760/18143 | . . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2760/18144 | . . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2760/18145 | . . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2760/18151 | . . . . | Methods of production or purification of viral material [2013-01] |
C12N 2760/18152 | . . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2760/18161 | . . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2760/18162 | . . . . . | by genetic engineering [2013-01] |
C12N 2760/18163 | . . . . . | by chemical treatment [2013-01] |
C12N 2760/18164 | . . . . . | by serial passage [2013-01] |
C12N 2760/18171 | . . . . | Demonstrated in vivo effect [2013-01] |
C12N 2760/18188 | . . . . | for redistribution [2022-02] |
C12N 2760/18211 | . . . | Henipavirus, e.g. hendra virus [2013-01] |
C12N 2760/18221 | . . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2760/18222 | . . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2760/18223 | . . . . | Virus like particles [VLP] [2013-01] |
C12N 2760/18231 | . . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2760/18232 | . . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2760/18233 | . . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2760/18234 | . . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2760/18241 | . . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2760/18242 | . . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2760/18243 | . . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2760/18244 | . . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2760/18245 | . . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2760/18251 | . . . . | Methods of production or purification of viral material [2013-01] |
C12N 2760/18252 | . . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2760/18261 | . . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2760/18262 | . . . . . | by genetic engineering [2013-01] |
C12N 2760/18263 | . . . . . | by chemical treatment [2013-01] |
C12N 2760/18264 | . . . . . | by serial passage [2013-01] |
C12N 2760/18271 | . . . . | Demonstrated in vivo effect [2013-01] |
C12N 2760/18288 | . . . . | for redistribution [2022-02] |
C12N 2760/18311 | . . . | Metapneumovirus, e.g. avian pneumovirus [2013-01] |
C12N 2760/18321 | . . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2760/18322 | . . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2760/18323 | . . . . | Virus like particles [VLP] [2013-01] |
C12N 2760/18331 | . . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2760/18332 | . . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2760/18333 | . . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2760/18334 | . . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2760/18341 | . . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2760/18342 | . . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2760/18343 | . . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2760/18344 | . . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2760/18345 | . . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2760/18351 | . . . . | Methods of production or purification of viral material [2013-01] |
C12N 2760/18352 | . . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2760/18361 | . . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2760/18362 | . . . . . | by genetic engineering [2013-01] |
C12N 2760/18363 | . . . . . | by chemical treatment [2013-01] |
C12N 2760/18364 | . . . . . | by serial passage [2013-01] |
C12N 2760/18371 | . . . . | Demonstrated in vivo effect [2013-01] |
C12N 2760/18388 | . . . . | for redistribution [2022-02] |
C12N 2760/18411 | . . . | Morbillivirus, e.g. Measles virus, canine distemper [2013-01] |
C12N 2760/18421 | . . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2760/18422 | . . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2760/18423 | . . . . | Virus like particles [VLP] [2013-01] |
C12N 2760/18431 | . . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2760/18432 | . . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2760/18433 | . . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2760/18434 | . . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2760/18441 | . . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2760/18442 | . . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2760/18443 | . . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2760/18444 | . . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2760/18445 | . . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2760/18451 | . . . . | Methods of production or purification of viral material [2013-01] |
C12N 2760/18452 | . . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2760/18461 | . . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2760/18462 | . . . . . | by genetic engineering [2013-01] |
C12N 2760/18463 | . . . . . | by chemical treatment [2013-01] |
C12N 2760/18464 | . . . . . | by serial passage [2013-01] |
C12N 2760/18471 | . . . . | Demonstrated in vivo effect [2013-01] |
C12N 2760/18488 | . . . . | For redistribution [2013-01] |
C12N 2760/18511 | . . . | Pneumovirus, e.g. human respiratory syncytial virus [2013-01] |
C12N 2760/18521 | . . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2760/18522 | . . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2760/18523 | . . . . | Virus like particles [VLP] [2013-01] |
C12N 2760/18531 | . . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2760/18532 | . . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2760/18533 | . . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2760/18534 | . . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2760/18541 | . . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2760/18542 | . . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2760/18543 | . . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2760/18544 | . . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2760/18545 | . . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2760/18551 | . . . . | Methods of production or purification of viral material [2013-01] |
C12N 2760/18552 | . . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2760/18561 | . . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2760/18562 | . . . . . | by genetic engineering [2013-01] |
C12N 2760/18563 | . . . . . | by chemical treatment [2013-01] |
C12N 2760/18564 | . . . . . | by serial passage [2013-01] |
C12N 2760/18571 | . . . . | Demonstrated in vivo effect [2013-01] |
C12N 2760/18588 | . . . . | for redistribution [2022-02] |
C12N 2760/18611 | . . . | Respirovirus, e.g. Bovine, human parainfluenza 1,3 [2013-01] |
C12N 2760/18621 | . . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2760/18622 | . . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2760/18623 | . . . . | Virus like particles [VLP] [2013-01] |
C12N 2760/18631 | . . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2760/18632 | . . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2760/18633 | . . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2760/18634 | . . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2760/18641 | . . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2760/18642 | . . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2760/18643 | . . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2760/18644 | . . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2760/18645 | . . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2760/18651 | . . . . | Methods of production or purification of viral material [2013-01] |
C12N 2760/18652 | . . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2760/18661 | . . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2760/18662 | . . . . . | by genetic engineering [2013-01] |
C12N 2760/18663 | . . . . . | by chemical treatment [2013-01] |
C12N 2760/18664 | . . . . . | by serial passage [2013-01] |
C12N 2760/18671 | . . . . | Demonstrated in vivo effect [2013-01] |
C12N 2760/18688 | . . . . | for redistribution [2022-02] |
C12N 2760/18711 | . . . | Rubulavirus, e.g. mumps virus, parainfluenza 2,4 [2013-01] |
C12N 2760/18721 | . . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2760/18722 | . . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2760/18723 | . . . . | Virus like particles [VLP] [2013-01] |
C12N 2760/18731 | . . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2760/18732 | . . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2760/18733 | . . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2760/18734 | . . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2760/18741 | . . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2760/18742 | . . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2760/18743 | . . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2760/18744 | . . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2760/18745 | . . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2760/18751 | . . . . | Methods of production or purification of viral material [2013-01] |
C12N 2760/18752 | . . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2760/18761 | . . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2760/18762 | . . . . . | by genetic engineering [2013-01] |
C12N 2760/18763 | . . . . . | by chemical treatment [2013-01] |
C12N 2760/18764 | . . . . . | by serial passage [2013-01] |
C12N 2760/18771 | . . . . | Demonstrated in vivo effect [2013-01] |
C12N 2760/18788 | . . . . | for redistribution [2022-02] |
C12N 2760/18811 | . . . | Sendai virus [2013-01] |
C12N 2760/18821 | . . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2760/18822 | . . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2760/18823 | . . . . | Virus like particles [VLP] [2013-01] |
C12N 2760/18831 | . . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2760/18832 | . . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2760/18833 | . . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2760/18834 | . . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2760/18841 | . . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2760/18842 | . . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2760/18843 | . . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2760/18845 | . . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2760/18851 | . . . . | Methods of production or purification of viral material [2013-01] |
C12N 2760/18852 | . . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2760/18861 | . . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2760/18862 | . . . . . | by genetic engineering [2013-01] |
C12N 2760/18863 | . . . . . | by chemical treatment [2013-01] |
C12N 2760/18864 | . . . . . | by serial passage [2013-01] |
C12N 2760/18871 | . . . . | Demonstrated in vivo effect [2013-01] |
C12N 2760/18888 | . . . . | for redistribution [2022-02] |
C12N 2760/20011 | . . | Rhabdoviridae [2013-01] |
C12N 2760/20021 | . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2760/20022 | . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2760/20023 | . . . | Virus like particles [VLP] [2013-01] |
C12N 2760/20031 | . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2760/20032 | . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2760/20033 | . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2760/20034 | . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2760/20041 | . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2760/20042 | . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2760/20043 | . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2760/20044 | . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2760/20045 | . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2760/20051 | . . . | Methods of production or purification of viral material [2013-01] |
C12N 2760/20052 | . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2760/20061 | . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2760/20062 | . . . . | by genetic engineering [2013-01] |
C12N 2760/20063 | . . . . | by chemical treatment [2013-01] |
C12N 2760/20064 | . . . . | by serial passage [2013-01] |
C12N 2760/20071 | . . . | Demonstrated in vivo effect [2013-01] |
C12N 2760/20088 | . . . | for redistribution [2022-02] |
C12N 2760/20111 | . . . | Lyssavirus, e.g. rabies virus [2013-01] |
C12N 2760/20121 | . . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2760/20122 | . . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2760/20123 | . . . . | Virus like particles [VLP] [2013-01] |
C12N 2760/20131 | . . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2760/20132 | . . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2760/20133 | . . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2760/20134 | . . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2760/20141 | . . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2760/20142 | . . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2760/20143 | . . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2760/20144 | . . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2760/20145 | . . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2760/20151 | . . . . | Methods of production or purification of viral material [2013-01] |
C12N 2760/20152 | . . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2760/20161 | . . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2760/20162 | . . . . . | by genetic engineering [2013-01] |
C12N 2760/20163 | . . . . . | by chemical treatment [2013-01] |
C12N 2760/20164 | . . . . . | by serial passage [2013-01] |
C12N 2760/20171 | . . . . | Demonstrated in vivo effect [2013-01] |
C12N 2760/20188 | . . . . | for redistribution [2022-02] |
C12N 2760/20211 | . . . | Vesiculovirus, e.g. vesicular stomatitis Indiana virus [2013-01] |
C12N 2760/20221 | . . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2760/20222 | . . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2760/20223 | . . . . | Virus like particles [VLP] [2013-01] |
C12N 2760/20231 | . . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2760/20232 | . . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2760/20233 | . . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2760/20234 | . . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2760/20241 | . . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2760/20242 | . . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2760/20243 | . . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2760/20244 | . . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2760/20245 | . . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2760/20251 | . . . . | Methods of production or purification of viral material [2013-01] |
C12N 2760/20252 | . . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2760/20261 | . . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2760/20262 | . . . . . | by genetic engineering [2013-01] |
C12N 2760/20263 | . . . . . | by chemical treatment [2013-01] |
C12N 2760/20264 | . . . . . | by serial passage [2013-01] |
C12N 2760/20271 | . . . . | Demonstrated in vivo effect [2013-01] |
C12N 2760/20288 | . . . . | for redistribution [2022-02] |
C12N 2770/00 | ssRNA viruses positive-sense [2022-02] |
C12N 2770/00011 | . | Details [2022-02] |
C12N 2770/00021 | . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2770/00022 | . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2770/00023 | . . | Virus like particles [VLP] [2013-01] |
C12N 2770/00031 | . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2770/00032 | . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2770/00033 | . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2770/00034 | . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2770/00041 | . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2770/00042 | . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2770/00043 | . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2770/00044 | . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2770/00045 | . . . | Special targeting system for viral vectors [2013-01] |
C12N 2770/00051 | . . | Methods of production or purification of viral material [2013-01] |
C12N 2770/00052 | . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2770/00061 | . . | Methods of inactivation or attenuation [2013-01] |
C12N 2770/00062 | . . . | by genetic engineering [2013-01] |
C12N 2770/00063 | . . . | by chemical treatment [2013-01] |
C12N 2770/00064 | . . . | by serial passage [2013-01] |
C12N 2770/00071 | . . | Demonstrated in vivo effect [2013-01] |
C12N 2770/00088 | . . | for redistribution [2022-02] |
C12N 2770/10011 | . . | Arteriviridae [2013-01] |
C12N 2770/10021 | . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2770/10022 | . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2770/10023 | . . . | Virus like particles [VLP] [2013-01] |
C12N 2770/10031 | . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2770/10032 | . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2770/10033 | . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2770/10034 | . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2770/10041 | . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2770/10042 | . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2770/10043 | . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2770/10044 | . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2770/10045 | . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2770/10051 | . . . | Methods of production or purification of viral material [2013-01] |
C12N 2770/10052 | . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2770/10061 | . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2770/10062 | . . . . | by genetic engineering [2013-01] |
C12N 2770/10063 | . . . . | by chemical treatment [2013-01] |
C12N 2770/10064 | . . . . | by serial passage [2013-01] |
C12N 2770/10071 | . . . | Demonstrated in vivo effect [2013-01] |
C12N 2770/10088 | . . . | for redistribution [2022-02] |
C12N 2770/12011 | . . | Astroviridae [2013-01] |
C12N 2770/12021 | . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2770/12022 | . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2770/12023 | . . . | Virus like particles [VLP] [2013-01] |
C12N 2770/12031 | . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2770/12032 | . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2770/12033 | . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2770/12034 | . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2770/12041 | . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2770/12042 | . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2770/12043 | . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2770/12044 | . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2770/12045 | . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2770/12051 | . . . | Methods of production or purification of viral material [2013-01] |
C12N 2770/12052 | . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2770/12061 | . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2770/12062 | . . . . | by genetic engineering [2013-01] |
C12N 2770/12063 | . . . . | by chemical treatment [2013-01] |
C12N 2770/12064 | . . . . | by serial passage [2013-01] |
C12N 2770/12071 | . . . | Demonstrated in vivo effect [2013-01] |
C12N 2770/12088 | . . . | for redistribution [2022-02] |
C12N 2770/14011 | . . | Bromoviridae [2013-01] |
C12N 2770/14021 | . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2770/14022 | . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2770/14023 | . . . | Virus like particles [VLP] [2013-01] |
C12N 2770/14031 | . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2770/14032 | . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2770/14033 | . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2770/14034 | . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2770/14041 | . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2770/14042 | . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2770/14043 | . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2770/14044 | . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2770/14045 | . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2770/14051 | . . . | Methods of production or purification of viral material [2013-01] |
C12N 2770/14052 | . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2770/14061 | . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2770/14062 | . . . . | by genetic engineering [2013-01] |
C12N 2770/14063 | . . . . | by chemical treatment [2013-01] |
C12N 2770/14064 | . . . . | by serial passage [2013-01] |
C12N 2770/14071 | . . . | Demonstrated in vivo effect [2013-01] |
C12N 2770/14088 | . . . | for redistribution [2022-02] |
C12N 2770/16011 | . . | Caliciviridae [2013-01] |
C12N 2770/16021 | . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2770/16022 | . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2770/16023 | . . . | Virus like particles [VLP] [2013-01] |
C12N 2770/16031 | . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2770/16032 | . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2770/16033 | . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2770/16034 | . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2770/16041 | . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2770/16042 | . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2770/16043 | . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2770/16044 | . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2770/16045 | . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2770/16051 | . . . | Methods of production or purification of viral material [2013-01] |
C12N 2770/16052 | . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2770/16061 | . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2770/16062 | . . . . | by genetic engineering [2013-01] |
C12N 2770/16063 | . . . . | by chemical treatment [2013-01] |
C12N 2770/16064 | . . . . | by serial passage [2013-01] |
C12N 2770/16071 | . . . | Demonstrated in vivo effect [2013-01] |
C12N 2770/16088 | . . . | for redistribution [2022-02] |
C12N 2770/18011 | . . | Comoviridae [2013-01] |
C12N 2770/18021 | . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2770/18022 | . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2770/18023 | . . . | Virus like particles [VLP] [2013-01] |
C12N 2770/18031 | . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2770/18032 | . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2770/18033 | . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2770/18034 | . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2770/18041 | . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2770/18042 | . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2770/18043 | . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2770/18044 | . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2770/18045 | . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2770/18051 | . . . | Methods of production or purification of viral material [2013-01] |
C12N 2770/18052 | . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2770/18061 | . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2770/18062 | . . . . | by genetic engineering [2013-01] |
C12N 2770/18063 | . . . . | by chemical treatment [2013-01] |
C12N 2770/18064 | . . . . | by serial passage [2013-01] |
C12N 2770/18071 | . . . | Demonstrated in vivo effect [2013-01] |
C12N 2770/18088 | . . . | for redistribution [2022-02] |
C12N 2770/20011 | . . | Coronaviridae [2013-01] |
C12N 2770/20021 | . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2770/20022 | . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2770/20023 | . . . | Virus like particles [VLP] [2013-01] |
C12N 2770/20031 | . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2770/20032 | . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2770/20033 | . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2770/20034 | . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2770/20041 | . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2770/20042 | . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2770/20043 | . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2770/20044 | . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2770/20045 | . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2770/20051 | . . . | Methods of production or purification of viral material [2013-01] |
C12N 2770/20052 | . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2770/20061 | . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2770/20062 | . . . . | by genetic engineering [2013-01] |
C12N 2770/20063 | . . . . | by chemical treatment [2013-01] |
C12N 2770/20064 | . . . . | by serial passage [2013-01] |
C12N 2770/20071 | . . . | Demonstrated in vivo effect [2013-01] |
C12N 2770/20088 | . . . | for redistribution [2022-02] |
C12N 2770/22011 | . . | Dicistroviridae [2013-01] |
C12N 2770/22021 | . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2770/22022 | . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2770/22023 | . . . | Virus like particles [VLP] [2013-01] |
C12N 2770/22031 | . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2770/22032 | . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2770/22033 | . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2770/22034 | . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2770/22041 | . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2770/22042 | . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2770/22043 | . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2770/22044 | . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2770/22045 | . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2770/22051 | . . . | Methods of production or purification of viral material [2013-01] |
C12N 2770/22052 | . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2770/22061 | . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2770/22062 | . . . . | by genetic engineering [2013-01] |
C12N 2770/22063 | . . . . | by chemical treatment [2013-01] |
C12N 2770/22064 | . . . . | by serial passage [2013-01] |
C12N 2770/22071 | . . . | Demonstrated in vivo effect [2013-01] |
C12N 2770/22088 | . . . | for redistribution [2022-02] |
C12N 2770/24011 | . . | Flaviviridae [2013-01] |
C12N 2770/24021 | . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2770/24022 | . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2770/24023 | . . . | Virus like particles [VLP] [2013-01] |
C12N 2770/24031 | . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2770/24032 | . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2770/24033 | . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2770/24034 | . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2770/24041 | . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2770/24042 | . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2770/24043 | . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2770/24044 | . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2770/24045 | . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2770/24051 | . . . | Methods of production or purification of viral material [2013-01] |
C12N 2770/24052 | . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2770/24061 | . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2770/24062 | . . . . | by genetic engineering [2013-01] |
C12N 2770/24063 | . . . . | by chemical treatment [2013-01] |
C12N 2770/24064 | . . . . | by serial passage [2013-01] |
C12N 2770/24071 | . . . | Demonstrated in vivo effect [2013-01] |
C12N 2770/24088 | . . . | for redistribution [2022-02] |
C12N 2770/24111 | . . . | Flavivirus, e.g. yellow fever virus, dengue, JEV [2013-01] |
C12N 2770/24121 | . . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2770/24122 | . . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2770/24123 | . . . . | Virus like particles [VLP] [2013-01] |
C12N 2770/24131 | . . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2770/24132 | . . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2770/24133 | . . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2770/24134 | . . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2770/24141 | . . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2770/24142 | . . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2770/24143 | . . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2770/24144 | . . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2770/24145 | . . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2770/24151 | . . . . | Methods of production or purification of viral material [2013-01] |
C12N 2770/24152 | . . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2770/24161 | . . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2770/24162 | . . . . . | by genetic engineering [2013-01] |
C12N 2770/24163 | . . . . . | by chemical treatment [2013-01] |
C12N 2770/24164 | . . . . . | by serial passage [2013-01] |
C12N 2770/24171 | . . . . | Demonstrated in vivo effect [2013-01] |
C12N 2770/24188 | . . . . | for redistribution [2022-02] |
C12N 2770/24211 | . . . | Hepacivirus, e.g. hepatitis C virus, hepatitis G virus [2013-01] |
C12N 2770/24221 | . . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2770/24222 | . . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2770/24223 | . . . . | Virus like particles [VLP] [2013-01] |
C12N 2770/24231 | . . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2770/24232 | . . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2770/24233 | . . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2770/24234 | . . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2770/24241 | . . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2770/24242 | . . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2770/24243 | . . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2770/24244 | . . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2770/24245 | . . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2770/24251 | . . . . | Methods of production or purification of viral material [2013-01] |
C12N 2770/24252 | . . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2770/24261 | . . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2770/24262 | . . . . . | by genetic engineering [2013-01] |
C12N 2770/24263 | . . . . . | by chemical treatment [2013-01] |
C12N 2770/24264 | . . . . . | by serial passage [2013-01] |
C12N 2770/24271 | . . . . | Demonstrated in vivo effect [2013-01] |
C12N 2770/24288 | . . . . | for redistribution [2022-02] |
C12N 2770/24311 | . . . | Pestivirus, e.g. bovine viral diarrhea virus [2013-01] |
C12N 2770/24321 | . . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2770/24322 | . . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2770/24323 | . . . . | Virus like particles [VLP] [2013-01] |
C12N 2770/24331 | . . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2770/24332 | . . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2770/24333 | . . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2770/24334 | . . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2770/24341 | . . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2770/24342 | . . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2770/24343 | . . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2770/24344 | . . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2770/24345 | . . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2770/24351 | . . . . | Methods of production or purification of viral material [2013-01] |
C12N 2770/24352 | . . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2770/24361 | . . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2770/24362 | . . . . . | by genetic engineering [2013-01] |
C12N 2770/24363 | . . . . . | by chemical treatment [2013-01] |
C12N 2770/24364 | . . . . . | by serial passage [2013-01] |
C12N 2770/24371 | . . . . | Demonstrated in vivo effect [2013-01] |
C12N 2770/24388 | . . . . | for redistribution [2022-02] |
C12N 2770/26011 | . . | Flexiviridae [2013-01] |
C12N 2770/26021 | . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2770/26022 | . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2770/26023 | . . . | Virus like particles [VLP] [2013-01] |
C12N 2770/26031 | . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2770/26032 | . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2770/26033 | . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2770/26034 | . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2770/26041 | . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2770/26042 | . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2770/26043 | . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2770/26044 | . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2770/26045 | . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2770/26051 | . . . | Methods of production or purification of viral material [2013-01] |
C12N 2770/26052 | . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2770/26061 | . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2770/26062 | . . . . | by genetic engineering [2013-01] |
C12N 2770/26063 | . . . . | by chemical treatment [2013-01] |
C12N 2770/26064 | . . . . | by serial passage [2013-01] |
C12N 2770/26071 | . . . | Demonstrated in vivo effect [2013-01] |
C12N 2770/26088 | . . . | for redistribution [2022-02] |
C12N 2770/28011 | . . | Hepeviridae [2013-01] |
C12N 2770/28021 | . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2770/28022 | . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2770/28023 | . . . | Virus like particles [VLP] [2013-01] |
C12N 2770/28031 | . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2770/28032 | . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2770/28033 | . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2770/28034 | . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2770/28041 | . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2770/28042 | . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2770/28043 | . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2770/28044 | . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2770/28045 | . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2770/28051 | . . . | Methods of production or purification of viral material [2013-01] |
C12N 2770/28052 | . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2770/28061 | . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2770/28062 | . . . . | by genetic engineering [2013-01] |
C12N 2770/28063 | . . . . | by chemical treatment [2013-01] |
C12N 2770/28064 | . . . . | by serial passage [2013-01] |
C12N 2770/28071 | . . . | Demonstrated in vivo effect [2013-01] |
C12N 2770/28088 | . . . | for redistribution [2022-02] |
C12N 2770/28111 | . . . | Hepevirus, e.g. hepatitis E virus [2013-01] |
C12N 2770/28121 | . . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2770/28122 | . . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2770/28123 | . . . . | Virus like particles [VLP] [2013-01] |
C12N 2770/28131 | . . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2770/28132 | . . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2770/28133 | . . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2770/28134 | . . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2770/28141 | . . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2770/28142 | . . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2770/28143 | . . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2770/28144 | . . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2770/28145 | . . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2770/28151 | . . . . | Methods of production or purification of viral material [2013-01] |
C12N 2770/28152 | . . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2770/28161 | . . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2770/28162 | . . . . . | by genetic engineering [2013-01] |
C12N 2770/28163 | . . . . . | by chemical treatment [2013-01] |
C12N 2770/28164 | . . . . . | by serial passage [2013-01] |
C12N 2770/28171 | . . . . | Demonstrated in vivo effect [2013-01] |
C12N 2770/28188 | . . . . | for redistribution [2022-02] |
C12N 2770/30011 | . . | Nodaviridae [2013-01] |
C12N 2770/30021 | . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2770/30022 | . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2770/30023 | . . . | Virus like particles [VLP] [2013-01] |
C12N 2770/30031 | . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2770/30032 | . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2770/30033 | . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2770/30034 | . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2770/30041 | . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2770/30042 | . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2770/30043 | . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2770/30044 | . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2770/30045 | . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2770/30051 | . . . | Methods of production or purification of viral material [2013-01] |
C12N 2770/30052 | . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2770/30061 | . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2770/30062 | . . . . | by genetic engineering [2013-01] |
C12N 2770/30063 | . . . . | by chemical treatment [2013-01] |
C12N 2770/30064 | . . . . | by serial passage [2013-01] |
C12N 2770/30071 | . . . | Demonstrated in vivo effect [2013-01] |
C12N 2770/30088 | . . . | for redistribution [2022-02] |
C12N 2770/32011 | . . | Picornaviridae [2013-01] |
C12N 2770/32021 | . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2770/32022 | . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2770/32023 | . . . | Virus like particles [VLP] [2013-01] |
C12N 2770/32031 | . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2770/32032 | . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2770/32033 | . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2770/32034 | . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2770/32041 | . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2770/32042 | . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2770/32043 | . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2770/32044 | . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2770/32045 | . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2770/32051 | . . . | Methods of production or purification of viral material [2013-01] |
C12N 2770/32052 | . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2770/32061 | . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2770/32062 | . . . . | by genetic engineering [2013-01] |
C12N 2770/32063 | . . . . | by chemical treatment [2013-01] |
C12N 2770/32064 | . . . . | by serial passage [2013-01] |
C12N 2770/32071 | . . . | Demonstrated in vivo effect [2013-01] |
C12N 2770/32088 | . . . | for redistribution [2022-02] |
C12N 2770/32111 | . . . | Aphthovirus, e.g. footandmouth disease virus [2013-01] |
C12N 2770/32121 | . . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2770/32122 | . . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2770/32123 | . . . . | Virus like particles [VLP] [2013-01] |
C12N 2770/32131 | . . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2770/32132 | . . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2770/32133 | . . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2770/32134 | . . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2770/32141 | . . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2770/32142 | . . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2770/32143 | . . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2770/32144 | . . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2770/32145 | . . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2770/32151 | . . . . | Methods of production or purification of viral material [2013-01] |
C12N 2770/32152 | . . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2770/32161 | . . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2770/32162 | . . . . . | by genetic engineering [2013-01] |
C12N 2770/32163 | . . . . . | by chemical treatment [2013-01] |
C12N 2770/32164 | . . . . . | by serial passage [2013-01] |
C12N 2770/32171 | . . . . | Demonstrated in vivo effect [2013-01] |
C12N 2770/32188 | . . . . | for redistribution [2022-02] |
C12N 2770/32211 | . . . | Cardiovirus, e.g. encephalomyocarditis virus [2013-01] |
C12N 2770/32221 | . . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2770/32222 | . . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2770/32223 | . . . . | Virus like particles [VLP] [2013-01] |
C12N 2770/32231 | . . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2770/32232 | . . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2770/32233 | . . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2770/32234 | . . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2770/32241 | . . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2770/32242 | . . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2770/32243 | . . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2770/32244 | . . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2770/32245 | . . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2770/32251 | . . . . | Methods of production or purification of viral material [2013-01] |
C12N 2770/32252 | . . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2770/32261 | . . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2770/32262 | . . . . . | by genetic engineering [2013-01] |
C12N 2770/32263 | . . . . . | by chemical treatment [2013-01] |
C12N 2770/32264 | . . . . . | by serial passage [2013-01] |
C12N 2770/32271 | . . . . | Demonstrated in vivo effect [2013-01] |
C12N 2770/32288 | . . . . | for redistribution [2022-02] |
C12N 2770/32311 | . . . | Enterovirus [2013-01] |
C12N 2770/32321 | . . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2770/32322 | . . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2770/32323 | . . . . | Virus like particles [VLP] [2013-01] |
C12N 2770/32331 | . . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2770/32332 | . . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2770/32333 | . . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2770/32334 | . . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2770/32341 | . . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2770/32342 | . . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2770/32343 | . . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2770/32344 | . . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2770/32345 | . . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2770/32351 | . . . . | Methods of production or purification of viral material [2013-01] |
C12N 2770/32352 | . . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2770/32361 | . . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2770/32362 | . . . . . | by genetic engineering [2013-01] |
C12N 2770/32363 | . . . . . | by chemical treatment [2013-01] |
C12N 2770/32364 | . . . . . | by serial passage [2013-01] |
C12N 2770/32371 | . . . . | Demonstrated in vivo effect [2013-01] |
C12N 2770/32388 | . . . . | for redistribution [2022-02] |
C12N 2770/32411 | . . . | Hepatovirus, i.e. hepatitis A virus [2013-01] |
C12N 2770/32421 | . . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2770/32422 | . . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2770/32423 | . . . . | Virus like particles [VLP] [2013-01] |
C12N 2770/32431 | . . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2770/32432 | . . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2770/32433 | . . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2770/32434 | . . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2770/32441 | . . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2770/32442 | . . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2770/32443 | . . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2770/32444 | . . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2770/32445 | . . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2770/32451 | . . . . | Methods of production or purification of viral material [2013-01] |
C12N 2770/32452 | . . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2770/32461 | . . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2770/32462 | . . . . . | by genetic engineering [2013-01] |
C12N 2770/32463 | . . . . . | by chemical treatment [2013-01] |
C12N 2770/32464 | . . . . . | by serial passage [2013-01] |
C12N 2770/32471 | . . . . | Demonstrated in vivo effect [2013-01] |
C12N 2770/32488 | . . . . | for redistribution [2022-02] |
C12N 2770/32511 | . . . | Parechovirus, e.g. human parechovirus [2013-01] |
C12N 2770/32521 | . . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2770/32522 | . . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2770/32523 | . . . . | Virus like particles [VLP] [2013-01] |
C12N 2770/32531 | . . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2770/32532 | . . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2770/32533 | . . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2770/32534 | . . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2770/32541 | . . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2770/32542 | . . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2770/32543 | . . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2770/32544 | . . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2770/32545 | . . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2770/32551 | . . . . | Methods of production or purification of viral material [2013-01] |
C12N 2770/32552 | . . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2770/32561 | . . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2770/32562 | . . . . . | by genetic engineering [2013-01] |
C12N 2770/32563 | . . . . . | by chemical treatment [2013-01] |
C12N 2770/32564 | . . . . . | by serial passage [2013-01] |
C12N 2770/32571 | . . . . | Demonstrated in vivo effect [2013-01] |
C12N 2770/32588 | . . . . | for redistribution [2022-02] |
C12N 2770/32611 | . . . | Poliovirus [2013-01] |
C12N 2770/32621 | . . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2770/32622 | . . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2770/32623 | . . . . | Virus like particles [VLP] [2013-01] |
C12N 2770/32631 | . . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2770/32632 | . . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2770/32633 | . . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2770/32634 | . . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2770/32641 | . . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2770/32642 | . . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2770/32643 | . . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2770/32644 | . . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2770/32645 | . . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2770/32651 | . . . . | Methods of production or purification of viral material [2013-01] |
C12N 2770/32652 | . . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2770/32661 | . . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2770/32662 | . . . . . | by genetic engineering [2013-01] |
C12N 2770/32663 | . . . . . | by chemical treatment [2013-01] |
C12N 2770/32664 | . . . . . | by serial passage [2013-01] |
C12N 2770/32671 | . . . . | Demonstrated in vivo effect [2013-01] |
C12N 2770/32688 | . . . . | for redistribution [2022-02] |
C12N 2770/32711 | . . . | Rhinovirus [2013-01] |
C12N 2770/32721 | . . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2770/32722 | . . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2770/32723 | . . . . | Virus like particles [VLP] [2013-01] |
C12N 2770/32731 | . . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2770/32732 | . . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2770/32733 | . . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2770/32734 | . . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2770/32741 | . . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2770/32742 | . . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2770/32743 | . . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2770/32744 | . . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2770/32745 | . . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2770/32751 | . . . . | Methods of production or purification of viral material [2013-01] |
C12N 2770/32752 | . . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2770/32761 | . . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2770/32762 | . . . . . | by genetic engineering [2013-01] |
C12N 2770/32763 | . . . . . | by chemical treatment [2013-01] |
C12N 2770/32764 | . . . . . | by serial passage [2013-01] |
C12N 2770/32771 | . . . . | Demonstrated in vivo effect [2013-01] |
C12N 2770/32788 | . . . . | for redistribution [2022-02] |
C12N 2770/34011 | . . | Potyviridae [2013-01] |
C12N 2770/34021 | . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2770/34022 | . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2770/34023 | . . . | Virus like particles [VLP] [2013-01] |
C12N 2770/34031 | . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2770/34032 | . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2770/34033 | . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2770/34034 | . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2770/34041 | . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2770/34042 | . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2770/34043 | . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2770/34044 | . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2770/34045 | . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2770/34051 | . . . | Methods of production or purification of viral material [2013-01] |
C12N 2770/34052 | . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2770/34061 | . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2770/34062 | . . . . | by genetic engineering [2013-01] |
C12N 2770/34063 | . . . . | by chemical treatment [2013-01] |
C12N 2770/34064 | . . . . | by serial passage [2013-01] |
C12N 2770/34071 | . . . | Demonstrated in vivo effect [2013-01] |
C12N 2770/34088 | . . . | for redistribution [2022-02] |
C12N 2770/36011 | . . | Togaviridae [2013-01] |
C12N 2770/36021 | . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2770/36022 | . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2770/36023 | . . . | Virus like particles [VLP] [2013-01] |
C12N 2770/36031 | . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2770/36032 | . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2770/36033 | . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2770/36034 | . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2770/36041 | . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2770/36042 | . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2770/36043 | . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2770/36044 | . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2770/36045 | . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2770/36051 | . . . | Methods of production or purification of viral material [2013-01] |
C12N 2770/36052 | . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2770/36061 | . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2770/36062 | . . . . | by genetic engineering [2013-01] |
C12N 2770/36063 | . . . . | by chemical treatment [2013-01] |
C12N 2770/36064 | . . . . | by serial passage [2013-01] |
C12N 2770/36071 | . . . | Demonstrated in vivo effect [2013-01] |
C12N 2770/36088 | . . . | for redistribution [2022-02] |
C12N 2770/36111 | . . . | Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki [2013-01] |
C12N 2770/36121 | . . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2770/36122 | . . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2770/36123 | . . . . | Virus like particles [VLP] [2013-01] |
C12N 2770/36131 | . . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2770/36132 | . . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2770/36133 | . . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2770/36134 | . . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2770/36141 | . . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2770/36142 | . . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2770/36143 | . . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2770/36144 | . . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2770/36145 | . . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2770/36151 | . . . . | Methods of production or purification of viral material [2013-01] |
C12N 2770/36152 | . . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2770/36161 | . . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2770/36162 | . . . . . | by genetic engineering [2013-01] |
C12N 2770/36163 | . . . . . | by chemical treatment [2013-01] |
C12N 2770/36164 | . . . . . | by serial passage [2013-01] |
C12N 2770/36171 | . . . . | Demonstrated in vivo effect [2013-01] |
C12N 2770/36188 | . . . . | for redistribution [2022-02] |
C12N 2770/36211 | . . . | Rubivirus, e.g. rubella virus [2013-01] |
C12N 2770/36221 | . . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2770/36222 | . . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2770/36223 | . . . . | Virus like particles [VLP] [2013-01] |
C12N 2770/36231 | . . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2770/36232 | . . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2770/36233 | . . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2770/36234 | . . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2770/36241 | . . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2770/36242 | . . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2770/36243 | . . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2770/36244 | . . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2770/36245 | . . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2770/36251 | . . . . | Methods of production or purification of viral material [2013-01] |
C12N 2770/36252 | . . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2770/36261 | . . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2770/36262 | . . . . . | by genetic engineering [2013-01] |
C12N 2770/36263 | . . . . . | by chemical treatment [2013-01] |
C12N 2770/36264 | . . . . . | by serial passage [2013-01] |
C12N 2770/36271 | . . . . | Demonstrated in vivo effect [2013-01] |
C12N 2770/36288 | . . . . | for redistribution [2022-02] |
C12N 2770/38011 | . . | Tombusviridae [2013-01] |
C12N 2770/38021 | . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2770/38022 | . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2770/38023 | . . . | Virus like particles [VLP] [2013-01] |
C12N 2770/38031 | . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2770/38032 | . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2770/38033 | . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2770/38034 | . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2770/38041 | . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2770/38042 | . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2770/38043 | . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2770/38044 | . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2770/38045 | . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2770/38051 | . . . | Methods of production or purification of viral material [2013-01] |
C12N 2770/38052 | . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2770/38061 | . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2770/38062 | . . . . | by genetic engineering [2013-01] |
C12N 2770/38063 | . . . . | by chemical treatment [2013-01] |
C12N 2770/38064 | . . . . | by serial passage [2013-01] |
C12N 2770/38071 | . . . | Demonstrated in vivo effect [2013-01] |
C12N 2770/38088 | . . . | for redistribution [2022-02] |
C12N 2770/40011 | . . | Tymoviridae [2013-01] |
C12N 2770/40021 | . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2770/40022 | . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2770/40023 | . . . | Virus like particles [VLP] [2013-01] |
C12N 2770/40031 | . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2770/40032 | . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2770/40033 | . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2770/40034 | . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2770/40041 | . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2770/40042 | . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2770/40043 | . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2770/40044 | . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2770/40045 | . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2770/40051 | . . . | Methods of production or purification of viral material [2013-01] |
C12N 2770/40052 | . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2770/40061 | . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2770/40062 | . . . . | by genetic engineering [2013-01] |
C12N 2770/40063 | . . . . | by chemical treatment [2013-01] |
C12N 2770/40064 | . . . . | by serial passage [2013-01] |
C12N 2770/40071 | . . . | Demonstrated in vivo effect [2013-01] |
C12N 2770/40088 | . . . | for redistribution [2022-02] |
C12N 2780/00 | Naked RNA viruses [2022-02] |
C12N 2780/00011 | . | Details [2022-02] |
C12N 2780/00021 | . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2780/00022 | . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2780/00023 | . . | Virus like particles [VLP] [2013-01] |
C12N 2780/00031 | . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2780/00032 | . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2780/00033 | . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2780/00034 | . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2780/00041 | . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2780/00042 | . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2780/00043 | . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2780/00044 | . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2780/00045 | . . . | Special targeting system for viral vectors [2013-01] |
C12N 2780/00051 | . . | Methods of production or purification of viral material [2013-01] |
C12N 2780/00052 | . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2780/00061 | . . | Methods of inactivation or attenuation [2013-01] |
C12N 2780/00062 | . . . | by genetic engineering [2013-01] |
C12N 2780/00063 | . . . | by chemical treatment [2013-01] |
C12N 2780/00064 | . . . | by serial passage [2013-01] |
C12N 2780/00071 | . . | Demonstrated in vivo effect [2013-01] |
C12N 2780/00088 | . . | for redistribution [2022-02] |
C12N 2780/10011 | . . | Narnaviridae [2013-01] |
C12N 2780/10021 | . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2780/10022 | . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2780/10023 | . . . | Virus like particles [VLP] [2013-01] |
C12N 2780/10031 | . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2780/10032 | . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2780/10033 | . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2780/10034 | . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2780/10041 | . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2780/10042 | . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2780/10043 | . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2780/10044 | . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2780/10045 | . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2780/10051 | . . . | Methods of production or purification of viral material [2013-01] |
C12N 2780/10052 | . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2780/10061 | . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2780/10062 | . . . . | by genetic engineering [2013-01] |
C12N 2780/10063 | . . . . | by chemical treatment [2013-01] |
C12N 2780/10064 | . . . . | by serial passage [2013-01] |
C12N 2780/10071 | . . . | Demonstrated in vivo effect [2013-01] |
C12N 2780/10088 | . . . | for redistribution [2022-02] |
C12N 2790/00 | Viroids or subviral agents [2022-02] |
C12N 2790/00011 | . | Details [2022-02] |
C12N 2790/00021 | . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2790/00022 | . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2790/00023 | . . | Virus like particles [VLP] [2013-01] |
C12N 2790/00031 | . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2790/00032 | . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2790/00033 | . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2790/00034 | . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2790/00041 | . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2790/00042 | . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2790/00043 | . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2790/00044 | . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2790/00045 | . . . | Special targeting system for viral vectors [2013-01] |
C12N 2790/00051 | . . | Methods of production or purification of viral material [2013-01] |
C12N 2790/00052 | . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2790/00061 | . . | Methods of inactivation or attenuation [2013-01] |
C12N 2790/00062 | . . . | by genetic engineering [2013-01] |
C12N 2790/00063 | . . . | by chemical treatment [2013-01] |
C12N 2790/00064 | . . . | by serial passage [2013-01] |
C12N 2790/00071 | . . | Demonstrated in vivo effect [2013-01] |
C12N 2790/00088 | . . | for redistribution [2022-02] |
C12N 2790/10011 | . . | Prions [2013-01] |
C12N 2790/10021 | . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2790/10022 | . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2790/10023 | . . . | Virus like particles [VLP] [2013-01] |
C12N 2790/10031 | . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2790/10032 | . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2790/10033 | . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2790/10034 | . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2790/10041 | . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2790/10042 | . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2790/10043 | . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2790/10044 | . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2790/10045 | . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2790/10051 | . . . | Methods of production or purification of viral material [2013-01] |
C12N 2790/10052 | . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2790/10061 | . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2790/10062 | . . . . | by genetic engineering [2013-01] |
C12N 2790/10063 | . . . . | by chemical treatment [2013-01] |
C12N 2790/10064 | . . . . | by serial passage [2013-01] |
C12N 2790/10071 | . . . | Demonstrated in vivo effect [2013-01] |
C12N 2790/10088 | . . . | for redistribution [2022-02] |
C12N 2790/12011 | . . | Satellite viruses [2013-01] |
C12N 2790/12021 | . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2790/12022 | . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2790/12023 | . . . | Virus like particles [VLP] [2013-01] |
C12N 2790/12031 | . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2790/12032 | . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2790/12033 | . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2790/12034 | . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2790/12041 | . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2790/12042 | . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2790/12043 | . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2790/12044 | . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2790/12045 | . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2790/12051 | . . . | Methods of production or purification of viral material [2013-01] |
C12N 2790/12052 | . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2790/12061 | . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2790/12062 | . . . . | by genetic engineering [2013-01] |
C12N 2790/12063 | . . . . | by chemical treatment [2013-01] |
C12N 2790/12064 | . . . . | by serial passage [2013-01] |
C12N 2790/12071 | . . . | Demonstrated in vivo effect [2013-01] |
C12N 2790/12088 | . . . | for redistribution [2022-02] |
C12N 2790/14011 | . . | Viroids [2013-01] |
C12N 2790/14021 | . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2790/14022 | . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2790/14023 | . . . | Virus like particles [VLP] [2013-01] |
C12N 2790/14031 | . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2790/14032 | . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2790/14033 | . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2790/14034 | . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2790/14041 | . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2790/14042 | . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2790/14043 | . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2790/14044 | . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2790/14045 | . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2790/14051 | . . . | Methods of production or purification of viral material [2013-01] |
C12N 2790/14052 | . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2790/14061 | . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2790/14062 | . . . . | by genetic engineering [2013-01] |
C12N 2790/14063 | . . . . | by chemical treatment [2013-01] |
C12N 2790/14064 | . . . . | by serial passage [2013-01] |
C12N 2790/14071 | . . . | Demonstrated in vivo effect [2013-01] |
C12N 2790/14088 | . . . | for redistribution [2022-02] |
C12N 2792/00 | Archaeabacteria viruses [2022-02] |
C12N 2792/00011 | . | Details [2022-02] |
C12N 2792/00021 | . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2792/00022 | . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2792/00023 | . . | Virus like particles [VLP] [2013-01] |
C12N 2792/00031 | . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2792/00032 | . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2792/00033 | . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2792/00034 | . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2792/00041 | . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2792/00042 | . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2792/00043 | . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2792/00044 | . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2792/00045 | . . . | Special targeting system for viral vectors [2013-01] |
C12N 2792/00051 | . . | Methods of production or purification of viral material [2013-01] |
C12N 2792/00052 | . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2792/00061 | . . | Methods of inactivation or attenuation [2013-01] |
C12N 2792/00062 | . . . | by genetic engineering [2013-01] |
C12N 2792/00063 | . . . | by chemical treatment [2013-01] |
C12N 2792/00064 | . . . | by serial passage [2013-01] |
C12N 2792/00071 | . . | Demonstrated in vivo effect [2013-01] |
C12N 2792/00088 | . . | for redistribution [2022-02] |
C12N 2792/10011 | . . | Fuselloviridae [2013-01] |
C12N 2792/10021 | . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2792/10022 | . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2792/10023 | . . . | Virus like particles [VLP] [2013-01] |
C12N 2792/10031 | . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2792/10032 | . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2792/10033 | . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2792/10034 | . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2792/10041 | . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2792/10042 | . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2792/10043 | . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2792/10044 | . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2792/10045 | . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2792/10051 | . . . | Methods of production or purification of viral material [2013-01] |
C12N 2792/10052 | . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2792/10061 | . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2792/10062 | . . . . | by genetic engineering [2013-01] |
C12N 2792/10063 | . . . . | by chemical treatment [2013-01] |
C12N 2792/10064 | . . . . | by serial passage [2013-01] |
C12N 2792/10071 | . . . | Demonstrated in vivo effect [2013-01] |
C12N 2792/10088 | . . . | for redistribution [2022-02] |
C12N 2792/12011 | . . | Guttaviridae [2013-01] |
C12N 2792/12021 | . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2792/12022 | . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2792/12023 | . . . | Virus like particles [VLP] [2013-01] |
C12N 2792/12031 | . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2792/12032 | . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2792/12033 | . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2792/12034 | . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2792/12041 | . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2792/12042 | . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2792/12043 | . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2792/12044 | . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2792/12045 | . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2792/12051 | . . . | Methods of production or purification of viral material [2013-01] |
C12N 2792/12052 | . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2792/12061 | . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2792/12062 | . . . . | by genetic engineering [2013-01] |
C12N 2792/12063 | . . . . | by chemical treatment [2013-01] |
C12N 2792/12064 | . . . . | by serial passage [2013-01] |
C12N 2792/12071 | . . . | Demonstrated in vivo effect [2013-01] |
C12N 2792/12088 | . . . | for redistribution [2022-02] |
C12N 2795/00 | Bacteriophages [2022-02] |
C12N 2795/00011 | . | Details [2022-02] |
C12N 2795/00021 | . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2795/00022 | . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2795/00023 | . . | Virus like particles [VLP] [2013-01] |
C12N 2795/00031 | . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2795/00032 | . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2795/00033 | . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2795/00034 | . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2795/00041 | . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2795/00042 | . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2795/00043 | . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2795/00044 | . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2795/00045 | . . . | Special targeting system for viral vectors [2013-01] |
C12N 2795/00051 | . . | Methods of production or purification of viral material [2013-01] |
C12N 2795/00052 | . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2795/00061 | . . | Methods of inactivation or attenuation [2013-01] |
C12N 2795/00062 | . . . | by genetic engineering [2013-01] |
C12N 2795/00063 | . . . | by chemical treatment [2013-01] |
C12N 2795/00064 | . . . | by serial passage [2013-01] |
C12N 2795/00071 | . . | Demonstrated in vivo effect [2013-01] |
C12N 2795/00088 | . . | for redistribution [2022-02] |
C12N 2795/10011 | . . | dsDNA Bacteriophages [2013-01] |
C12N 2795/10021 | . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2795/10022 | . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2795/10023 | . . . | Virus like particles [VLP] [2013-01] |
C12N 2795/10031 | . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2795/10032 | . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2795/10033 | . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2795/10034 | . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2795/10041 | . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2795/10042 | . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2795/10043 | . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2795/10044 | . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2795/10045 | . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2795/10051 | . . . | Methods of production or purification of viral material [2013-01] |
C12N 2795/10052 | . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2795/10061 | . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2795/10062 | . . . . | by genetic engineering [2013-01] |
C12N 2795/10063 | . . . . | by chemical treatment [2013-01] |
C12N 2795/10064 | . . . . | by serial passage [2013-01] |
C12N 2795/10071 | . . . | Demonstrated in vivo effect [2013-01] |
C12N 2795/10088 | . . . | for redistribution [2022-02] |
C12N 2795/10111 | . . . | Myoviridae [2013-01] |
C12N 2795/10121 | . . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2795/10122 | . . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2795/10123 | . . . . | Virus like particles [VLP] [2013-01] |
C12N 2795/10131 | . . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2795/10132 | . . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2795/10133 | . . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2795/10134 | . . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2795/10141 | . . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2795/10142 | . . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2795/10143 | . . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2795/10144 | . . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2795/10145 | . . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2795/10151 | . . . . | Methods of production or purification of viral material [2013-01] |
C12N 2795/10152 | . . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2795/10161 | . . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2795/10162 | . . . . . | by genetic engineering [2013-01] |
C12N 2795/10163 | . . . . . | by chemical treatment [2013-01] |
C12N 2795/10164 | . . . . . | by serial passage [2013-01] |
C12N 2795/10171 | . . . . | Demonstrated in vivo effect [2013-01] |
C12N 2795/10188 | . . . . | for redistribution [2022-02] |
C12N 2795/10211 | . . . | Podoviridae [2013-01] |
C12N 2795/10221 | . . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2795/10222 | . . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2795/10223 | . . . . | Virus like particles [VLP] [2013-01] |
C12N 2795/10231 | . . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2795/10232 | . . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2795/10233 | . . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2795/10234 | . . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2795/10241 | . . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2795/10242 | . . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2795/10243 | . . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2795/10244 | . . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2795/10245 | . . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2795/10251 | . . . . | Methods of production or purification of viral material [2013-01] |
C12N 2795/10252 | . . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2795/10261 | . . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2795/10262 | . . . . . | by genetic engineering [2013-01] |
C12N 2795/10263 | . . . . . | by chemical treatment [2013-01] |
C12N 2795/10264 | . . . . . | by serial passage [2013-01] |
C12N 2795/10271 | . . . . | Demonstrated in vivo effect [2013-01] |
C12N 2795/10288 | . . . . | for redistribution [2022-02] |
C12N 2795/10311 | . . . | Siphoviridae [2013-01] |
C12N 2795/10321 | . . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2795/10322 | . . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2795/10323 | . . . . | Virus like particles [VLP] [2013-01] |
C12N 2795/10331 | . . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2795/10332 | . . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2795/10333 | . . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2795/10334 | . . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2795/10341 | . . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2795/10342 | . . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2795/10343 | . . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2795/10344 | . . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2795/10345 | . . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2795/10351 | . . . . | Methods of production or purification of viral material [2013-01] |
C12N 2795/10352 | . . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2795/10361 | . . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2795/10362 | . . . . . | by genetic engineering [2013-01] |
C12N 2795/10363 | . . . . . | by chemical treatment [2013-01] |
C12N 2795/10364 | . . . . . | by serial passage [2013-01] |
C12N 2795/10371 | . . . . | Demonstrated in vivo effect [2013-01] |
C12N 2795/10388 | . . . . | for redistribution [2022-02] |
C12N 2795/12011 | . . | dsRNA Bacteriophages [2013-01] |
C12N 2795/12021 | . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2795/12022 | . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2795/12023 | . . . | Virus like particles [VLP] [2013-01] |
C12N 2795/12031 | . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2795/12032 | . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2795/12033 | . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2795/12034 | . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2795/12041 | . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2795/12042 | . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2795/12043 | . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2795/12044 | . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2795/12045 | . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2795/12051 | . . . | Methods of production or purification of viral material [2013-01] |
C12N 2795/12052 | . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2795/12061 | . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2795/12062 | . . . . | by genetic engineering [2013-01] |
C12N 2795/12063 | . . . . | by chemical treatment [2013-01] |
C12N 2795/12064 | . . . . | by serial passage [2013-01] |
C12N 2795/12071 | . . . | Demonstrated in vivo effect [2013-01] |
C12N 2795/12088 | . . . | for redistribution [2022-02] |
C12N 2795/14011 | . . | ssDNA Bacteriophages [2013-01] |
C12N 2795/14021 | . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2795/14022 | . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2795/14023 | . . . | Virus like particles [VLP] [2013-01] |
C12N 2795/14031 | . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2795/14032 | . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2795/14033 | . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2795/14034 | . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2795/14041 | . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2795/14042 | . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2795/14043 | . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2795/14044 | . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2795/14045 | . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2795/14051 | . . . | Methods of production or purification of viral material [2013-01] |
C12N 2795/14052 | . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2795/14061 | . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2795/14062 | . . . . | by genetic engineering [2013-01] |
C12N 2795/14063 | . . . . | by chemical treatment [2013-01] |
C12N 2795/14064 | . . . . | by serial passage [2013-01] |
C12N 2795/14071 | . . . | Demonstrated in vivo effect [2013-01] |
C12N 2795/14088 | . . . | for redistribution [2022-02] |
C12N 2795/14111 | . . . | Inoviridae [2013-01] |
C12N 2795/14121 | . . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2795/14122 | . . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2795/14123 | . . . . | Virus like particles [VLP] [2013-01] |
C12N 2795/14131 | . . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2795/14132 | . . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2795/14133 | . . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2795/14134 | . . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2795/14141 | . . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2795/14142 | . . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2795/14143 | . . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2795/14144 | . . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2795/14145 | . . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2795/14151 | . . . . | Methods of production or purification of viral material [2013-01] |
C12N 2795/14152 | . . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2795/14161 | . . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2795/14162 | . . . . . | by genetic engineering [2013-01] |
C12N 2795/14163 | . . . . . | by chemical treatment [2013-01] |
C12N 2795/14164 | . . . . . | by serial passage [2013-01] |
C12N 2795/14171 | . . . . | Demonstrated in vivo effect [2013-01] |
C12N 2795/14188 | . . . . | for redistribution [2022-02] |
C12N 2795/14211 | . . . | Microviridae [2013-01] |
C12N 2795/14221 | . . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2795/14222 | . . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2795/14223 | . . . . | Virus like particles [VLP] [2013-01] |
C12N 2795/14231 | . . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2795/14232 | . . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2795/14233 | . . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2795/14234 | . . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2795/14241 | . . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2795/14242 | . . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2795/14243 | . . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2795/14244 | . . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2795/14245 | . . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2795/14251 | . . . . | Methods of production or purification of viral material [2013-01] |
C12N 2795/14252 | . . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2795/14261 | . . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2795/14262 | . . . . . | by genetic engineering [2013-01] |
C12N 2795/14263 | . . . . . | by chemical treatment [2013-01] |
C12N 2795/14264 | . . . . . | by serial passage [2013-01] |
C12N 2795/14271 | . . . . | Demonstrated in vivo effect [2013-01] |
C12N 2795/14288 | . . . . | for redistribution [2022-02] |
C12N 2795/16011 | . . | ssRNA Bacteriophages negative-sense [2013-01] |
C12N 2795/16021 | . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2795/16022 | . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2795/16023 | . . . | Virus like particles [VLP] [2013-01] |
C12N 2795/16031 | . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2795/16032 | . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2795/16033 | . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2795/16034 | . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2795/16041 | . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2795/16042 | . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2795/16043 | . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2795/16044 | . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2795/16045 | . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2795/16051 | . . . | Methods of production or purification of viral material [2013-01] |
C12N 2795/16052 | . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2795/16061 | . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2795/16062 | . . . . | by genetic engineering [2013-01] |
C12N 2795/16063 | . . . . | by chemical treatment [2013-01] |
C12N 2795/16064 | . . . . | by serial passage [2013-01] |
C12N 2795/16071 | . . . | Demonstrated in vivo effect [2013-01] |
C12N 2795/16088 | . . . | for redistribution [2022-02] |
C12N 2795/18011 | . . | ssRNA Bacteriophages positive-sense [2013-01] |
C12N 2795/18021 | . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2795/18022 | . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2795/18023 | . . . | Virus like particles [VLP] [2013-01] |
C12N 2795/18031 | . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2795/18032 | . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2795/18033 | . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2795/18034 | . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2795/18041 | . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2795/18042 | . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2795/18043 | . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2795/18044 | . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2795/18045 | . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2795/18051 | . . . | Methods of production or purification of viral material [2013-01] |
C12N 2795/18052 | . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2795/18061 | . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2795/18062 | . . . . | by genetic engineering [2013-01] |
C12N 2795/18063 | . . . . | by chemical treatment [2013-01] |
C12N 2795/18064 | . . . . | by serial passage [2013-01] |
C12N 2795/18071 | . . . | Demonstrated in vivo effect [2013-01] |
C12N 2795/18088 | . . . | for redistribution [2022-02] |
C12N 2795/18111 | . . . | Leviviridae [2013-01] |
C12N 2795/18121 | . . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013-01] |
C12N 2795/18122 | . . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013-01] |
C12N 2795/18123 | . . . . | Virus like particles [VLP] [2013-01] |
C12N 2795/18131 | . . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013-01] |
C12N 2795/18132 | . . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013-01] |
C12N 2795/18133 | . . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013-01] |
C12N 2795/18134 | . . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013-01] |
C12N 2795/18141 | . . . . | Use of virus, viral particle or viral elements as a vector [2013-01] |
C12N 2795/18142 | . . . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013-01] |
C12N 2795/18143 | . . . . . | viral genome or elements thereof as genetic vector [2013-01] |
C12N 2795/18144 | . . . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013-01] |
C12N 2795/18145 | . . . . . | Special targeting system for viral vectors [2013-01] |
C12N 2795/18151 | . . . . | Methods of production or purification of viral material [2013-01] |
C12N 2795/18152 | . . . . . | relating to complementing cells and packaging systems for producing virus or viral particles [2013-01] |
C12N 2795/18161 | . . . . | Methods of inactivation or attenuation [2013-01] |
C12N 2795/18162 | . . . . . | by genetic engineering [2013-01] |
C12N 2795/18163 | . . . . . | by chemical treatment [2013-01] |
C12N 2795/18164 | . . . . . | by serial passage [2013-01] |
C12N 2795/18171 | . . . . | Demonstrated in vivo effect [2013-01] |
C12N 2795/18188 | . . . . | for redistribution [2022-02] |
C12N 2796/00 | Viruses not covered by groups C12N 2710/00 - C12N 2795/00 [2022-02] |
| C12N 2799/00 | Uses of viruses [2013-01] WARNING
|
C12N 2799/02 | . | as vector [2013-01] |
C12N 2799/021 | . . | for the expression of a heterologous nucleic acid [2013-01] |
C12N 2799/022 | . . . | where the vector is derived from an adenovirus [2013-01] |
C12N 2799/023 | . . . | where the vector is derived from a poxvirus [2013-01] |
C12N 2799/025 | . . . | where the vector is derived from a parvovirus [2013-01] |
C12N 2799/026 | . . . | where the vector is derived from a baculovirus [2013-01] |
C12N 2799/027 | . . . | where the vector is derived from a retrovirus [2013-01] |
C12N 2799/028 | . . . | where the vector is derived from a herpesvirus [2013-01] |
C12N 2799/04 | . . | in vivo [2013-01] |
C12N 2799/06 | . . | in vitro [2013-01] |
C12N 2800/00 | Nucleic acids vectors [2013-01] |
C12N 2800/10 | . | Plasmid DNA [2013-01] |
C12N 2800/101 | . . | for bacteria [2013-01] |
C12N 2800/102 | . . | for yeast [2013-01] |
C12N 2800/103 | . . | for invertebrates [2013-01] |
C12N 2800/105 | . . . | for insects [2013-01] |
C12N 2800/106 | . . | for vertebrates [2013-01] |
C12N 2800/107 | . . . | for mammalian [2013-01] |
C12N 2800/108 | . . | episomal vectors [2013-01] |
C12N 2800/20 | . | Pseudochromosomes, minichrosomosomes [2013-01] |
C12N 2800/202 | . . | of bacteriophage origin [2013-01] |
C12N 2800/204 | . . | of bacterial origin, e.g. BAC [2013-01] |
C12N 2800/206 | . . | of yeast origin, e.g. YAC, 2u [2013-01] |
C12N 2800/208 | . . | of mammalian origin, e.g. minichromosome [2013-01] |
C12N 2800/22 | . | Vectors comprising a coding region that has been codon optimised for expression in a respective host [2013-01] |
C12N 2800/24 | . | Vectors characterised by the absence of particular element, e.g. selectable marker, viral origin of replication [2013-01] |
C12N 2800/30 | . | Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT [2013-01] |
C12N 2800/40 | . | Systems of functionally co-operating vectors [2013-01] |
C12N 2800/50 | . | Vectors for producing vectors [2013-01] |
C12N 2800/60 | . | Vectors containing traps for, e.g. exons, promoters [2013-01] |
C12N 2800/70 | . | Vectors containing special elements for cloning, e.g. topoisomerase, adaptor sites [2013-01] |
C12N 2800/80 | . | Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites [2013-01] |
C12N 2800/90 | . | Vectors containing a transposable element [2013-01] |
C12N 2800/95 | . | Protection of vectors from inactivation by agents such as antibodies or enzymes, e.g. using polymers [2013-01] |
C12N 2810/00 | Vectors comprising a targeting moiety [2013-01] |
C12N 2810/10 | . | Vectors comprising a non-peptidic targeting moiety [2013-01] |
C12N 2810/40 | . | Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source [2013-01] |
C12N 2810/405 | . . | Vectors comprising RGD peptide [2013-01] |
C12N 2810/50 | . | Vectors comprising as targeting moiety peptide derived from defined protein [2013-01] |
C12N 2810/55 | . . | from bacteria [2013-01] |
C12N 2810/60 | . . | from viruses [2013-01] |
C12N 2810/6009 | . . . | dsDNA viruses [2013-01] |
C12N 2810/6018 | . . . . | Adenoviridae [2013-01] |
C12N 2810/6027 | . . . | ssDNA viruses [2013-01] |
C12N 2810/6036 | . . . | DNA rev transcr viruses [2013-01] |
C12N 2810/6045 | . . . | RNA rev transcr viruses [2013-01] |
C12N 2810/6054 | . . . . | Retroviridae [2013-01] |
C12N 2810/6063 | . . . | ds RNA viruses [2013-01] |
C12N 2810/6072 | . . . | negative strand RNA viruses [2013-01] |
C12N 2810/6081 | . . . . | rhabdoviridae, e.g. VSV [2013-01] |
C12N 2810/609 | . . . | positive strand RNA viruses [2013-01] |
C12N 2810/65 | . . | from plants [2013-01] |
C12N 2810/70 | . . | from fungi [2013-01] |
C12N 2810/75 | . . | from invertebrates [2013-01] |
C12N 2810/80 | . . | from vertebrates [2013-01] |
C12N 2810/85 | . . . | mammalian [2013-01] |
C12N 2810/851 | . . . . | from growth factors; from growth regulators [2013-01] |
C12N 2810/852 | . . . . | from cytokines; from lymphokines; from interferons [2013-01] |
C12N 2810/853 | . . . . . | from tumor necrosis factor, TNF [2013-01] |
C12N 2810/854 | . . . . | from hormones [2013-01] |
C12N 2810/855 | . . . . | from receptors; from cell surface antigens; from cell surface determinants [2013-01] |
C12N 2810/856 | . . . . . | from integrins [2013-01] |
C12N 2810/857 | . . . . | from blood coagulation or fibrinolysis factors [2013-01] |
C12N 2810/858 | . . . . | from apolipopeptides [2013-01] |
C12N 2810/859 | . . . . | from immunoglobulins [2013-01] |
C12N 2810/90 | . . . | avian [2013-01] |
C12N 2820/00 | Vectors comprising a special origin of replication system [2013-01] |
C12N 2820/002 | . | inducible or controllable [2013-01] |
C12N 2820/005 | . | cell-cycle regulated [2013-01] |
C12N 2820/007 | . | tissue or cell-specific [2013-01] |
C12N 2820/10 | . | multiple origins of replication [2013-01] |
C12N 2820/55 | . | from bacteria [2013-01] |
C12N 2820/60 | . | from viruses [2013-01] |
C12N 2820/65 | . | from plants [2013-01] |
C12N 2820/70 | . | from fungi [2013-01] |
C12N 2820/702 | . . | yeast [2013-01] |
C12N 2820/704 | . . . | S. cerevisae [2013-01] |
C12N 2820/706 | . . . | S. pombe [2013-01] |
C12N 2820/708 | . . . | C. albicans [2013-01] |
C12N 2820/75 | . | from invertebrates [2013-01] |
C12N 2820/80 | . | from vertebrates [2013-01] |
C12N 2820/85 | . . | mammalian [2013-01] |
C12N 2820/90 | . . | avian [2013-01] |
C12N 2830/00 | Vector systems having a special element relevant for transcription [2013-01] |
C12N 2830/001 | . | controllable enhancer/promoter combination [2013-01] |
C12N 2830/002 | . . | inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor [2013-01] |
C12N 2830/003 | . . . | tet inducible [2013-01] |
C12N 2830/005 | . . | repressible enhancer/promoter combination, e.g. KRAB [2013-01] |
C12N 2830/006 | . . . | tet repressible [2013-01] |
C12N 2830/007 | . | cell cycle specific enhancer/promoter combination [2013-01] |
C12N 2830/008 | . | cell type or tissue specific enhancer/promoter combination [2013-01] |
C12N 2830/15 | . | chimeric enhancer/promoter combination [2013-01] |
C12N 2830/20 | . | transcription of more than one cistron [2013-01] |
C12N 2830/205 | . . | bidirectional [2013-01] |
C12N 2830/30 | . | being an enhancer not forming part of the promoter region [2013-01] |
C12N 2830/32 | . | being an silencer not forming part of the promoter region [2013-01] |
C12N 2830/34 | . | being a transcription initiation element [2013-01] |
C12N 2830/36 | . | being a transcription termination element [2013-01] |
C12N 2830/38 | . | being a stuffer [2013-01] |
C12N 2830/40 | . | being an insulator [2013-01] |
C12N 2830/42 | . | being an intron or intervening sequence for splicing and/or stability of RNA [2013-01] |
C12N 2830/46 | . | elements influencing chromatin structure, e.g. scaffold/matrix attachment region, methylation free island [2013-01] |
C12N 2830/48 | . | regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE [2013-01] |
C12N 2830/50 | . | regulating RNA stability, not being an intron, e.g. poly A signal [2013-01] |
C12N 2830/52 | . | encoding ribozyme for self-inactivation [2013-01] |
C12N 2830/55 | . | from bacteria [2013-01] |
C12N 2830/60 | . | from viruses [2013-01] |
C12N 2830/65 | . | from plants [2013-01] |
C12N 2830/70 | . | from fungi [2013-01] |
C12N 2830/702 | . . | yeast [2013-01] |
C12N 2830/704 | . . . | S. cerevisiae [2013-01] |
C12N 2830/706 | . . . | S. pombe [2013-01] |
C12N 2830/708 | . . . | C. albicans [2013-01] |
C12N 2830/75 | . | from invertebrates [2013-01] |
C12N 2830/80 | . | from vertebrates [2013-01] |
C12N 2830/85 | . . | mammalian [2013-01] |
C12N 2830/90 | . . | avian [2013-01] |
C12N 2840/00 | Vectors comprising a special translation-regulating system [2013-01] |
C12N 2840/002 | . | controllable or inducible [2013-01] |
C12N 2840/005 | . | cell cycle specific [2013-01] |
C12N 2840/007 | . | cell or tissue specific [2013-01] |
C12N 2840/10 | . | regulates levels of translation [2013-01] |
C12N 2840/102 | . . | inhibiting translation [2013-01] |
C12N 2840/105 | . . | enhancing translation [2013-01] |
C12N 2840/107 | . . | inhibiting translational read-through [2013-01] |
C12N 2840/20 | . | translation of more than one cistron [2013-01] |
C12N 2840/203 | . . | having an IRES [2013-01] |
C12N 2840/206 | . . . | having multiple IRES [2013-01] |
C12N 2840/44 | . | being a specific part of the splice mechanism, e.g. donor, acceptor [2013-01] |
C12N 2840/445 | . . | for trans-splicing, e.g. polypyrimidine tract, branch point splicing [2013-01] |
| C12N 2840/50 | . | utilisation of non-ATG initiation codon [2013-01] NOTE
|
C12N 2840/55 | . | from bacteria [2013-01] |
C12N 2840/60 | . | from viruses [2013-01] |
C12N 2840/65 | . | from plants [2013-01] |
C12N 2840/70 | . | from fungi [2013-01] |
C12N 2840/702 | . . | yeast [2013-01] |
C12N 2840/704 | . . . | S. cerevisiae [2013-01] |
C12N 2840/706 | . . . | S. pombe [2013-01] |
C12N 2840/708 | . . . | C. albicans [2013-01] |
C12N 2840/75 | . | from invertebrates [2013-01] |
C12N 2840/80 | . | from vertebrates [2013-01] |
C12N 2840/85 | . . | mammalian [2013-01] |
C12N 2840/90 | . . | avian [2013-01] |
| C12N 2999/00 | Further aspects of viruses or vectors not covered by groups C12N 2710/00 - C12N 2796/00 or C12N 2800/00 [2022-02] NOTES
|
C12N 2999/002 | . | Adverse teaching [2013-01] |
C12N 2999/005 | . | Biological teaching, e.g. a link between protein and disease, new virus causing pandemic [2013-01] |
C12N 2999/007 | . | Technological advancements, e.g. new system for producing known virus, cre-lox system for production of transgenic animals [2013-01] |